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Tmax time taken to reach the maximum concentration
WRES weighted residuals
Var(.) variance of a scalar random variable
Vi volume of distribution of compartment 1
V2 volume of distribution of compartment 2
Vss volume of distribution at steady state
V/F volume/bioavailability
Wss weighted sum of squares
Wssr weighted residuals sum of squares
Y measured response
Y predicted response
r| random interindividual error
e residual error (between measured data and model predictions)
£2 v a r ia n c e -c o v a r ia n c e  m a tr ix  o f  th e  ra n d o m  p aram eters T]; c o l le c t io n  o f
co2
Xn e x p o n e n t  o f  th e  n th e x p o n e n tia l
£  variance-covariance matrix of the random parameters 8; collection of
a 2
y Hill coefficient
0 parameter to be estimated
a 2 variance of e
co2 variance of r\
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SUMMARY
In spite of being in use for more than 50 years, the pharmacokinetics of gentamicin still 
remain controversial. Advances in analytical techniques during the 70s made it possible 
to identify a long elimination phase of gentamicin. At that time several studies were 
published documenting accumulation of gentamicin for a long period of time and the 
inadequacy of a mono-exponential decline model to describe the elimination phase.
Since then, several studies investigating the pharmacokinetics of gentamicin have been 
carried out. These studies involved either a general patient population or specific 
subgroups of the patient population. It is only in the last decade that the first report 
documenting an increased volume of distribution in patients with cancer was published. 
To date only eight studies have been performed to investigate the volume of distribution 
of gentamicin. They have all used a mono-exponential decline model and the 
parameters were estimated either by a Bayesian technique, by the Sawchuck-Zaske 
method or by the non-parametric expectation maximization (NPEM) algorithm. The 
nonlinear mixed effects approach has never been employed to characterize the 
population pharmacokinetics of gentamicin. Most of these studies enrolled a small 
number of patients and the results obtained were compared with values assumed for the 
rest of population. A matched control group was used in only a few studies. Therefore 
the conclusion drawn by these investigators was contradictory. In this thesis the 
population pharmacokinetics of gentamicin were investigated in patients with cancer 
using a nonlinear mixed effects approach (NONMEM) using data collected from routine 
therapeutic drug monitoring.
The data were best fit with a bi-exponential disposition model with a combined residual 
error structure. Several covariates were examined for a possible influence on the 
pharmacokinetics of gentamicin. The best covariate model related clearance to 
estimates of creatinine clearance (minimum creatinine value 60 pmol L'1) and volume of 
the central compartment to body surface area and albumin concentration.
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Since gentamicin is mainly eliminated by glomerular filtration, creatinine clearance 
estimates are often used to determine initial doses of gentamicin. However, there are 
limitations to the value of creatinine concentration as a measure of renal function. 
Disease states that affect the normal production of creatinine will yield estimates of 
creatinine clearance that do not represent the renal function of the patient, putting 
patients at risk of overdosing and toxicity. Several strategies have been proposed in the 
literature to overcome this problem. In this study the influence of low creatinine 
concentration by deriving three new covariates corresponding to three different 
minimum creatinine values of 60, 70 and 88.4 pmol L'1 was investigated. In this study 
it was found that setting concentrations less than or equal to 60 pmol L 1 to 60 pmol L‘ 
]or concentrations less than or equal to 70 pmol L 1 to 70 pmol L 1 was superior to using 
either actual creatinine concentration or minimum value of 88.4 pmol L 1.
The usefulness of linear regression as a complementary technique in the covariate model 
building process was evaluated. It performed well when the relationship between 
individual parameter estimates and covariate was close to a straight line.
The best model obtained in the population analysis was then used to simulate 
concentration-time profiles in two simulated “patients” with different clinical 
characteristics according to two published nomograms: one that used a ‘once daily’ 
regimen and one based on traditional target ranges. In the context of published 
nomograms this analysis indicated that both nomograms achieve satisfactory 
concentrations in cancer patients. These results confirm the wide interpatient variability 
in aminoglycoside pharmacokinetics and the need for dosage optimisation of this drug.
Mibefradil is a new calcium antagonist used for the treatment of hypertension. Several 
studies have been published comparing the efficacy and tolerability of mibefradil with 
other calcium antagonists. However, comparative studies between mibefradil and slow 
release formulations of verapamil and diltiazem were lacking. This analysis was carried 
out aiming to characterise the pharmacokinetics and pharmacodynamics of mibefradil 
relative to verapamil and diltiazem after a single dose and also to characterise the
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concentration-effect relationships of single and multiple doses of mibefradil and 
verapamil in hypertensive patients. Data collected during a phase II clinical trial from 
patients with mild to moderate hypertension were used in this analysis. 
Pharmacodynamic endpoints were changes in diastolic blood pressure, heart rate and PQ 
prolongation.
An Emax pharmacokinetic/pharmacodynamic model best described the concentration- 
effect relationship for diastolic blood pressure (DBP) and heart rate (HR) for the three 
drugs whereas a linear model was used for PQ prolongation.
For mibefradil, as far as DBP is concerning, the concentration-effect relationships were 
best described by an Emax model for some patients and a linear model for other 
patients, rendering the comparison impossible. This was caused by the fact that drug 
concentrations were not high enough to fully characterise the Emax model. The 
parameters were poorly estimated. An investigator recently proposed a solution to this 
problem which consisted of introducing a new parameter (SO equal to Emax/EC50) that 
could be used to evaluate the potency of a drug even when the maximal effect was not 
attained. In this thesis, the parameterisation mentioned above was applied and the 
results obtained were compared with those from the Emax model using a standard 
parameterisation.
Mibefradil produced sustained effects on blood pressure and heart rate. Diltiazem 
produced a greater effect on blood pressure and a similar effect on heart rate. The effect 
of verapamil on blood pressure was similar to diltiazem. However, the effect on heart 
rate was more pronounced. At steady state, both mibefradil and verapamil produced 
antihypertensive responses consistent with those characterised after the first dose. For 
mibefradil the effect on heart rate was also consistent. In both the single, and multiple 
dose studies, mibefradil showed the weakest effect on PQ prolongation compared with 
diltiazem and verapamil. For all three calcium antagonist drugs there were close and 
reproducible relationships between plasma drug concentrations and the effects on blood 
pressure, heart rate and PQ interval. Important differential effects were observed
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between the compounds, which should be of value in determining optimal dosage 
regimens.
There are several ways of combining pharmacokinetic and pharmacodynamic 
information during the modelling process. The pharmacokinetic and pharmacodynamic 
data as well as the link between them can either be modelled separately or 
simultaneously. The data may be analysed sequentially; the pharmacokinetic model is 
first described and the results from that can be included in the pharmacodynamic 
analysis. Alternatively, the data may be analysed simultaneously. In the present 
analyses, the data sets used in Chapter 3, were collected after the administration of 150 
mg of mibefradil as a single dose. The data were analysed in four different ways 1) 
pharmacokinetic data were fitted and then the population pharmacokinetic parameters 
were fixed during the pharmacodynamic data fitting, only pharmacodynamic 
measurements were included in the data set. 2) pharmacokinetic data were fitted and 
then the population pharmacokinetic parameters were fixed during the 
pharmacodynamic data fitting, using a full data set. 3) pharmacokinetic and 
pharmacodynamic data were analysed simultaneously. 4) individual predicted 
concentrations from the pharmacokinetic analysis were used as independent variable in 
the pharmacodynamic analysis. Since in most cases the pharmacokinetic model is better 
known than the pharmacodynamic model, a subsequent, stepwise modelling approach is 
often preferred, avoiding pitfalls due to poor pharmacodynamic data or a wrong model 
selection. It was concluded that the pharmacokinetic data should be left in the data set 
while estimating pharmacodynamic parameters.
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CHAPTER 1 INTRODUCTION
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1.1 SUMMARY
First an overview of the reason for modelling is given. Particular emphasis is given to 
the role of modelling in clinical pharmacology. Differences in the various analytical 
approaches are highlighted as they were applied in the thesis. Finally, technical 
concepts used in the analyses presented in the thesis are reviewed.
1.2 OUTLINE OF THE THESIS
The aim of this thesis is to apply different techniques to pharmacokinetic- 
pharmacodynamic modelling.
The advantages and disadvantages of applying these techniques are explored through 
application to different types of data. In Chapter 2 the nonlinear mixed effects approach 
is applied to a sparse data set obtained from therapeutic drug monitoring. In Chapter 3, 
the standard two-stage approach is used to analyse rich data obtained from Phase II 
clinical trials of the development of a new compound. Finally, in Chapter 4 different 
methods of combining pharmacokinetic and pharmacodynamic data are explored and 
the results are compared.
The conclusions from all the chapters are presented in Chapter 5.
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1.3 MODELLING METHODOLOGY
The reasons for modelling have been discussed from a philosophical point of view by 
Boxenbaum (1992). Biological processes are very complex and difficult to understand. 
Complications arising from the analyses of biological data from pharmacokinetic and 
metabolism studies have also been recognised. To overcome the problem, one can 
represent the system being analysed by a model. Models provide a conceptual 
framework for phenomena by taking into account the structural and operational 
characteristics of the system. Nonetheless, models that completely explain and predict 
the process are complex and limited in their applications. One way to approach the 
problem is to simplify the process by assuming that the model is a representation and 
typifies a class of similar systems. From that perspective the overall function of a model 
is to assist in characterising and explaining phenomena.
During pharmacokinetic and/or pharmacodynamic studies, an enormous amount of data 
may be generated. Mathematical models are then used to extract information and the 
results are summarised by the parameters estimated from fitting the model to the data. 
The model parameter functions as a measure of comparison of results both within and 
between experiments. Mathematical modelling can also help in exploring the 
mechanism involved in the process. The modelling process can lead to an empirical 
representation and from this empirical representation a theoretical basis can be 
developed to explain the observations. Once a model is selected and parameter values 
estimated, it can be used to make predictions. In conclusion, the ultimate goal of 
pharmacokinetic and pharmacodynamic modelling is to learn something about the 
parameters of the study population so as to allow generalisation of results to the wider 
population, or to predict alternative scenarios such as the effect of different dosage 
regimens.
1.3.1 MODELLING APPLICATIONS IN CLINICAL PHARMACOLOGY
The use of population pharmacokinetic/pharmacodynamic models has been an object of
researchers’ attention over the last decades, and has been discussed in detail in the
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literature. Applications include the development of dosing recommendations, the 
optimisation of dosage adjustments, drug regulatory agency submissions, and guidance 
for future research.
Academic research is the driving force in this field and two main areas benefit from 
those applications and they are: therapeutic drug monitoring in hospitals and drug 
development in industry.
1.3.1.1 Optimisation of Dosage Regimens
The establishment of appropriate dosage regimens has attracted the attention of 
investigators for many years. Theoretically, dosage regimens for drugs with a low 
therapeutic index should be determined from the pharmacokinetic and 
pharmacodynamic parameters for each individual. This implies that for these drugs a 
complete concentration-time profile should be available for each patient when selecting 
a dosage regimen. A full pharmacokinetic profile involves obtaining several blood 
samples, which would be both costly and cumbersome for the patient and impractical to 
carry out in routine patient care.
In the literature, different approaches have been proposed to establishing ideal dosage 
regimens. Initially, individual pharmacokinetic parameters estimated from a specific 
population were used to relate pharmacokinetic parameters such as clearance to patient 
characteristics such as age and sex. These relationships were used to develop 
nomograms (Siersbaek-Nielsen et al., 1971; Chan et al., 1972; Cockcroft and Gault, 
1976). The selection of a maintenance dosage regimen for an individual patient based 
on nomograms gained popularity as it reduced the chances of overdosing or underdosing 
patients. The limitations of this approach are that the relationship between the 
physiological and pharmacokinetic parameters may differ widely among individuals and 
that the approach does not make use of pharmacokinetic information directly obtained 
from an individual patient. Another aspect to note is that, in many cases, the 
nomograms were obtained from classic pharmacokinetic studies of small, relatively 
homogeneous groups of volunteers or patients who were not representative of the whole
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patient population. The extrapolation of such results to different patient populations is 
not recommended.
Other methods have been proposed to select more accurately the dosage regimen for an 
individual patient. For example, Sawchuk et al. (1977) suggested using 3 measured 
concentrations of gentamicin per patient. However, although this approach served well 
for gentamicin, it is not generally applicable to a wide variety of drugs. Another 
approach, described by Slattery, was to adjust dosage on the basis of a single test dose. 
This ‘one point method’ gave a maintenance dose to achieve a desired trough 
concentration at steady state (Slattery, 1980). The method did not aid in the selection of 
the first dose and dosing interval, which had to be obtained from a nomogram. Chiou et 
al. (1978) proposed the estimation of theophylline clearance based on two drug 
concentrations. One advantage of this method was that it only requires minimal 
pharmacokinetic information and it selected the safe and effective dose early in the 
course of treatment.
The generalised use of computers on the one hand and the development of reliable drug 
assays on the other have helped in the application of feedback control methods in 
clinical pharmacokinetics. A detailed description of the concept for drug dosage 
optimisation was presented by Vozeh et al. (1985). Technological advances have also 
led to the development of nonlinear least squares regression programs (Peck and Barret, 
1979). One of the most widely used methods for dosage optimisation is the Bayesian 
algorithm. The Bayesian algorithm allows the combination of population 
pharmacokinetic information as ‘a priori’ information with patient drug concentration 
information to determine individual dosage regimens. Ideally, the information to be 
used as ‘a priori’ for dosage recommendations should be derived from data collected 
from the patient population (Sheiner et al., 1979b) who will receive the drug treatment. 
Several Bayesian software packages have been developed (Sheiner et al., 1979b; Peck et 
al., 1980; Kelman et al., 1982; Sheiner and Beal, 1982) and a review of commonly used 
dosing methods has been published (Burton et al., 1985).
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With the advent of these techniques, the pharmacokinetic information from a specific 
patient was no longer the object of interest as far as dosage recommendation is 
concerned. The knowledge of mean values and variances of the parameters of a specific 
patient population became the main aim of research. Therefore an alternative approach 
to population pharmacokinetic data analysis was implemented: that of the nonlinear 
mixed effect model (Sheiner et al., 1977; Sheiner and Grasela, 1984).
1.3.1.2 Drug Development
The implemention of population pharmacokinetic/pharmacodynamic modelling to drug 
development was first advocated by Sheiner & Benet (1985) but it was only in 1991 that 
a conference was held to discuss the topic (Peck et al., 1992). During this conference 
the integration and roles of pharmacokinetics, pharmacodynamics and toxicokinetics in 
rational drug development were identified and discussed. Since then the topic has 
expanded. The European Commission, through the COST B1 project, supported the 
realization of two important meetings, the first in 1992 and the second in 1997, and 
several conferences of experts in the field. The FDA has also encouraged the 
implementation of the population approach during drug development by producing 
guidance documents on the topic (Sun et al., 1999).
The application of pharmacokinetic and pharmacodynamic principles in drug 
development can be seen as tools for scientific and strategic decision making. Ideally, 
the application of the approach should start in phase I, tolerability trials. It should 
continue with PK/PD investigations in phase II to provide guidance on dose selection to 
be used in subsequent clinical trials. In addition, in phase n, a full pharmacokinetic 
screen is a potential alternative to detect possible clinically relevant drug-drug 
interactions and to study the drug in sub-groups of patients.
PK/PD modelling from phase 13 and phase IE studies has been sucessfully applied 
during drug development using the population approach (Vozeh et al., 1996). Some 
examples showing the merits of PK/PD modelling in drug development have been 
published (Reigner et al., 1997). The population approach can be a valuable
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complement to conventional approaches for collection of PK/PD data for assessment of 
efficacy and tolerability in relation to drug plasma concentration and to help in the 
selection of drug dosage in the target population, including special sub-groups. Today, 
most pharmaceutical companies, to different extents, are using this approach during 
development of drugs in a wide variety of therapeutic areas.
1.3.2 STUDY DESIGN
One of the points to consider when implementing any clinical trial is the selection of 
appropriate subjects to be included in the study. Ideally, the population who will need 
the drug should be included in the trials. Conducting pharmacokinetic studies only in 
‘healthy volunteers’ or ‘selected patients’ excludes special patient populations, such as 
geriatric, paediatric and critically ill patients from being investigated. Since the 
collection of data from such patients by conventional methods gives rise to ethical 
questions, the use of sparse information obtained during the routine care of patients was 
advocated (Sheiner, 1984). Data collected during routine care comprises few data per 
individual and therefore traditional methods of data analysis cannot be applied. 
Difficulties encountered in the analysis of these data motivated investigators to 
implement an alternative approach using a nonlinear mixed effect model (Sheiner et al., 
1977).
These type of data are characterised by having few design restrictions and are collected 
at a wide range of times and under a variety of circumstances. This contrasts with 
experimental data in which sampling times are fixed and all subjects are handled in 
exactly the same manner. A major criticism of using observational data is the 
uncertainty of conclusions drawn from such data. Firstly there is a lack of balance, 
resulting from different numbers of data points in different individuals. Usually it is the 
more critically ill patients who have more samples collected. Secondly, the sparseness 
of data may present a problem as very few data points are obtained from each 
individual.
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1.4 NONLINEAR REGRESSION MODELLING
1.4.1 GENERAL MODEL
The pharmacokinetic/pharmacodynamic modelling process can be represented by a 
general function. Considering all individuals, i = 1, ..., N, each individual will have nj 
observations. The general model can then be represented by:
dosing history and covariates. © represents the mean parameter estimates. r|i represents 
the ith individual vector of r| where r\ are the values of the interindividual variability, 
and 8jj is diference between the measured and model predicted observations.
1.4.2 ESTIMATION ALGORITHMS
Nonlinear regression involves parameter estimation. The parameters are estimated 
based on a mathematical criterion. The best known is the least squares estimation. The 
least squares objective function is based on minimising the sum of squared differences 
between the measured and model predicted responses.
1.4.2.1 Ordinary Least Squares (OLS)
The ordinary least squares method computes the model parameters at a value that 
minimises the sum of the squared deviations from the measured (Yy) and model
predicted Y y responses. The least squares objective function (O q ls )  is given by:
Y ij  -  M i  ( 0 ,  T |j, Bjj) Eq. 1.1
where Yy denotes the vector of observations for individual ith at time j. Mi includes the
N n
Eq. 1.2
i=lj=l
where n is the number of observations. Ordinary least squares estimates assume that 
that all errors have the same magnitude. Inspection of the plots of residuals (measured-
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chosen by the analyst but estimated by the method. ELS is a generalisation of WLS and 
it is reduced to ordinary least squares when the variance is 1.
The performance of ELS has been evaluated and compared with the other minimisation 
methods. Some investigators concluded that ELS estimates the parameters with greater 
accuracy and precision than WLS (Peck et al., 1984). However, Metzler (1987) and van 
Houwelingen (1988) did not find the ELS method superior to the other methods but 
found that the IRLS method was almost always better than WLS. They did not 
recommend the routine use of ELS.
1.4.3 METHODS TO ESTIMATE POPULATION PARAMETERS 
Population parameter estimation can be carried out by a number of different methods. 
All the methods are associated with a minimisation of a least squares objective function 
as a fitting criterion.
1.4.3.1 Standard Two-Stage (STS)
The standard two-stage approach proceeds in two steps. First, the data from each 
individual is analysed and the individual parameters estimated, then the individual 
parameter values are combined to derive the population parameters. For example, the 
mean can be calculated as follows:
where 0 is the estimate of the population mean vector of parameters, 0j are estimates 
of the individual pharmacokinetic or pharmacodynamic parameters and N represents the 
number of individuals. The final stage of STS can also include the analysis of 
dependencies between parameters and covariates using classical statistical approaches 
(linear stepwise regression, cluster analysis, covariance analysis). The interindividual 
variability is given by the standard deviation of the individual values.
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Studies carried out on simulated data concluded that STS yielded good estimates of 
mean parameter values and residual variability but imprecise estimates of 
interindividual variability (Sheiner and Beal, 1980; Sheiner and Beal, 1981; Sheiner, 
1984). STS performs well provided the residual error is low (Sheiner and Beal, 1983).
1.4.3.2 Naive Pooled Data (NPD)
The data from all individuals are pooled as if they all came from one individual and was 
analysed simultaneously. The ordinary least squares objective function with respect to 
the parameters is described as follows:
and Yy is the model predicted measurement. N represents the number of individuals
and n the number of data points for each individual. The least squares function is 
minimised with respect to parameters.
The NPD has the advantage that it can deal easily with non-standardised data, i.e. 
different number of data points per individual, and data sets with few data points can be 
used. It is easy and fast to perform as all the parameters are estimated in one fitting. 
However, it is associated with some drawbacks. This approach fails to recognise that 
the information arises from different individuals and consequently it does not estimate 
the random inter and intraindividual variability. It performs well when the variability 
between subjects is small but its use has been discouraged (Sheiner, 1984). Studies on 
simulated data indicate that this approach produces imprecise estimates of mean 
kinetics, either with sparse data (Sheiner and Beal, 1980) or experimental data (Sheiner 
and Beal, 1981). That contrasts with the conclusions of others investigators, who 
recommended its use (Egan et al., 1993; Kataria et al., 1994).
N n
Eq. 1.6
where Yy represents the measured response for the ith individual at the jth time data point
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1.4.3.3 Nonlinear Mixed Effects
In the nonlinear mixed effects method, as with NPD, the data from all individuals are 
analysed at once. In contrast to NPD, the information from each individual is explicitly 
kept and the interindividual random effects are taken into account. Nonlinear mixed 
effects uses information from each individual to estimate typical values for the 
population.
An advantage of the mixed effect model technique is that it uses data pooled from 
several different studies. Because a mixed effect model allows a different magnitude of 
residual error variance to be estimated for the data from different sources, they can be 
combined appropriately to estimate their common structural model parameters.
The first algorithm proposed for estimation of population parameters in a nonlinear 
mixed effect model was the First Order method (Sheiner et al., 1977) implemented in 
the NONMEM software. The nonlinear mixed effect model has been implemented in 
different maximum likelihood algorithms, available through several software packages. 
Parametric maximum likelihood methods are implemented in software such as 
NONMEM, in NLME (Pinheiro and Bates, 1989), expectation maximization (EM) and 
in P-Pharm (Gomeni et al., 1994). Non-parametric approaches are implemented in non- 
parametric maximum likelihood (NPML) (Steimer et al., 1985; Mallet, 1986) and non- 
parametric expectation maximization (NPEM) (Schumitzky, 1991). The semi- or 
smooth non-parametric approach was implemented by Davidian and collaborators, in 
NLMIX (Davidian and Gallant, 1992; Davidian, 1993). The Bayesian approach to 
estimate population pharmacokinetic modelling was available in the POPKAN software 
package (Wakefield and Racine-Poon, 1995). POPKAN uses a Gibbs sampler 
technique to estimate parameters. A paper reporting a study designed to compare the 
estimates of seven population pharmacokinetic modelling methods discusses the validity 
of some of the methods (Roe, 1997) and demonstrated that NONMEM yielded 
satisfactory results compared to other methods.
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1.4.3.4 Comparison of Methods to Estimate Population Parameters
Several studies have reviewed these approaches to the estimation of population 
parameters (Sheiner and Beal, 1980; Sheiner and Beal, 1981; Sheiner and Beal, 1983; 
Steimer et al., 1984; Hashimoto and Sheiner, 1991). The standard two-stage approach 
can only be used if the number of observations per individual is sufficiently large (rich- 
data) to allow an estimation of individual parameters. From a theoretical point of view, 
the STS population parameter estimates should agree well with the true value provided 
the study is well designed and performed. However the interindividual variability 
estimates are expected to be biased upward. This is because the standard deviations 
include not only the true biological interindividual variability but also the variability due 
to imprecision in the individual parameter estimation. Improved methods have been 
proposed that take into account imprecision in parameter estimates. Steimer and 
collaborators implemented a global two-stage approach and the iterated two-stage 
approach (Steimer et al., 1984). Another improved method is the Bayesian two-stage 
proposed by Racine-Poon (1985). In a study to compare the performance of the STS 
approach with NONMEM in the analysis of simulated data, Sheiner and Beal (1981) 
found that both approaches yielded acceptable (nonbiased and precise) estimates for the 
fixed effect parameters. The same conclusion, however, cannot be made with regard to 
the estimates of interindividual variability. In the same study, Sheiner and Beal found 
that the STS approach systematically overestimated these parameters. This error 
accounts for the residual error and interindividual variability and therefore adds 
variability to the parameter estimates that is not biological in origin, resulting in an 
upward-biased estimate of interindividual variability. NONMEM estimates of 
interindividual variability tend to be more reliable because they are not contaminated 
with the error involved in the estimation of individual parameters. Although NONMEM 
estimates of these parameters have been shown to be relatively unbiased, they become 
increasingly imprecise as the number of subjects decreases.
1.4.4 NONMEM - NONLINEAR MIXED EFFECTS
The best-documented and most widely used method of parameter estimation is the
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nonlinear mixed-effects model proposed by Sheiner and Beal (1992) and implemented 
in the software package NONMEM. NONMEM is a Fortran 77 software most 
extensively used for mixed effect modelling and is the acronym of Nonlinear Mixed 
Effects Model. NONMEM minimises the extended least squares objective function 
from Equation 1.4, which, under Gaussian conditions, provides maximum likelihood 
estimates.
1.4.4.1 First-Order Method
In certain cases, the extended least squares method has difficulties in computing Yj and
the var ( Yj) rendering the minimisation of the objective function impossible. To 
overcame this problem an approximation of this method is used, the first-order method 
(FO). The FO method is the default algorithm in NONMEM. It consists of a 
linearization of the ELS equation through a first-order Taylor series expansion around 
zero, the expected values of the rj’s and s’ (Beal and Sheiner, 1992). The first-order 
estimation method produces estimates of the typical population parameters O, Q, and £  
but it does not produce estimates of the individual random interindividual effects, r|i.. 
During the search for the best parameter combination, all subjects have the same 
parameter values. However, r|j can be estimated after the population parameters have 
been obtained.
Beal investigated the effect of the approximation involved in the first-order method on 
parameter estimates and he acknowledged that linearization can affect the accuracy of 
the estimates. However, where accuracy was affected, this was by not more than 10 per 
cent (Beal, 1984). In this study, the STS was also compared with the FO method and it 
was concluded that the STS method performed poorly when there are just a few 
observations per individual but behaves as well as the FO method when there are as 
many as seven observations per individual.
1.4.4.2 First-Order Conditional Estimation Method
Version IV of NONMEM (Beal and Sheiner, 1992) incorporated the First-Order
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Conditional Estimation method (FOCE) first investigated by Lindstrom & Bates (1990). 
The difference between these methods and the FO method lies in the way the 
linearization is done. The FOCE method uses a first order Taylor series expansion 
around the conditional estimates of rjs. This is done in an iterative way: first, equation 
1.4 is fitted to the data using the conditional rj’s based on the current value of 0, £2 and 
X and second, new conditional estimates are calculated using the updated 0, Q  and X. 
The parameter values r\ are calculated for each individual during each step of the 
parameter search. The FOCE method produces estimates of the population parameters 
and, simultaneously, estimates of the random interindividual effects.
1.4.5 ERROR MODELS
Two types of error models can be defined under the nonlinear mixed effects approach. 
One type, the residual error model, accounts for the difference between the measured 
observation and that predicted by the model. The second type of error model, the 
interindividual error model, accounts for differences between individuals.
1.4.5.1 Residual Error Models
In the general model, as described by equation Eq.1.1, (Yy = M j (©, r\i, By)), © can 
include the estimated model’s parameters and the fixed effects. This can be represented 
by the following mathematical expressions:
Yy = / (Pi, Xy, Bij) Eq. 1.7
where Yjj represents the jth observation for the ith individual,^ ) is a vector-function 
that represents the structural model (PK or PD) and relates the independent variables, Xij 
(e.g. time and dose) to the response given the vector of model parameters of the ith 
individual Pj. By is the residual error and accounts for the errors due to the assay, model 
misspecification and intraindividual variability. Bij are assumed to be independently 
symmetrically distributed around zero and with variance a 2.
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The residual error can be modelled by several mathematical expressions. Under the 
NONMEM nomenclature, F represents Y ij, and EPS is the £jj. Examples of residual 
error models are:
Additive error model
Y=F+EPS (1) Eq. 1.8
the variability, a  is constant, expressed as a SD.
Proportional error model
Y=F*(1+EPS (1)) Eq. 1.9
the variability, a  is proportional to the Y jj, expressed as % CV.
Exponential error model
Y=F*EXP(EPS (1)) Eq. 1.10
The FO method does not distinguish the exponential and the proportional model.
These models can be combined in more complex structures such as:
Y=F*(1+EPS (1)) + EPS (2) Eq. 1.11
Y=F* EXP (EPS (1)) + EPS (2) Eq. 1.12
where EPS(l) and EPS (2) represent two independent errors, Ejji E^- The combined 
error model has some advantages as it allows the expression of two models within the 
same model. This produces a variance at the lower limit of the assay that tends towards 
an additive error structure and at high concentrations tends towards a proportional
(exponential) structure. From these model structures two independent variances a  add 
~ 2 2and Yjj a exp are estimated. The additive component of the error is expressed as a SD
whereas the proportional component of the error is expressed as %CV. In NONMEM, 
the variance and covariance for the e ’^s are estimated as a block matrix (X).
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1.4.5.2 Interindividual Variability Error Model
Pi, the vector of the individual parameters, is distributed around the typical values (TV), 
0k. These relationships can be described by the equation:
Pi = 0k, + ilki representing the interindividual error Eq. 1.13
where T]ki is the difference between the typical values and the individual parameters. 
The r|ki are assumed to arise from a Gaussian distribution, independent and identically 
distributed (i.i.d.) with mean zero and variance-covariance matrix, co .
For each parameter, several interindividual error models can be used under the 
NONMEM terminology. For example:
Additive
CL = TVCL + ETA (1) Eq. 1.14
Where CL represents the individual parameter, and TVCL is the typical value. ETA 
represents r|.
Proportional
CL = TVCL * (1+ ETA (1)) Eq.1.15
Exponential
CL = TVCL * EXP (ETA(l)) Eq.1.16
The FO model does not distinguish between proportional and exponential models.
1.4.6 BAYESIAN ESTIMATES
Information about the distribution of the parameters in a population can be used to 
determine the most likely set of pharmacokinetic parameters for an individual by 
applying Bayes’ theorem. The Bayesian technique merges the pre-existing population
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information (mean and variances) of pharmacokinetic parameters with the measured 
plasma concentrations from an individual. Population parameters are estimated by 
setting to 0 the interindividual random effects (r] set at 0). This information is used as 
‘a priori’ information for the Bayesian technique to calculate the individual 
pharmacokinetic parameters, also called ‘POSTHOC estimates’. The extended least 
square objective function is minimised with respect to the interindividual random effects 
parameters (r|) in the estimation of the posterior POSTHOC estimates of the parameters.
The relative contributions of the individual and population data depend on how much 
information is supplied by the individual and the magnitude of the interindividual 
variability. If an individual has a large number of accurate data points the empirical 
POSTHOC estimates for that individual will mainly be determined by that individual 
alone. The information from population parameters will predominate if the individual 
only has a few data points.
1.4.7 MODEL SELECTION
Model selection in NONMEM analyses has been based on several criteria. The 
difference in objective function value (AOFV) obtained when two hierarchical models 
are fitted to the same data set has been used as a criterion to compare the two models 
when one model is a sub-model from the other. A sub-model is defined as a model that 
is identical to the full model except that one or more parameters of the latter are set to a 
fixed value. AOFV is minus twice the difference in the log likelihood (-2 log 
likelihood) of the two models, each likelihood evaluated at its maximum. Minimisation 
of the objective function is equivalent to maximising the probability of the data. The 
AOFV is asymptotically distributed as % , with degrees of freedom equal to the number 
of parameters of the full model that are fixed in the reduced model. If the difference in 
log likelihood exceeds the critical value, the reduced model can be rejected in favour of 
the full one at whatever p value was used (Sheiner et al., 1977).
The magnitude of the standard error (SE) of the parameter estimates denotes the
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confidence in the parameter estimates and can give an indication about the goodness of 
fit.
Analysis of residuals is designed to test the adequacy of a model and check assumptions 
made during non-linear regression analysis. Residuals are assumed to be independent, 
with a zero mean, constant variance, and to follow a normal distribution. If the 
assumptions are verified, residuals and weighted residuals should be randomly 
distributed and scattered within a lower and upper horizontal band along the predicted 
values of dependent variable and time. A change in the sign of the residuals when 
displayed in time order is called a run. It can be determined whether runs arise at 
random or whether they are systematic. Systematic deviations are an indication of 
model misspecification (Boxenbaum et al., 1974).
Inspection of the plots is a very useful tool for model selection. Basic plots include the 
measured concentration against the model-predicted concentration based on the typical 
population parameters and on predictions based on the POSTHOC parameter estimates.
1.4.8 COVARIATES
The principal aims of the population pharmacokinetic and pharmacodynamic 
approaches are to estimate the typical values of the population parameters and to 
identify the factors (covariates) that have an influence on PK/PD parameters. Models 
try to minimise the extent of unexplained variability present in the data by incorporating 
covariates. Covariates are factors such as patient characteristics (age, weight, height, 
and sex) or pathology (such as renal or hepatic impairment) or other factors that can 
influence drug disposition, such as concomitant drug therapy, smoking habits and 
alcohol intake.
The sequences of NONMEM runs which are necessary to determine relationships can 
become very complicated and time-consuming as the structural model becomes more 
complex and the number of covariates increases. The use of statistical techniques like 
linear regression and generalized additive modelling (GAM) and graphical examination
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outside NONMEM have been advocated to help in the identification of the structure of 
the relationships between covariates and parameter estimates. As regression analysis 
assumes that covariates are not correlated, the existence of collinearity that might 
influence the model building has to be excluded. Therefore an exploratory analysis 
should be performed on covariates to examine the distribution and correlation between 
covariates. The shape of the relationship between POSTHOC parameter estimates and 
covariates can be identified by mean of bivariate scatterplots. Plots of population 
residuals and weighted residuals (WRES) provide an indication as to whether a 
covariate should be included in the model.
Covariates can be incorporated in the model in a stepwise manner, one at a time, starting 
with the one with the strongest influence until the best model is obtained. Categorical 
covariates can be included as a “step model”. For each NONMEM analysis, the 
improvement in fit obtained by the addition of one covariate in the regression model can 
be assessed by the change in the objective function value. Following the forward 
inclusion of parameter-covariate relationships is a backward elimination process. In 
each step, each parameter-covariate relationship in the model is replaced by the next 
lower model. The least important, given that it is not significant, is dropped in favour of 
the simpler model. This continues until no more terms can be dropped.
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1.5 PHARMACOKINETIC AND PHARMACOLOGICAL RESPONSE 
RELATIONSHIPS
1.5.1 PHARMACOLOGICAL EFFECT
A pharmacological response is a result of the interaction between a drug molecule and a 
receptor. The pharmacological response is assumed to follow the law of mass action as 
long as the interaction between drug and receptor is reversible. The interaction between 
a single drug molecule and single binding site of the receptor causing a response (effect) 
can be represented by:
[Drug] + [Receptor] <-» [Drug-Receptor Complex] —> Response 
where the brackets represents molar concentrations.
The pharmacological response at the receptor site can be classified as:
i) Agonist -  the molecule interacts with the receptor and produces a maximal 
pharmacological response
ii) Partial agonist -  the drug interacts and produces a partial maximal effect
iii) Antagonist -  the drug inhibits the interaction of another compound with the 
receptor.
The triggering of a pharmacological response is a result of intricate mechanisms. 
Modelling techniques are applied to simplify, quantify and help in the understanding of 
the pharmacological response. Pharmacological response is combined with 
pharmacokinetics in pharmacokinetic/pharmacodynamic modelling and has been used to 
predict the time course of action of several drugs.
The pharmacokinetic properties of a drug and the dose determine the onset, intensity 
and duration of the effect. Increasing the dose causes an increase in the drug 
concentration at the receptor site leading to an increase in the effect up to a maximum 
effect. The half-life of a drug affects the duration of activity. A prolonged half-life
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causes the drug to remain longer in the body and thereby increasing the duration of 
effect. The drug action is also dependent on the fraction of the dose that reaches the 
receptor site. This process depends on the delivery rate of the drug. At the receptor site, 
the onset, duration and intensity of the pharmacological responses is controlled by 
concentration of the drug and its metabolites. By combining pharmacokinetics and 
pharmacodynamics, complex pharmacological responses have been described by 
pharmacodynamic models accounting for their onset, intensity and duration of action.
Once the pharmacodynamic models have been selected, it is possible to predict the time 
course of action obtained from different dosage regimens.
1.5.2 PHARMACODYNAMIC MODELS
Pharmacodynamic models correlate the time-course of pharmacological action with the 
concentration. These models are quite simple if the pharmacological effect of a drug is 
directly related to concentration (Holford and Sheiner, 1981).
1.5.2.1 Linear Model
The linear model assumes a direct proportionality between pharmacological effect and 
drug concentration. This relationship can be expressed as:
E = m * Y Eq. 1.17
where E is the effect measurement, m is a proportionality constant (the slope estimated 
by linear regression) and Y is the drug concentration.
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1.5.23 Sigmoidal Emax Model
For some drugs the relationship between concentration and effect has a sigmoidal shape, 
an S-shape instead of a hyperbolic shape as described above. Hill first applied this 
model to describe the association of oxygen with haemoglobin (1910). The sigmoidal 
model is represented by:
Emax * Y y
E = -----------------  Eq. 1.21
E C 50y+ Y y
where E denotes the effect, y is a factor, also known as the Hill coefficient, Emax is the 
maximal effect, Y is the drug concentration and EC50 represents the drug concentration 
that produces half of the maximal response. When y is 1 the Hill model reduces to the 
Langmuir Emax model. The Hill coefficient determines the degree of sigmodicity of the 
curve and thus the value of y influences the slope of the sigmoid curve.
PK/PD modelling was first developed in drugs with a reversible mechanism of action 
and with continuous effect data. Recently, these concepts have been successfully 
applied to drugs with an irreversible effect, like cancer chemotherapy (Jusko, 1971) as 
well as categorical or dichotomous responses, e.g. the analgesic effect of ketorolac 
(Mandema and Stanski, 1996).
1.5.3 PHARMACOKINETIC/PHARMACODYNAMIC MODELS 
The PK/PD models can be categorised by different aspects. One is classified by the way 
PK data relates to the PD data, the link model. Another way is to classify PD models is 
by the mechanism of action of the drug (response models). Also they can be classified 
if the PD parameters change with the time or not.
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1.5.3.1 Pharmacokinetic/Pharmacodynamic Link Models
a) Direct Link Models
Direct link models relate plasma concentrations in the central compartment to the 
pharmacological effect. In this case, the peak plasma concentration occurs at the same 
time as the peak effect. It is assumed that a rapid equilibrium between plasma 
concentration and concentration at the effect site is achieved under steady state as well 
as non steady-state conditions. The measured plasma concentrations serve as the 
independent variable in the PD model, as shown in Figure 1.4.3.a, panel A.
b) Indirect Link Models
The relationship between plasma concentration and effect can often show a delay that 
accounts for the time necessary to allow the equilibrium between concentrations in 
plasma and at the effect-site to be reached. This phenomenon is called hysteresis.
When effect is plotted against plasma concentration, and points are connected in time 
order, a counterclockwise loop profile may be observed as shown in Figure 1.4.3.b, 
upper panel. This is removed when concentrations at the effect-site are used to draw the 
plots (Figure 1.4.3.b, lower panel). The incorporation of a link model between the 
pharmacokinetic and pharmacodynamic models will help in describing the relationship. 
The link can be established either by predicting the concentration in a peripheral 
compartment, or by predicting the concentration at the effect-site, including a 
hypothetical effect-compartment as shown in Figure 1.4.3.a panel B. The use of steady- 
state plasma concentration, when the concentration at the effect site is presumed to be in 
equilibrium with plasma concentration, also removes hysteresis.
Initially, Segre (1968) and later Dahlstrom et al. (1978) proposed the incorporation of a 
hypothetical link model, “effect-compartment” to simultaneously characterise the 
pharmacokinetics and pharmacodynamics of a drug. The effect-compartment accounts 
for the time delay between pharmacological effect and plasma drug concentration and it 
is a link between the pharmacokinetic model and effect. Hull et al. (1978) proposed the 
addition of an effect-compartment linked to the plasma by a first-order process 
represented by a rate constant. keQ was estimated only with two time points (one time,
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Figure 1.4.3.a Schematic representation of the relationship between pharmacokinetic, 
link and pharmacodynamic models of a drug
Phar macokinet ics Pha rmaeod yna m ics
D
PD Model Effect
a  Direct Link
Pharm acokinetics Effect compartment Pharm acodynam ics
PD Model Effect
b Indirect Link
Key: D  represents D ose; C is the drug concentration at the central compartment; Cc is the concentration at the 
effect site
Figure 1.4.3.b Representation of the relationship between effect and plasma concentration 
in the presence of hysteresis (upper panel) and effect and concentration at the effect site 
(lower panel)
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during drug input and one later, as drug concentration was falling). With the estimated 
keo, the Ce was predicted for all time points to obtain a full concentration-response 
curve. No assumption regarding the pharmacodynamic model was made.
Sheiner et al. (1979a) further developed this approach and proposed using all data points 
to calculate ke0. A traditional pharmacokinetic model was used to describe the 
concentration-time data. The hypothetical compartment model is linked to the central 
compartment by a first-order rate constant (kie), in which the amount of drug transferred 
to the effect-compartment is negligible and therefore does not interfere with the 
properties of the pharmacokinetic model. The removal of the drug from the effect- 
compartment follows a first-order process, represented by the rate constant ke0. It is 
assumed that the drug lost from the effect-compartment does not return to the central 
compartment but rather leaves the body. The time delay between effect and plasma drug 
concentration is determined by ke0. The amount of drug in the effect compartment is 
given by the solution of the differential equation:
= k leA, -k e „ A e Eq. 1.22
dt
where Ae is the amount of drug in the effect-compartment, Ai represents the amount of 
drug in the central compartment, and kie and ke0 are the rate constants as described 
above. Pharmacodynamic models can be used to relate the pharmacologic effect to the 
hypothetical amount of drug in the effect-compartment.
Fuseau et al. (1984) proposed a variation of the approach proposed by Hull, which was a 
parametric pharmacodynamic model in which all the effect-time points were used to 
estimate ke0. This variation chose keo so that the two limbs of the Ce-effect curve were 
superimposed. Another approach was developed by Unadkat et al. (1986), where the 
pharmacokinetic model was approximated nonparametrically.
The PK and PD data as well as the link between them can either be modelled separately 
or simultaneously. Since in most cases the pharmacokinetic model is better understood 
than the PD model, a subsequent, stepwise modelling approach is often preferred. This
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avoids the pitfalls due to poor pharmacodynamic data or a wrong model selection.
1.5.3.2 Physiological Response Models
The Emax-type of models are empirical models and do not reflect the underlying 
physiological mechanism involved. Models using a mechanism-based approach offer an 
insight into the physiological process involved. The use of these types of model is 
increasing and has been advocated by Levy (1994). The physiological response models 
can be classified as direct response models or indirect response models. The effect of a 
drug can be a result of a direct relationship of the concentration at the effect site or 
might be an indirect effect that is secondary to one or several intermediate response 
steps, depending on the physiological mechanisms involved (Jusko and Ko, 1994). The 
link models discussed above are examples of direct response models. However when a 
delay in time between the peak concentration at the effect site and maximum drug effect 
occurs it can be described using an indirect response model, which results in a 
counterclockwise hysteresis for the observed response. The delay in time is not caused 
by a slow distribution but by an indirect response mechanism, such as stimulation or 
inhibition of a response variable.
1.5.3.3 Time Variant/ Time Invariant Models
PD models can also be classified according to the time dependency of their PD 
parameters.
a) Time Invariant Models
This type of model is characterised by the fact that the PD parameters stay constant over 
time. Most drugs follow this type of model, with changes in PD parameters related 
solely to the concentration at the effect site.
b) Time Variant Models
In some cases, the PD parameters, Emax and EC50, may change. This phenomenon is 
explained by the occurrence of tolerance or sensitization. Tolerance is a decrease in the 
response, caused by a decrease in the number of receptors or in the receptor affinity.
50
Tolerance causes a clockwise hysteresis loop for the concentration-effect relationship. 
Sensitisation is the increase in a response with time and results in a counterclockwise 
hysteresis.
Over the last years, pharmacokinetics has expanded from therapeutic drug monitoring 
services to a more complex PK/PD based dosage individualisation. The concepts of 
PK/PD modelling have been applied in clinical settings to provide a more rational basis 
for a specific patient individualised dosing regimen. In industry, the PK/PD based 
concepts can be applied as a decision making tools throughout all stages of drug 
development process leading to a reduction in the cost and time of the drug 
development.
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CHAPTER 2 POPULATION PHARMACOKINETICS OF 
GENTAMICIN IN CANCER PATIENTS
52
2.1 SUMMARY
This chapter describes an approach to characterising the pharmacokinetics of gentamicin 
in cancer patients. A population pharmacokinetic model was developed and evaluated 
and the clinical factors that influence clearance and volume were explored.
The ability of creatinine clearance, estimated by the Cockroft-Gault equation, to 
accurately predict gentamicin handling was investigated.
Finally, the performance of existing nomograms was evaluated in the light of the 
population model developed in this section. Concentration-time profiles for two 
simulated patients (with low and high clearance) were obtained by simulation, using the 
derived population model.
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2.2 INTRODUCTION
Gentamicin is an aminoglycoside antibiotic obtained from cultures of Actinomycetes 
micromonospora and has been in clinical use for over 30 years.
2.2.1 CHEMISTRY
Gentamicin consists of an aminocyclitol nucleus glycosidically linked to an amino 
sugar. 2-deoxystreptamine is the aminocyclitol nucleus of gentamicin, amikacin, 
kanamycin, neomycin, netilmicin and tobramycin
2.2.2 PHARMACOLOGY
2.2.2.1 Mechanism of Action
Gentamicin is a bactericidal antibiotic, and while important advances have been made in 
the understanding of the cellular mechanisms of its bactericidal action, the exact 
mechanism of action of gentamicin has not yet been fully elucidated. It appears to 
inhibit protein synthesis in susceptible bacteria by irreversible binding to the 30S 
ribosomal subunit, causing a disruption of protein synthesis eventually resulting in cell 
death. However, this mechanism does not completely explain the rapid bactericidal 
effect. The uptake of aminoglycosides into the bacterial cell is an irreversible, oxygen- 
dependent process. Aminoglycosides are therefore especially active against growing 
bacteria and practically inactive under anaerobic conditions (Janknegt, 1990).
2.2.2.2 Spectrum of Activity
Aminoglycosides have a broad spectrum of activity against gram-negative aerobic 
bacteria, including Acinectobacter, Citrobacter, Enterobacter, Eschirichia coli, 
Klebsiella, Proteus, Providencia, Pseudomonas, Salmonella, Serratia and Shigella. In 
vitro, susceptible organisms are generally inhibited by gentamicin concentrations of 1-8 
mg L'1. However, different species and different strains of the same species may exhibit
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wide variations in susceptibility. In addition, in vitro susceptibility does not always 
correlate with in vivo activity. Aminoglycosides have little activity against anaerobic 
bacteria. Some gram-positive bacteria are relatively resistant. However, gentamicin is 
active against Staphylococcus aureus and S. epidermidis. When used alone, it has only 
minimal activity against streptococci and most strains of enterococci, but it has a 
synergistic effect when used in combination with a penicillin or vancomycin (Janknegt, 
1990).
2.2.23 Toxicity
Ototoxicity and nephrotoxicity are the most serious adverse effects of the 
aminoglycosides. They are most likely to occur in geriatric or dehydrated patients, 
patients with renal impairment, patients who are receiving high doses or prolonged 
therapy, and patients who are receiving, or have received, other ototoxic and/or 
nephrotoxic drugs (Mattie et al., 1989).
The exact mechanism of aminoglycoside nephrotoxicity has not been fully characterised 
but several mechanisms have been proposed. Aminoglycosides are taken up into the 
cells lining the proximal tubule after they bind to cell membrane phospholipids. As a 
consequence of aminoglycoside digestion, some toxic enzymes are released into the 
cytoplasm of the cell causing cellular necrosis. Nephrotoxicity is usually a reversible 
phenomenon because the cells of the tubule have a regenerative capacity that completely 
restores the nephron activity. However, prolonged exposure to aminoglycosides causes 
loss of this regenerative capacity and leads to irreversible damage.
The occurrence of aminoglycoside nephrotoxicity has been reported to vary from 0.5 to 
63 per cent (Garrison et al., 1990). This wide range is largely due to the way 
nephrotoxicity has been characterised and to the different criteria used in the studies. 
Creatinine clearance or creatinine serum concentrations are often used to report 
nephrotoxicity. For example, an increase of 45 jttmol L'1 or 10 per cent over the baseline 
serum creatinine value is often used as an indicator or alternatively, a decrease in more 
than 50 per cent in the calculated creatinine clearance is also used. Aminoglycoside
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nephrotoxicity can also be detected by the presence of some endogenous substances in 
the urine. While such detection has the advantage of giving an indication of 
nephrotoxicity at an early stage of its development, the measurements are imprecise and 
non-specific and therefore they cannot be used as specific indicators of aminoglycoside- 
associated nephrotoxicity. Other drugs, such as amphotericin B, vancomycin, 
frusemide, cisplatin, and cyclosporin may potentiate aminoglycoside-induced 
nephrotoxicity (Garrison et al., 1990).
Ototoxicity is also associated with aminoglycoside usage. It is manifested as auditory 
and/or vestibular toxicity that affects the eighth cranial nerve. Tinnitus is usually a sign 
of ototoxicity although it can also occur without any clinical signs. Auditory toxicity is 
frequently reversible if detected early. Vertigo, dizziness, nausea, and nystagmus are 
usually manifestations of vestibular toxicity. This kind of toxicity is irreversible and 
markedly affects the everyday lifestyle of the patient, especially the elderly (Garrison et 
al., 1990).
The exact mechanism of ototoxicity is unclear. It is thought that prolonged exposure to 
high concentrations of aminoglycosides is responsible for the destruction of the hair 
cells in the organ of Corti (Wersall et al., 1969). The incidence of aminoglycoside 
ototoxicity is generally reported to range from 0.5 to 5 per cent. Depending on the 
sensitivity of the detection method, however, the incidence of toxicity can be up to 43 
per cent (Chan, 1989).
2.2.3 PHARMACOKINETICS
Traditionally, the disposition of gentamicin has been described by a one-compartment 
pharmacokinetic model, which assumes rapid distribution to the tissues (Wilson et al., 
1973; Regamey et al., 1973; Siber et al., 1975; Barza et al., 1975). These studies were 
based on concentration data collected between 0 and 10 hours after dosing.
Investigators who proposed a mono-exponential decline model probably did not collect 
data for long enough to characterise a late elimination phase and the limitations of the 
early bioassay methods prevented the detection of low concentrations.
It has been reported (Kaye et al., 1974; Barza et al., 1975) that there was considerable 
variability in serum concentrations following gentamicin administration. A study 
(Kahlmeter and Kamme, 1975) revealed the case of a patient with normal renal function 
who excreted gentamicin for 20 days after therapy had been discontinued. Later, other 
investigators (Schentag et al., 1977) reported a slow increase in sequential serum 
concentration peaks throughout the course of treatment even although no change was 
noted in renal function.
A progressive increase in concentrations, and the incomplete recovery of doses of the 
drug in the urine of patients with normal renal function (Kahlmeter and Kamme, 1975) 
are all incompatible with a mono-exponential elimination phase and indicate that 
gentamicin persists in serum and tissues for relatively long periods. In 1977, a two- 
compartment model was used to describe gentamicin elimination from the body 
(Schentag and Jusko, 1977a). They reported an initial decline phase followed by a 
second, slower phase, which corresponded to an average terminal half-life of 1 1 2  hours 
(range, 27-693 hours).
2.2.3.1 Absorption
Gentamicin, which is a highly polar molecule, is minimally absorbed from the 
gastrointestinal tract and penetration of the central nervous system is poor. It is rapidly 
absorbed following topical administration and it is rapidly and completely absorbed 
after intramuscular administration, reaching peak levels in 30 to 60 minutes. However, 
the rate of absorption is erratic and usually associated with a high variability in serum 
concentrations. Furthermore, absorption is reduced by decreased perfusion at the site of 
administration, as can occur in critically ill patients. Therefore, the intravenous route, 
either bolus or short infusion is recommended.
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22.3.2 Distribution
Gentamicin is primarily distributed in the extracellular fluid with a volume of 
distribution of 0.25 L kg' 1 (range 0.1-0.5 Lkg'1) which approximates to the extracellular 
compartment (Zaske, 1992). Due to poor lipid solubility, it distributes well in lean body 
tissues but the extent of the distribution in tissues varies enormously from patient to 
patient. Following administration, gentamicin is widely distributed into body fluids 
including ascitic, pericardial, peritoneal, pleural, synovial and abscess fluids. It diffuses 
poorly into the central nervous system and it is minimally protein bound.
A wide range of factors such as age, pyrexia (Pennington et al., 1975), body weight, 
anaemia, albumin (Davis et al., 1991), platelet count (Phillips et al., 1988) and disease 
states can influence the distribution of the aminoglycosides. Oncology and haematology 
patients have been reported to have higher volumes of distribution. However, these 
studies were undertaken either without a control group (Manny and Huston, 1986; Higa 
and Murray, 1987) and assuming a control value of 0.25 - 0.30 L kg' 1 or without 
reporting creatinine clearance or other renal function indices (Phillips et al., 1988).
Thus, it is difficult to assess whether or not a true difference in renal function could 
explain the differences in the pharmacokinetic parameters. Nevertheless, several 
mechanisms have been proposed to explain the apparent increase in the volume of 
distribution in cancer patients. Zeitany et al (1990) reported an increased volume of 
distribution of 0.40 L kg' 1 in patients with haematological malignacy compared to 0.27 
L kg _1 in the control group, but patients in the control group were matched only for age 
and gender. More recently Bertino et al. (1991) reported a volume of distribution of
0.34 or 0.35 L kg' 1 for haematology or oncology, respectively. These authors found no 
statistically significant differences from the control group. Table 2.2.3 summarises the 
results carried out to evaluate volume of distribution in oncology patients.
Studies using gentamicin indicate that febrile patients may have slightly lower serum 
gentamicin concentrations than afebrile patients (Pennington et al., 1975). However, the 
clinical importance of this effect is unclear (Zeitany et al., 1990).
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Serum gentamicin concentrations may also be lower and the elimination prolonged in 
patients with marked oedema or altered fluid distribution.
The disposition of gentamicin is described by an initial rapid phase, representing the 
distribution of gentamicin from the central to peripheral compartments, followed by an 
elimination phase. In the literature there are few data to document the duration of the 
initial distribution phase. It is common practice to administer gentamicin as a 30min 
intravenous infusion with peak serum concentrations obtained 30 minutes after the end 
of infusion. However, it was recently reported (Demczar et al., 1997) that distribution 
was not complete until approximately 30 minutes after the end of a 60 minute infusion 
with gentamicin. Previous studies (MacGowan et al., 1994) have also suggested that the 
distribution phase might not be complete by an hour after infusion.
2.2.33 Elimination
In adults with normal renal function, gentamicin is almost completely cleared 
unchanged from the body by glomerular filtration (GF). Only a small amount of drug 
undergoes renal tubular secretion. Very high concentrations are reached in urine: over 
40-97 per cent of a dose is normally excreted in the urine within 24 hours. There may 
also be biliary excretion when the GFR is low (Sande and Mandell, 1996). Current 
evidence indicates that gentamicin elimination follows a biphasic decline. In adults 
with normal renal function, the initial elimination phase is characterised by a half-life of 
2-3 hours. This contrasts with the terminal elimination phase associated with a half-life 
of 112 hours (Schentag and Jusko, 1977a). This slow elimination is caused by tissue 
accumulation and probably tissue binding. Despite its polarity, gentamicin is distributed 
into adipose tissue (Schwartz et al., 1978) and accumulates in body tissues where it is 
tightly bound intracellularly. It is then slowly released from these tissues. According to 
some authors, the complete recovery of the dose in urine requires approximately 1 0 - 2 0  
days in patients with normal renal function (Schentag and Jusko, 1977b).
Patients with impaired renal function have elevated serum concentrations and prolonged 
elimination half-lives. Gender has been reported to influence gentamicin elimination,
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but the clinical importance of this factor is a matter of debate (Zaske et al., 1982;
Phillips et al., 1988).
2.2.4 PHARMACODYNAMICS
The therapeutic effect of gentamicin results from a combination of several factors. It 
has been demonstrated (Moore et al., 1987) that there is a strong association between the 
clinical response and the ratio of the peak concentration to the minimal inhibitory 
concentration for the infecting organism.
Gentamicin also has a marked concentration-dependent bactericidal activity. In vitro 
data document more extensive and rapid bactericidal killing and continually increasing 
post-antibiotic effects with increasing aminoglycoside peak concentrations (Barriere, 
1988). This effect has practical consequences in the design of dosage regimens (Mattie 
et al., 1989).
Post-antibiotic effect (PAE) is a period of time after complete elimination of an 
antibiotic during which there is no growth of the organism. The mechanism by which 
the post-antibiotic effect occurs has not been completely clarified. It is thought to be the 
result of irreversible binding of the aminoglycoside to ribosomal subunits. The PAE of 
these agents for both gram-positive cocci and gram-negative bacilli is explained by this 
irreversible binding and the time needed to synthesize new proteins. Several factors 
influence the presence or duration of the PAE such as type of organism, type of 
antibiotic, concentration of antibiotic, duration of antibiotic exposure, and antibiotic 
combinations (Zhanel et al., 1991).
Recent studies suggest that antibiotic combinations have synergistic, additive, or 
indifferent effects on the duration of the PAE. A synergistic increase in the PAE of up 
to three hours was observed when Enterococcus faecalis was tested against penicillin G 
plus gentamicin. These data suggest that the combination of certain antibiotics can 
allow the choice of a different dosing regimen.
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It has been demonstrated that gentamicin shows adaptive resistance when in the 
presence of Pseudomonas aeruginosa. Adaptive resistance involves reversible down 
regulation of gentamicin uptake into bacteria. It develops within 1 or 2 hours of initial 
exposure to an aminoglycoside and persists for 6  to 7 hours during growth in a drug-free 
medium. Adaptive resistance increases with continous exposure to gentamicin (Daikos 
et al., 1990). The aminoglycosides have a biphasic rate of bactericidal action on aerobic 
gram-negative bacilli. The passive ionic binding of the drug to bacterial 
lipopolysacharide induces an initial phase of rapid bacterial killing. A second phase of 
slower bacterial killing is associated with decreased energy-dependent uptake of 
aminoglycoside, and the rate is independent of the initial or persistent drug level. Those 
bacteria that survive first exposure develop adaptive resistance, which is characterised 
by impermeability to aminoglycoside. Adaptive resistance is reversed during growth in 
drug-free media (Barclay et al., 1992).
2.2.5 DOSAGE REGIMENS
Information related to the effect of the drug should be incorporated in the design of 
dosage regimens. The target plasma concentration-time profiles should be based on the 
pharmacodynamic characteristics of the drug. The associations between a) serum 
concentrations of aminoglycoside and therapeutic outcome, b) bactericidal activity and 
clinical efficacy, and c) in vitro inhibitory concentrations and clinical outcome have all 
been well documented. Thus high serum concentrations should be obtained early in 
therapy (Moore et al., 1984). It has been suggested that data on adaptive resistance 
should be considered when selecting the most effective dosing regimen for therapeutic 
use (Klastersky et al., 1974; Mattie et al., 1989).
Application of pharmacokinetic techniques may help in the choice of an individual drug 
regimen for a target concentration-time profile. Dosage regimens should be based on 
patient-specific pharmacokinetic parameters. The identification of subgroups of 
populations with particular pharmacokinetic characteristics is useful in the design of 
initial dosage regimens and individual dosage adjustments can be made after obtaining 
the first set of concentration measurements.
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2.3 AIMS OF THE ANALYSIS
The aims of the analysis were:
i) To determine the population pharmacokinetic characteristics of gentamicin in
patients with cancer.
ii) To investigate the influence of clinical factors on the pharmacokinetics of
gentamicin.
iii) To investigate the influence of low creatinine concentrations on clearance
estimates.
iv) To examine the relevance of existing dosage nomograms in the light of the
population model developed in this particular patient population.
2.4 METHODS
2.4.1 PATIENTS
All patients with cancer, treated in the Beatson Oncology Centre, Western Infirmary in 
Glasgow, who received gentamicin and had at least one measured serum gentamicin 
concentration, were eligible for inclusion in the study. Patients on haemodialysis or 
continuous venovenous haemofiltration (CVVH) were excluded from the study. Data 
were collected prospectively from January 1993 to August 1996.
Gentamicin was administered intravenously either by a short infusion or bolus. The 
exact and complete dosing history as well as times of blood sampling were recorded as 
part of the routine drug monitoring using specialised recording charts. Dosage regimens 
were adjusted according to patients’ renal function (Cockcroft and Gault, 1976) to 
achieve a peak concentration (lhour post dose) of 8-12 mg L' 1 and trough less than 2 
m gL1. For each patient the following information was also collected: gender; weight; 
age; height; creatinine; urea; albumin; platelets; haemoglobin; white cell count; and
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temperature. Biochemical and haematological factors and temperature, were generally 
checked daily during therapy. Additional clinical factors such as ideal body weight, 
body surface area, body mass index and lean body mass, were determined using the 
equations shown in Table 2.4.1. Patients were classified as obese if the actual body 
weight exceeded the ideal body weight by 2 0 % and pyrexia was defined as a 
temperature equal to or above 38 °C. The measurement of creatinine concentration 
closest in time to each measured gentamicin concentration was used to estimate 
creatinine clearance. Patients with missing clinical, dosage or sampling data and 
patients with rapidly changing renal function were excluded from the study.
2.4.2 ASSAY
Gentamicin serum concentrations were analysed by fluorescence polarisation 
immunoassay (TDX, Abbott Laboratories) in the Microbiology Laboratory, Western 
Infirmary. The lower limit of detection of this method was 0.1 mg L"1 and the interassay 
coefficients of variation were 6.3% at 1 mg L"1, 3.7% at 4.0 mg L' 1 and 4.3% at 8  mg L'1.
2.4.3 DATA ANALYSIS
The analysis was performed with the population pharmacokinetic package NONMEM 
(Non Linear Mixed Effects Model), version IV, level 2 (Beal and Sheiner, 1992). Data 
such as: patient identification; date; time; dose (mg); infusion rate (mg h 1); duration of
64
Table 2.4.1 Equations used to derive clinical factors used in the analysis
CLINICAL
FACTOR
EQUATION REFERENCE
Creatinine 
clearance 
(ml min'1)
(140 - Age) * Ideal body weight (kg) 
Creatinine (|Limol L'1) 
Females * 1.04 and males * 1.23
(Cockcroft and 
Gault, 1976)
Ideal body weight 
(kg)
50 kg + 2.3 kg for every 1” > 5 ft for males; 
45.5 kg + 2.3 kg for every 1” > 5 ft for females.
(Devine, 1974)
Body surface area 
(m2)
71.84 * W t0 425 (kg) * Ht °'725(cm) (Du Bois and Du 
Bois, 1916)
Body mass index 
(kg m'2)
Wt (kg) / Ht2(m)
Lean body mass Males (1.1 * Wt) - (128 * Wt2(kg)/Ht2(cm)) 
Females (1.07 * Wt) - (148 * Wt2/Ht2)
(Hallynck et al., 
1981)
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infusion (min); concentration (mg L'1); age (years); sex; weight (kg); height (cm); ideal 
body weight (kg); creatinine concentration (jimol L'1); urea (mmol L'1); albumin (g L'1); 
white cell count (*109 L'1); haemoglobin (g dL'1); platelets (*109 L 1); temperature; 
obesity and lean body mass were entered into a spreadsheet package, Excel®, in the 
format required by NONMEM. Body surface area and body mass index were derived 
from NONMEM control files. FORTRAN subroutines were compiled using 
FORTRAN Power-Station® (version 1.0a, Microsoft Corporation). Both programs 
were implemented on an Opus personal computer with a Pentium processor.
The data file was investigated for possible errors or outliers. A control file was created 
using the “Checkout” option in NONMEM and scatter plots of data items against patient 
identification number were produced.
The data were then split into two sets: a population data set comprising two thirds of the 
patients and a test data set comprising the remaining one third of the patients. Patients 
were randomly allocated to the population or test data sets.
Data were fitted simultaneously by non-linear regression with NONMEM. Models were 
implemented using the data pre-processor NMTRAN and the PREDPP subroutines. 
Mono-, bi- and tri-exponential structural models were fitted to the gentamicin 
concentration-time data. The PREDPP subroutines ADVAN1/TRANS2 and 
ADVAN3/TRANS4, were implemented to run a mono- and bi-exponential model 
respectively, whereas for the tri-exponential model the subroutine ADVAN7 was 
chosen.
Models were parameterised to give estimates of clearance (CL), intercompartmental 
clearance (Q), and volumes of distribution (Vj, V2, V3). The mathematical equations for 
intravenous, bolus and infusion administration are shown in Appendix I. The 
microscopic rate constants represent the transfer rate from compartment 1 to 2  and vice- 
versa and they were derived from the macroparameters obtained from NONMEM output 
for a bi-exponential model as follows:
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klO = CU V  i 
kl2 = Q/V, 
k2 1  = Q/V2
and then the half-lives (T1/2) were derived as follows:
T i /2 initial =  0 . 6 9 3  / X\
T i / 2 terminal =  0 . 6 9 3  /  A,2
Where Xi and X2 are the roots of the quadratic equations calculated from:
A,i; A,2 = 0.5*[(ki2+k2i+kio) ± ((kj2 +k2i + kio) 2 - 4 k2i kio)1/2]
Interindividual variability, ETA  (rji) was assumed to arise from a Gaussian distribution,
i.e. to be a random variable, independent and identically distributed, with a mean zero 
and variance (Var(Ttj)), expressed as cop2.
Preliminary analysis revealed that the data were best fitted assuming a logarithmic 
Normal distribution on r|j. Therefore, Pjk, the individual estimates of the 
pharmacokinetic parameters, where k could be CL, Q, Vi, V2, etc. of the ith individual, 
were described by the following equation:
Pik= P k *E xp(r |[>k)
P
where Pk is the typical population estimate of the parameter k, and r|i k is the difference
between the population parameter and the parameter for the ith individual.The residual 
error on concentrations was investigated using the additive, proportional and combined 
(exponential and additive) models. A description of these models is given in Chapter 1. 
The distributions of the POSTHOC parameter estimates obtained from the basic model 
were then examined by means of histograms. The distribution of each parameter was 
tested for normality using the Anderson-Darling test.
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Another assumption made in regression analysis is that residuals and weighted residuals 
are random variables with zero-mean, and therefore are symmetrically distributed 
around zero and have unit variance. An indication of the shape of the residual 
distributions was obtained from distribution plots. Residual analyses were performed 
using both the residuals and weighted residuals.
In the present study a preliminary analysis was first carried out to examine distributions 
of all covariates and identify any abnormalities in clinical factors such as renal and 
hepatic function. This exploratory analysis was carried out on the following covariates: 
age; gender; weight; height; ideal body weight; creatinine concentration; urea 
concentration; albumin concentration; white cell count; haemoglobin; platelet count; 
temperature; obesity; lean body mass; body mass index; and body surface area. The 
frequency distributions of covariates were examined by means of histograms. 
Collinearity that might influence the model building was inspected graphically by a 
matrix scatter plots and by the correlation coefficient obtained by correlating each 
covariate against all the others.
Each covariate was plotted against POSTHOC parameter estimates of clearance and 
volume of the central compartment calculated from the basic model. The shape of the 
plots gave an indication about the possible mathematical form for the relationship when 
the covariate was added to the kinetic model. Similar plots were also produced using 
population residuals and weighted residuals (WRES). These plots provided an 
indication as to whether a covariate should be included in the model. Multiple linear 
regression was also used to examine the relationship between the POSTHOC parameter 
estimates and covariates. Firstly, one covariate at a time was regressed against each 
POSTHOC pharmacokinetic parameter. The judgement of goodness of fit was 
evaluated by the reduction in the residual sum of squares associated with the 
incorporation of each covariate in the model. The significance in the reduction in the 
residual sum of squares was formally tested by F-test and p<0.01 was used as the 
criterion for covariate inclusion or exclusion. Only those covariates associated with a 
significant change were then used in the “bestsubsef ’ regression. This option first
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selected the two covariates associated with the largest coefficient of determination (R2). 
Using this model the next most significant covariate was included. This process was 
repeated until all significant covariates were included in the model. All the statistical 
analyses were carried out using the statistical software package Minitab (1996b).
The model was built up assuming no covariance between elements of r\. Once the 
structural pharmacokinetic model was finalised, both the diagonal elements of the 62- 
matrix and the covariance terms of the lower triangle of the 62-matrix were estimated. 
Plots of T]‘s against each other provide an indication of which covariance to consider for 
inclusion in the model.
Once the final model was obtained, the structural model was reinvestigated. The one- 
compartment model was re-run with the full covariate model. Covariates identified by 
this preliminary analysis were then investigated using NONMEM as described in 
section 1.4.8.
2.4.4 INVESTIGATION OF CREATININE CONCENTRATION 
The influence of low creatinine concentrations was investigated by comparing the model 
obtained using creatinine clearance based on measured creatinine concentration with the 
models using new covariates derived from the corrected creatinine concentration. Three 
new covariates corresponding to the three different minimum creatinine values were 
derived as follows:
(i) All creatinine concentrations less than or equal to 60 pmol L' 1 were set at 60 pmol 
L' 1 (the lower limit of the reference range used in the hospital).
(ii) All creatinine concentrations less than or equal to 70 pmol L' 1 were set at 70 pmol 
L 1 (an arbitrary intermediate value).
(iii) All creatinine concentrations less than or equal to 88.4 pmol L' 1 were set at 88.4 
pmol L' 1 (equivalent to 1 mg dl'1).
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2.4.5 MODEL EVALUATION
Evaluation of the models obtained from the population analysis was performed using the 
test data set. Concentrations were predicted for each patient at each sampling time 
using the dosing history and the relevant clinical data. Prediction errors were then 
calculated to evaluate how well the population model predicted the measured 
concentrations. These prediction errors were obtained by subtracting the measured 
concentrations from the predicted concentrations as follows:
% Prediction error (PE) = 100*[I( Yy -YyVN]/ Yy
A j.1.
where Yy is the predicted and Yy is the measured concentration in the i individual at
the jth measurement. For each patient only the first peak and trough concentrations were 
used to calculate the prediction error. The mean prediction error for the two 
concentrations for each individual was first calculated and then the mean for all 
individuals. A t-test was used to test whether the prediction errors were significantly 
different from zero, when statistical significance was set at p<0.05. The prediction 
errors for peaks and troughs, calculated separately, were compared with the combined 
peak and trough results for each individual.
For each observed concentration the expected concentration distribution was obtained 
using the population derived parameter estimates by simulating 1000 data points. This 
allowed the probability of the measured concentration being within the 2.5-97.5 
percentile ranges of the expected value to be determined.
2.4.6 DOSAGE GUIDELINES
The best model was then run using the data from a pooled data set including all patients, 
to obtain the most accurate parameter estimates. The results of this analysis were used 
to predict the concentration-time profile in simulated patients who were males, aged 50 
years, weighed 70 kg, had heights of 1.7 m and albumin concentrations of 40 g L"1.
Three creatinine concentrations were used: 70 pmol L'1, 112 pmol L' 1 and 290 pmol L'1,
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which corresponded to creatinine clearances of 25 ml min'1, 65 ml min' 1 and 105 ml 
m in1, respectively. One thousand simulations were performed for each ‘patient’, and 
the median (25-75 percentile range) concentration-time profiles were determined 
according to two published nomograms: one that used a “once daily” regimen (Nicolau 
et al., 1995) and one based on traditional target ranges (Thomson et al., 1996).
2.5 RESULTS
2.5.1 PATIENTS
Data were collected from 210 patients. The exact dosing history, times of blood 
sampling and measured concentrations were recorded prospectively and demographic 
and clinical characteristics were recorded prospectively and retrospectively.
The option “Data Checkout” from NONMEM revealed no problems when scatter plots 
were produced of data items against patient identification number. Gentamicin was 
administered by intravenous bolus or by short infusion over 10-30 minutes. Doses 
ranged from 40 mg to 300 mg and the sampling times ranged from 1 to 26 hours after 
the dose. Five hundred and seventy four concentrations were available for analysis, 
ranging from 0.1 mg L 1 to 13.5 mg L' 1 with a median of 1.7 mg L'1.
Patients were given an identification number according to the chronological order of 
recruitment. A random number table was then generated using the statistical software 
Minitab (1996b). Patients whose identification numbers were within the first 140 
random numbers were allocated to the population data set and the remaining 70 patients 
were allocated to the test data set.
The population data set comprised three hundred and seventy eight concentrations 
ranging from 1 to 9 for most patients. Three patients had 14, 17, and 22 concentrations 
measured over several treatment courses. Fifty-seven per cent of the measured 
concentrations were troughs and 92% were measured within the first 7 days of therapy.
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A summary of the demographic and clinical characteristics of the patients included in 
both population and test data sets is presented in Table 2.5.1. There were no significant 
differences in characteristics between patients in the population and test data sets. 
According to the definition of obesity, 108 patients (81.8% of the concentrations) were 
not obese. Only 6  out of the 140 ‘population’ patients weighed more than 100 kg and 
half of the patients weighed less than 6 6  kg. Twenty-two per cent of the concentrations 
used in the analysis were taken from pyrexial patients (flag = 1) but temperature was 
missing for 29% of the concentrations. Forty-nine per cent of the serum albumin 
concentrations were below the lower limit of the reference range, median 34 g L'1, 
creatinine concentration was also low in many cases with a median of 71 pmol L'1. The 
majority of patients had creatinine concentrations less than 100 pmol L'1. The median 
albumin concentration was 34 g L' 1 and 49% of the albumin concentrations were below 
36 g L"1, the lower limit of the reference range. Some patients in whom low creatinine 
concentrations were measured had creatinine clearance estimates from the Cockroft- 
Gault equation of 320 ml m in 1 (greater than 200 ml min' 1 is not physiological).
2.5.2 DATA ANALYSIS
The bi-exponential model was found to be superior to the mono-exponential, and the tri­
exponential model offered no advantage, based in the criteria. Model selection was 
based in the analysis of residuals as described in the section 1.4.7. Figure 2.5.2.a shows 
the weighted residuals against time after the dose obtained from different structural
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Figure 2.5.2.a Weighted residuals of gentamicin against time from last dose, obtained 
from mono-exponential and bi-exponential decline models
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Key: Panel A - mono-exponential decline model; Panel B - bi-exponential decline model.
Table 2.5.1 Summary of demographic and clinical characteristics of patients 
included in the study
Reference
range
Population set 
N=140
Median (range) 
or number (%) of 
patients/samples
Test set 
N=70
Median (range) 
or number (%) of 
patients/samples
Females 70 (50%) 42 (60%)
Age (years) 50(15-81) 53(14-77)
Weight (kg) 6 6  (38- 117) 65 (38 - 95)
Height (cm) 170(146- 188) 165 (147- 188)
Ideal body weight (kg) 59.2 (38.0 - 82.2) 55.0 (38.0-77.6)
Lean body mass 49.5 (32.3 - 73.8) 47.1 (31.1 -65.6)
Body mass index (kg m'2) 23.0(14.8-36.9) 23.0(16.2-33.2)
Body surface area (m2) 1.7 (1.3-2.3) 1.7 (1.3-2.1)
Obesity (20% above IBW) 69(18.2%) 64 (32.3%)
Urea (mmol L"1) 2.5 - 6.7 4.5 (0.8-22.1) 3.9 (1.1 -17.0)
Creatinine (pmol L"1) 60-110 71 (26-258) 74 (38 - 292)
Creatinine clearance (ml min'1)3 89.7 (22.9-319.7) 77.2(15.8-213.9)
Creatinine clearance (ml min1)b 86.1 (22.9-183.7) 74.9(15.8- 179.1)
Albumin (g L 1) 36-50 34.0(17.0-53.0) 33.5(18.0-52.0)
White cell count ( * 109 L 1) 4.1-11.0 0.8 (0.04- 194.1) 1.1 (0.1-57.0)
Haemoglobin (g df1) 13-18 10.4 (5.6-16.1) 10.3 (6.7 -15.4)
Platelets (*109 L‘1) 150 - 400 52 (2 - 670) 79 (4 - 883)
Temperature (> 38°C) 84 (22.2%) 36(18.2%)
Key: a Calculated by Cockcroft Gault equation (Cockcroft and Gault, 1976); creatinine 
concentrations < 60/Jmol L 1 set at 60 fimol L 1
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models. Weighted residuals produced from the monoexponential decline model were 
overestimated at early time points, whereas this was not observed with the bi­
exponential model. However, towards later time points both models tended to 
underestimate the concentration. Bi- and tri-exponential models produced similar plots, 
the pharmacokinetic parameters were estimated with a similar degree of confidence and 
there was no decrease in the variability associated with the residual error. The objective 
function value dropped 83.7 points when the bi-exponential model was compared to the 
mono-exponential model but only 9 points between the bi- and tri-exponential models. 
The parameter estimates obtained from the mono- and bi-exponential models are shown 
in Table 2.5.2.a. The plot of measured against predicted data points for bi-exponential 
model showed a distribution along the line of identity (Figure 2.5.2.b). The weighted 
residuals against predicted concentrations for the bi-exponential decline model showed a 
more random scatter around zero (Figure 2.5.2.c) than for the mono-exponential decline.
Interindividual variability was assumed to follow a logarithmic-normal distribution.
The shape of the distributions of r|jCL, t|jV1, ei and 82 were investigated by an Anderson- 
Darling normality test. Figure 2.5.2.d shows scatter plots from r|‘s in clearance against 
r| ‘s in volume obtained from the three residual error models. The combined error 
structure was associated with a more random pattern around the axis line than the other 
two models. The combined residual error model was also superior to both additive and 
proportional models when the objective function values were compared. The combined 
model was associated with a drop in objective function value of 177.4 points compared 
to the proportional and 76.7 points compared to the additive model. Weighted residuals 
obtained from the combined model were normally distributed.
The distributions of the POSTHOC r| values for clearance and volume of the central 
compartments were tested for normality.
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Figure 2.5.2.d Scatter plots of r|CL against r|vl obtained from three residual error 
models
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Figure 2.5.2.b Measured against predicted concentration obtained from the bi-exponential 
decline model
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Table 2.5.2 a Gentamicin pharmacokinetic parameters estimated from two 
structural models, mono- and bi-exponential decline models
Parameter Estimates 
(SE%)
Mono-exponential Bi-exponential
decline decline
Clearance (L h'1) 3.86 3.98
(4.1) (4.1)
V or Vi (L) 17.2 13.9
(2.9) (5.8)
V2 (L) - 13.4
(22)
Q (L h'1) - 2 .2
(19)
Interindividual Variability
CL 31.7% 33.9%
(29) (24)
V or Vj 12.9% 15.5%
(75) (72)
V2 indeterminate
Q
Residual variability
indeterminate
at 1 mg L' 1 45.0% 38.4%
at 8  mg L' 1 16.3% 14.6%
OFV 322.0 238.3
Key: OFV - Objective Function Value; SE represents the standard error; V represents the 
volume o f  distribution; VI is the volume o f  distribution o f  the central compartment; V2 the 
volume o f  distribution o f  the peripheral compartment; Q is the intercompartmental clearance 
between the central and peripheral compartments.
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The “basic model”, a bi-exponential decline model with an exponential interindividual 
variability and a combined structure for residual error, was used to estimate population 
pharmacokinetic parameters. The mean of the individual (POSTHOC) clearance 
estimates using this model was 4.39 L h' 1 (range 1.55 to 7.69 L h"1), the mean 
intercompartmental clearance was 2.21 L h'1, Vi was 13.9 L and V2 was 13.4 L. The 
intersubject variability was 33.9% on CL with a standard error of 23.8% and 15.5% on 
Vi with a standard error of 72.3% but the intersubject variabilities on Q and V2 were 
very low with wide standard errors, i.e. indeterminate. The standard deviations of the 
residual error were 0.38 mg L' 1 at 1 mg L' 1 and 1.17 mg L' 1 at 8  mg L'1.
Possible relationships between POSTHOC parameter estimates, residuals and weighted 
residuals and covariates such as age, ideal body weight, weight, lean body mass, height, 
gender, body surface area, urea, albumin, creatinine concentration and creatinine 
clearance were identified from the scatter plots. In Figure 2.5.2.e plots from the 
coavariates that showed a relationship are depicted. Haematological indices 
(haemoglobin, white cell count, and platelet count) showed no obvious trends nor did 
the presence or absence of pyrexia. Volume of distribution tended to increase with 
indices of body size: weight; height; body surface area; and lean body mass, and 
decrease with serum albumin concentration, as shown in Figure 2.5.2.e.
The results obtained from the linear regression analysis are presented in Table 2.5.2.b. 
Covariates associated with significant influence were used in a “bestsubset” multiple 
linear regression and the results are shown in Table 2.5.2.C. For clearance, creatinine 
clearance and urea were the two models selected with the highest R2 for a single- 
covariate model. The second covariates for a two-covariate model were clearance of 
creatinine and age. Body surface area and ideal body weight were selected as the third 
covariate on a 3-covariate model. For volume of distribution, lean body mass and body 
surface area were the best single-covariate models selected. Albumin was selected a 
covariate for a 2-covariate model and creatinine for a 3-covariate model. Urea was not 
incorporated in the model because it was highly correlated with creatinine.
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Figure 2.5.2.e Plots of individual pharmacokinetic parameters, 
residual and weighted residuals against covariate that show a 
relationship
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Figure 2.5.2.e Plots of individual pharmacokinetic parameters, residuals and 
weighted residuals against covariate that show a relationship
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Table 2.5.2 b Summary of the results from the linear regression of POSTHOC 
pharmacokinetic parameter estimates against covariates values
CLEARANCE VOLUME (V,)
SS Total - 618.925 SS Total - 362.54
SS error P SSerror P
Age 450.6 <0 .0 1 362.2 0 .6
Height 542.9 <0 .0 1 328.2 <0 .0 1
Ideal body weight 568.9 <0 .0 1 308.2 <0 .0 1
Weight 592.9 <0 .0 1 313.7 <0 .0 1
Lean body mass 555.4 <0 .0 1 303.6 <0 .0 1
Body mass index 616.9 0.27 336.0 <0 .0 1
Body surface area 571.6 <0 .0 1 304.9 <0 .0 1
Albumin 558.2 <0 .0 1 360.6 0.159
White cell count 618.8 0.82 358.9 0.05
Haemoglobin 617.3 0.31 362.6 0.9
Platelets 616.0 0.18 359.6 0.08
Urea 448.3 <0 .0 1 362.1 0.5
Creatinine 471.3 <0 .0 1 361.3 0.3
Creatinine clearance 375.9 <0 .0 1 351.6 0 .0 1
Note: POSTHOC parameter estimates obtained from the ‘basic model’ were the response variables 
and covariates were the predictor variables.
Key: SS Total represents both residual sum o f  squares that is explained and not explained by the 
model; SS error represents the residual sum o f  squares that was not explained with the inclusion o f  
a variable; p  is the level o f  significance o f  the decrease in sum o f  squares.
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Table 2.5.2 c Models obtained by “bestsubset” multiple linear regression of 
clinical factors and POSTHOC pharmacokinetic parameter estimates 
(clearance, CL and volume of the central compartment, Vj)
Model R2 adj %
CL Creatinine clearance 39.1
Urea 27.4
~ Urea + Creatinine clearance 47.8
Creatinine + Age 43.6
Creatinine + Body surface area + Age 53.9
Creatinine + Ideal body weight + Age 53.8
~ Urea + Creatinine + Ideal body weight + Age 56.0
Creatinine + Body surface area + Weight + Age 56.0
V! Lean body mass 16.0
Body surface area 15.6
Lean body mass + Albumin 18.6
Body surface area + Albumin 18.1
Body surface area + Albumin + Creatinine 20.8
Lean body mass + Albumin + Creatinine 20.8
Key: R adj represents the coefficient o f  determination adjusted fo r  a multicovariate model
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Analysis of single covariates by NONMEM identified weight, age, height, ideal body 
weight, albumin, urea, creatinine clearance, gender, body surface area, lean body mass 
platelets and pyrexia as influencing clearance. A summary of the results is presented in 
Table 2.5.2.d. Creatinine clearance and creatinine concentration were the two covariates 
with the strongest influence on clearance. Two different approaches were then used in 
the analysis of these data. The first involved building the model from an estimate of 
creatinine clearance calculated from age, weight, creatinine concentration and gender. 
The second approach used the individual clinical characteristics such as age, body 
surface area and serum creatinine concentration.
With the ‘creatinine clearance’ approach, in addition to a linear relationship between 
creatinine clearance and clearance, a linear relationship was found between Vi, and 
BSA (or lean body mass and ideal body weight) and a nonlinear relationship with 
albumin. BSA was chosen for inclusion in the model as a measure of body size because 
it is widely used in oncology. Model building with the creatinine clearance approach 
produced the results presented in Table 2.5.2.e. The best model was represented by:
CL = 0i * (1 + 63  Creatinine clearance)
^  * (  Albumin^! ^Vi = 02  * Body surface area * ------------
I 34 J
Q = 05 
V2 = 06
where ©i, 0 2 , 0 3 , 0 4 , 05 and 06  are typical population parameter estimates.
With the ‘clinical factors’ approach the inclusion of body surface area, ideal body 
weight or lean body mass as a second covariate caused similar drops in the objective 
function value. As BSA gave the same results as height and weight but required one 
less parameter, BSA was chosen as the covariate. A third covariate, age as a power 
model, was added to the previous model causing a further drop in objective function 
value.
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Table 2.5.2 d Summary of results of individual covariates tested by NONMEM
Covariates Tested (reduction of OFV from basic model)
Pharmacokinetic Significant A OFVa Insignificant A OFVa
Parameter addition addition
CL (L h'1) Creatinine clearance 123.1 Body mass index 3.4
Creatinine 67.2 Platelets 6 .8
Urea 59.7 Pyrexia 4.3
Age 46.2 White cell count 2.3
Lean body mass 23.1 Obesity 1.4
Ideal body weight 2 0 .6 Haemoglobin 0.5
Body surface area 18.5
Gender 18.4
Height 18.2
Albumin 13.5
Weight 12.9
V| (L) Body surface area 2 0 .1 Height 6 .0
Lean body weight 2 0 .0 Obesity 3.7
Ideal body weight 17.4 Platelets 1.9
Albumin 9.5 Haemoglobin 0 .2
Weight 9.3 White cell count 0
Gender 8.4 Urea 0
Key: OFV represents the objective function value; a) A reduction in OFV o f  more than 7.9 units was 
considered statistically significant, i.e. p  < 0.05.
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Table 2.5.2 e Summary of covariate selection by NONMEM using the creatinine 
clearance approach
Model OFV Model for 
comparison
AOFV
1. CL = 0) 
V, = 0 2
238.3
2. CL = 0! * (1+ 03 * Creatinine clearance) 
V, = 0 2
115.2 l 123.1
3. CL = 0i * (1 + 03 * Creatinine clearance) 
V, = 02 * Weight
107.4 2 7.8
4. CL = 0] * (1 + 03 * Creatinine clearance) 
V, = 02 * (Albumin/34)04
104.5 2 10.7
5. CL = 0i * (1 + 03 * Creatinine clearance) 
Vi = 02 * Ideal body weight
90.1 2 25.1
6. CL = 0 ] * ( l + 0 3* Creatinine clearance) 
V 1 = 02 * Lean body mass
92.5 2 22.7
7. CL = 0i * (1 + 03 * Creatinine clearance) 
Vi = 02 * Body surface area
91.9 2 23.3
8. CL = 0i * (1 + 03 * Creatinine clearance)
Vi = 02 * Body surface area * (Albumin/34)04
73.9 7 18.0
Key: OFV Objective function value; A OFV - logarithmic likelihood difference asymptotically 
distributed as j^ , with 1 degree o f  freedom; 6n represent parameters estimated from  the population 
analysis; significance set at 99.5%, corresponds to a difference o f  7.9 in OFV.
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The best fit of the data was achieved by modelling volume of the central compartment 
with body surface area as a linear, and albumin as a power model. Discrete covariates 
such as temperature, obesity and gender were incorporated as step models. The 
influence of gender on clearance was no longer statistically significant. Table 2.5.2.f 
shows a summary of the covariate models tested. The best model was:
r Creatinine concentration ^ 05 * r Age>
I 71 J k 46 jC L — 0i *
Vi = 02  * Body surface area
Body surface area
Albumin
34
07
Q = 03 
V2 = 04
No covariates were found that influenced V2 and Q and the interindividual variabilities 
in Vj and V2 were indeterminate using both approaches.
Backward stepping was then carried out on the full model such that each covariate was 
removed from the model one at a time to confirm its influence on the full model.
All covariates were associated with a significant increase in the objective function value 
when removed from the model. The analysis was carried out using a diagonal 
covariance matrix on the vector of rj. A full covariance matrix on clearance and 
intercompartmental clearance was estimated using the best models obtained from the 
two approaches. From the model including the covariance matrix, the covariates were 
removed one at a time to check the influence of each one on the pharmacokinetic 
parameter estimates; thus the results showed that the choice of covariates was not 
influenced by correlation among the pharmacokinetic parameters. The inclusion of the 
covariance matrix did not affect the choice of the structural model.
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Table 2.5.2 f  Summary of covariate selection by NONMEM using the clinical factors
approach
Model OFV
Model for 
comparison AOFV
1 CL = 0, 
VI = 0 2
238.3 - -
9 CL = 0, * (Creatinine/71)03 
VI =02
171.1 1 67.2
10 CL = 0] * (Creatinine/71)03 * Body mass index 
VI = 02
177.4 9 60.9
11 CL = 0j * (Creatinine/71)03 * Height 
VI = 02
154.5 9 83.8
12 CL = 0) * (Creatinine/71)03 * Weight 
VI = 0 2
148.2 9 90.1
13 CL = 0! * (Creatinine/71)03 * Body surface area 
VI = 02
132.9 9 105.4
14 CL = 0] * (Creatinine/71)03 * Lean body mass 
VI = 0 2
122.1 9 116.2
15 CL = CL = 0] * (Creatinine/71)03 * Ideal body weight 
VI = 0 2
129.9 9 108.4
16 CL = CL = 0, * (Creatinine/71)03 * (Age/46)03 
VI = 0 2
133.5 9 104.8
17 CL = CL = 0i * (Creatinine/71)03 * Weight * (Age/46)04 
VI = 0 2
113.5 12 34.7
18 CL = CL = 0i * (Creatinine/71)03 Ideal body weight *
(Age/46)04
VI = 0 2
100.1 15 29.9
19 CL = 0j * (Creatinine/71)03 * Lean body mass * (Age/46)04 
VI = 0 2
94.2 14 27.9
20 CL = 0j * (Creatinine/71)03 * Body surface area *(Age/46)04 
VI = 0 2
95.9 13 37.0
21 CL = 0] * (Creatinine/71)03 * Body surface area * (Age/46)04 
V = 02 * (Albumin/34)05
83.6 20 12.3
22 CL = 0! * (Creatinine/71)03 * Body surface area * (Age/46)04 
V = 02 * Body mass index
88.5 20 7.4
23 CL = 0! * (Creatinine/71)03 * Body surface area * (Age/46)04 
V = 02 * Weight
85.8 20 10.1
24 CL = 0] * (Creatinine/71)03 * Body surface area * (Age/46)04 
V = 02 * Ideal body weight
74.4 20 21.5
25 CL = 0i * (Creatinine/71)03 * Body surface area * (Age/46)04 
V = 02 * Lean body mass
73.9 20 22
26 CL = 0! * (Creatinine/71)03 * Body surface area * (Age/46)04 
V = 02 * Body surface area
72.1 20 23.8
27 CL = 0i * (Creatinine/71)03 * Body surface area * (Age/46)04 
V = 02 * Body surface area * (Albumin/34)05
52.9 26 19.2
k e y :  O F V  - O b j e c t i v e  F u n c t i o n  V a l u e ;  A O F V  -  l o g a r i t h m i c  l i k e l i h o o d  d i f f e r e n c e  a s y m p t o t i c a l l y  d i s t r i b u t e d  a s  
w i t h  1  d e g r e e  o f f r e e d o m ;  G„ r e p r e s e n t  p a r a m e t e r s  e s t i m a t e d  f r o m  t h e  p o p u l a t i o n  a n a l y s i s ;  s i g n i f i c a n c e  s e t  a t  9 9 . 5 %  
c o r r e s p o n d s  a  d i f f e r e n c e  o f  7 . 9  o f  O B V .
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From the population analysis two models were obtained, one using clinical factors and 
the other using the estimated creatinine clearance. The residual error model was also 
reconfirmed.
2.5.3 INVESTIGATION OF CREATININE CONCENTRATION 
The results obtained using the measured and three different minimum creatinine 
concentrations are presented in Table 2.5.3.a. With the creatinine clearance model there 
was no major difference between using a lower value of 60 pmol L 1 or 70 pmol L' 1 but 
both were superior to 88.4 pmol L 1 and the measured concentration. In contrast, 70 
pmol L' 1 proved the optimal minimum with the clinical factor model. Figure 2.5.3 
shows the POSTHOC clearance estimates against creatinine clearance obtained when 
the creatinine concentration was set at 60, 70 or 88.4 fxmol L 1. The best correlation 
between estimated creatinine clearance and gentamicin clearance was obtained when the 
creatinine concentration was set at 60 pmol L'1. That observation is in agreement with 
the results obtained from NONMEM. The weighted residuals plots were also consistent 
with these results.
After comparing the plots and parameter estimates from the two best models, no firm 
conclusion could be drawn about which approach was better. Table 2.5.3.b shows the 
parameter estimates and the error associated with the two models.
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Figure 2.5.3 Gentamicin clearance estimates against creatinine clearance (ml min'1) 
obtained from creatinine concentration set at 60, 70 and 88.4 jjmol L"1
<70 set to 70 micromol/L
R - sq = 55.9 %
Measured creatinine 9 - 1
Creatinine clearance (ml/min)
0  100 200 300
Creatinine clearance (ml/min)
<88.4 set to 88.4 micromol/L
R-sq = 49.0 %
100 200 
Creatinine clearance (ml/min)
<60 set to 60 micromol/L
R-sq = 60 %
100 200 
Creatinine clearance (ml/min)
Table 2.5.3 a Summary of objective function values obtained using the best models
with the creatinine concentration set to different minimum values
MODEL CLEARANCE MODEL CREATININE 
CONCENTRATION (nmol L 1)
OFV
8 Creatinine clearance measured 73.9
Creatinine clearance < 60 set at 60 32.0
Creatinine clearance < 70 set at 70 28.9
Creatinine clearance < 88.4 set at 88.4 61.0
27 Creatinine, BSA, Age measured 52.9
Creatinine, BSA, Age < 60 set at 60 24.5
Creatinine, BSA, Age < 70 set at 70 17.9
Creatinine, BSA, Age < 88.4 set at 88.4 31.6
Key: BSA - Body surface area; OBV— objective function value
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Table 2.5.3 b Summary of the parameter estimates obtained from the two best models
using the population data set (N=140)
CL = 0 i ( l + 0 5 *CLcr)
cut o ff 60 pmoll'1
V, = 02 * BSA (Alb/34) 66
CL = 0 ! * 
*BSA
Vi = 0 2 *
: (Cr/71)65 * (Age/46)06
cut o ff 70 jjmoll'1 
BSA (Alb/34) 07
Estimate SE (%) Estimate SE (%)
CL 01 1.02 22.7 CL 01 2.56 2.8
05 0.037 30.6 05 -0.86 8.8
06 -0.33 14.6
V, 02 8.49 5.6 v, 02 8.45 4.4
06 -0.61 24.2 07 -0.63 22.0
Q 03 1.61 30.7 Q 03 1.62 23.7
V2 04 8.22 21.2 v2 04 7.87 13.5
Intersubject variability
cdcl(CV%) 17.7 22.9 17.8 21.2
(Dvi (CV%) indeterminate indeterminate
(Dq(CV%) 29.5 222 33.6 142
0)V2(CV%) indeterminate indeterminate
Residual variability
® at ] mgL ( 30.6 14.7 28.5 14.0
at 8 mgL ( 16.7 27.0 16.7 27.9
Derived Parameters
T]/2 a (h) 1.5 1.4
Ti/2 p (h) 6.2 6.0
Vss (L kg'1) 0.37 0.36
Key: Clcr - Creatinine clearance; alb - albumin; Cr - Creatinine concentration; BSA - Body surface area; 
CL -Clearance; V} - Central volume o f  distribution; V2 - Peripheral volume o f  distribution; o f - Variance 
o f intersubject variability, o2 - Variance o f  residual variability; T]/2- H alf life.
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2.5.4 MODEL EVALUATION
The model evaluation was carried out with 70 patients and 132 concentrations.
The mean percentage prediction error was -7.2% for the model based on creatinine 
clearance and -6 .6 % for the model based on clinical factors. For the model using 
creatinine clearance, peak concentrations had a prediction error of -3.4% whereas 
troughs had a prediction error of -6.5%. For the model using clinical factors, the 
prediction error associated with the peak concentration was -3.7% whereas the trough 
concentrations had a mean error of -2.5%. There was no bias in the prediction errors. 
The probability that a measured concentration lay within the 2.5-97.5 percentile of the 
simulated concentration was 0.9 for both models. Figure 2.5.4 shows the 2.5-97.5 
percentile range of the simulated concentration for each data point for all patients in 
whom peak and trough concentrations were measured.
2.5.5 DOSAGE GUIDELINES
The parameters obtained by fitting the full data set are shown in Table 2.5.5. Due to its 
simplicity, the model based on creatinine clearance was selected for the evaluation of 
dosage guidelines arising from two nomograms. Concentration-time profiles were 
simulated for 1000 patients for three values of creatinine clearance (105 mlmin'1, 65 
mlmin' 1 and 25 mlmin'1) assuming the dose regimens recommended by Nicolau et al. 
(1995) and Thomson et al. (1996). The mean concentration time profiles, the dosage 
regimens, and the 25 -  75 percentile ranges are shown in Figure 2.5.5.
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Figure 2.5.5 Simulated mean and 50 per cent interquartile range of the concentration­
time profile obtained using the best model with two different nomograms
‘Once daily nomogram” 
A
Traditional nomogram 
D
§ 25 ■as 2°
§  15 
§ 10 I
J
10 20 30 40 50 60
T im e  (hou rs)
15 -
■a 10 -
o -1
0 10 20 30 40 50
T im e (hou rs)
35 -i
|
bO
a.
8 20 “
15 ~
oU
0 -1
0 50 100
15 ~
.2  1 0 "
0 10 20 30 40 50 60 70
Time (hours) T im e  (hou rs)
35 - |
30 -
e  2 5 -  O
'2 20 -
0 50 100 150
T im e  (hou rs)
15 -
10 -
CO
CO
c
<DOcoO
0 -1
0 10 20 30 40 50 60 70
Time (hours)
Creatinine
Clearance
Panel Dosage for Extended 
Interval
Panel Dosage for Traditional 
nomogram
105 ml min A 490 mg/24h D 200 mg/12h
65 ml min'1 B 490 mg/36h E 160 mg/24h
25 ml min'1 C 490 mg/48h F 100 mg/24h
Table 2.5.5 Summary of results of parameter estimates from the two best models using the 
combined data set (N=210)
CL = 6 , (1  + 0 5 * Clcr) CL = 0, * (Cr/71)65* (Age/46)96*BSA
cut o ff 60 nmol L'1 cut o ff 70/Jmol L 1
V, = 6 2 * BSA (alb/34) 06 V, = 0 2 * BSA (alb/34)67
Estimate SE (%) Estimate SE (%)
CL 01 0.88 19.2 CL 01 2.46 3.1
05 0.043 24.4 05 -0 .78 9.2
06 -0 .33 14.5
V, 02 8.59 3.8 v t 02 8.52 3.9
06 -0.39 30.0 07 -0 .40 28.5
Q 03 1.30 23.4 Q 03 1.34 24.2
V2 04 9.79 28.5 v2 04 9.05 20.6
Intersubject Variability
(Oc l (C V % ) 18.5 18.1 19.6 17.4
G)vi (CV%) indeterminate indeterminate
coq(C V % ) 28.2 189.2 30.1 174.4
(Ov2(CV%) indeterminate indeterminate
Residual Variability
G at 1 mgL ( Vo) 36.4 17.9 35.6 20.8
at 8 mgL (  Vo) 16.5 24.6 16.3 27.4
Derived Parameters
T,/2a(h) 1.8 - 1.7 -
T1/2 p (h) 8.0 - 7.5 -
Vss (L kg'1) 0.38 - 0.38 -
Key: Clcr - Creatinine clearance; alb - Albumin; Cr - Creatinine concentration; BSA - Body surface area; 
CL - Clearance; V/ - Central volume o f  distribution; V2 - Peripheral volume o f  distribution; (1f  - Variance 
o f intersubject variability; o2 - Variance o f  residual variability .T 1/2 - H a lf life.
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2.6 DISCUSSION
Despite the fact that the pharmacokinetics of the aminoglycoside antibiotic gentamicin 
have been extensively studied, only limited and conflicting data have been published on 
the most appropriate pharmacokinetic model. For instance, a one-compartment model is 
usually assumed in clinical settings but several studies have found that gentamicin 
pharmacokinetics are better described by a two- or three-compartment model (Schentag 
et al., 1977; Laskin et al., 1983; MacGowan et al., 1994). Furthermore, with particular 
respect to patients with cancer, there are conflicting reports about the magnitude of the 
volume of distribution. In this study, the pharmacokinetics of gentamicin in patients 
with cancer have been investigated and characterised using a population approach 
applied to data collected during routine therapeutic drug monitoring.
The population mean clearance estimate was 4.2 L h"1, and is consistent with 4.6 L h' 1 
/1.73m2 reported by Bertino et al. (1991). As expected, estimated creatinine clearance 
and serum creatinine concentration were the covariates that had the strongest influence 
on gentamicin clearance. However, the relatively high intercept obtained is probably 
because few patients showed creatinine clearance estimates < 30 ml min'1. It is 
therefore important that these results are not extrapolated to patients with very poor 
renal function in whom gentamicin clearance might be overestimated. The use of 
estimated creatinine clearance as a measure of renal function has some limitations, 
especially with low serum creatinine concentrations. In order to overcome this problem, 
some authors have recommended the use of a creatinine concentration corrected to 88.4 
pmol L' 1 (1 mg dL'1) for concentrations less than or equal to 88.4 [imol L' 1 (Winter, 
1988; Robert et al., 1991). Nonetheless, other authors feel this might lead to 
underdosing of some patients (Bertino, 1993; Smythe et al., 1994). It has been noted 
(Duffull et al., 1997) that a better prediction of clearance was obtained when all serum 
creatinine values below 60 pmol L' 1 were set at 60 jxmol L' 1 In the institution where 
this research took place, values of creatinine concentration less than 60 jxmol L' 1 are set 
at 60 jxmol L 1 (the lower limit of the reference range) for estimating gentamicin 
clearance and calculating dosage recommendations. The present study investigated the
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consequences of setting low creatinine concentrations at 60 pmol L'1, 70 pmol L' 1 or
88.4 i^mol L 1. There was little difference using creatinine concentrations set at 60 nmol 
L' 1 or 70 nmol L 1 when the creatinine clearance model was applied (model 8 ), whereas 
for the model including clinical values (model 27) the best fit was obtained when low 
creatinine concentrations were set at 70 nmol L' 1 (Table 2.5.3.a). With both models the 
value 88.4 nmol L' 1 was too high, but better than using the measured creatinine 
concentration.
The influence of gender on gentamicin clearance remains unclear. Cockcroft and Gault 
(1976) suggested a correction factor of 0.85 for women, having this value been chosen 
arbitrarily. Phillips et al. (1988) suggested that adjustment for gender was not 
necessary. In the present study, gender was included as a single covariate and associated 
with a significant influence in clearance but in the final clinical factors model the 
influence of gender was not significant. One possible explanation is that any gender 
difference in clearance is already taken into account via the differences in body surface 
area.
Gentamicin volume of distribution in oncology patients remains the subject of debate. It 
is often reported to range between 0.25 and 0.31 L kg' 1 in adults from a general 
population (Zaske, 1992; Sande and Mandell, 1996) whereas in patients with cancer an 
increased volume of distribution in the range 0.38 L kg' 1 to 0.43 L kg' 1 has been 
reported (Phillips et al., 1988; Zeitany et al., 1990; Davis et al., 1991). In contrast, 
however, a study carried out on 880 cancer patients found a mean volume of distribution 
of 0.35 L kg' 1 compared to 0.34 L kg' 1 for the control group (Bertino et al., 1991).
These authors concluded that the volume of distribution of gentamicin was not 
increased in patients with cancer. More recently, MacGowan et al. (1994) reported a 
volume of distribution of 24.5 L in patients with haematological malignancies. In this 
study, the value of 0.38 L kg'1, equivalent to 24.6 L, is consistent with the values 
reported by both Bertino et al. (1991) and MacGowan et al. (1994) in similar patients. 
However the differences in volume of distribution in the published literature may simply
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reflect different sampling protocols and the application of different pharmacokinetic 
models.
Significant relationships were found between the volume of the central compartment 
(Vi), and measures of body size (IBW, LBM, Wt and BSA) and serum albumin 
concentration. A relationship between low serum albumin and volume of distribution 
was also reported by Etzel et al. (1992) and, in a study of amikacin in patients with 
cancer, Davis et al. (1991) detected a significant influence of albumin on the volume of 
distribution. In contrast, Phillips et al. (1988) found no influence of albumin on volume 
of distribution but they did not report the range of albumin concentrations in their study. 
Since low serum albumin concentrations have been shown to alter intra- and extra­
cellular fluid distributions, leading to an expanded extracellular fluid volume, the wide 
range of values in the present study may have favoured the identification of the 
influence of albumin on the volume of distribution. In this analysis, the volume of 
distribution ranged from 0.55 to 0.35 L kg' 1 with albumin concentrations of 17 g L' 1 to 
53 gL ’1.
Gentamicin concentration-time profiles are frequently characterised by two- 
compartment models and in the present study the half-life of the initial phase was 1.7 
hours (range 0.8-3.8 ), which is similar to previous observations (Wenk et al., 1979; 
Laskin et al., 1983; Aarons et al., 1989; MacGowan et al., 1994). However, the half-life 
of the late phase was found to be 8.0 hours (range 3.7-17.8) which is significantly 
shorter than in other reports. Laskin (1983), for instance, identified a terminal 
elimination half-life of 94 hours, although this only became dominant 12 hours after 
administration of gentamicin. In contrast, Aarons et al. (1989) reported a much shorter 
terminal half-life of 26.6 hours for the related aminoglycoside tobramycin but, 
according to these authors, limitations of their study design prevented identification of 
the long terminal elimination phase. A similar limitation probably applies to the results 
presented here: a long terminal half-life was not identified because 71% of the 
concentrations were measured in the first 1 2  hours post-dose and only two patients had 
concentrations taken more than 24 hours after gentamicin administration. The data were
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collected during the first few days of routine monitoring, tissue accumulation would 
have been incomplete and the protracted elimination phase would not have been 
appropriately characterised. Lack of data at later times post dose probably also 
contributed to the inability to estimate intersubject variability on Q and V2. The large 
residual error corresponding to a standard deviation of about 0.36 mg L"1 at low 
concentration values (1 mg L'1) contrasts with the lower relative residual error with a 
standard deviation of 1.32 mg L 1 obtained at high concentrations (8  mg L'1). Large 
residual errors may reflect poor assay performance and precision at low concentrations 
(White et al., 1994) although the assay standard deviation in this case was only 0.06 mg 
L 1 at 1 mg L 1. Examination of the data identified a few patients in whom trough 
concentrations were unexpectedly higher or lower than predicted by the model and it is 
likely that these data points contributed to the high variability observed.
It has been shown that high gentamicin peak concentrations are associated with a better 
outcome and that target peak serum gentamicin concentrations should ideally be above 7 
mg L 1 (Sculier and Klastersky, 1984; Moore et al., 1987). The dosage regimen 
recommended using the traditional nomogram (Thomson et al., 1996) yielded serum 
gentamicin concentrations within the target range (peak greater than 7 mg L' 1 and trough 
less than 2 mg L'1) for patients with normal renal function (Figure 2.5.5, panel D and E). 
However, in renal impairment, the mean peak concentration obtained from dosage 
regimens derived from the traditional nomogram (Thomson et al., 1996) was slightly 
lower than ideal (between 6-7 mg L' 1 as shown in Figure 2.5.5 panel F). Target 
concentrations for the high dose regimen have not yet been established but very high 
peaks and low troughs should be obtained in patients with both normal and impaired 
renal function (Figure 2.5.5 panels A, B and C).
The use of multiple linear regression as an preliminary analysis for covariate model 
building in NONMEM has been advocated (Mandema et al., 1992), along with plots of 
the POSTHOC parameter estimates versus covariates (Ette and Ludden, 1995), for the 
decision which covariate to include in the model. The use of the plots can be 
misleading as false relationships can be exhibited due to correlation between covariates.
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In this study, linear regression selected the same covariates as NONMEM (Table 2.5.2.b 
and Table 2.5.2.d). However, when the relationship was not linear, linear regression did 
not perform well and the plots were examined to suggest a suitable relationship. This 
was the case for creatinine concentration. NONMEM selected this as the second most 
influencial covariate while linear regression selected it as the fourth. Similar results 
were observed with albumin on volume.
In conclusion, this NONMEM analysis has shown that creatinine clearance estimated 
from creatinine concentrations was associated with a better fit when low values were set 
at 60 or 70 pmol L'1 rather than using the measured creatinine concentration. Volume 
of distribution was similar to values estimated by other authors and was influenced by 
body surface area and serum albumin concentration. Examination of the results in the 
context of published nomograms has indicated that both the traditional approach and the 
new, “once daily” approach should usually achieve satisfactory concentrations in this 
patient group. Nevertheless, due to the high interpatient and residual variabilities, 
serum concentration monitoring is required to confirm optimal dosing in individual 
patients.
93
CHAPTER 3 A PHARMACOKINETIC-PHARMACODYNAMIC 
COMPARISON OF MIBEFRADIL, DILTIAZEM AND VERAPAMIL
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3.1 SUMMARY
In this chapter the pharmacokinetic and pharmacodynamic characteristics of mibefradil, 
verapamil and diltiazem were determined after a single dose. The pharmacodynamics 
were measured with regard to diastolic blood pressure, heart rate and changes in PQ 
interval. In addition concentration-effect relationships for diastolic blood pressure, heart 
rate and changes in PQ interval for mibefradil and verapamil after both single and 
multiple doses were characterised and compared.
3.2 INTRODUCTION
3.2.1 CALCIUM CHANNELS
Calcium ions (Ca2+) play an important role in biochemical reactions and participate in 
various intracellular messenger systems and processes. Changes in intracellular calcium 
concentration provoke the release of neurotransmitters and hormones, and the 
subsequent cellular responses to these substances. In the cardiovascular system, an 
increase in Ca2+ activates the actin-myosin interaction, causing myocardial contraction. 
Calcium is also implicated in the pacemaker activity of sinus node cells and in the 
conduction through the atrio-ventricular node.
Maintenance of intracellular calcium concentration is of pivotal importance. To achieve 
this, different proteins located in the cell membrane act as pathways or channels: In
9-i-recent years, at least six different types of Ca channel have been identified in 
mammalian cells. However, only two types can be found in heart and in vascular 
muscles: the long-lasting, L-type; and the transient, T-type. These voltage-operated 
Ca2+ channels play a crucial role in the cardiovascular system and it is recognised that 
they differ in some aspects such as threshold, entrance and expression within various
9-i-cardiovascular tissues. The L-type Ca channels initiate cardiac and vascular muscle 
contraction. The T-type Ca2+ channels take part in the pacemaker activity of the heart 
and in the regulation of hormone secretion (Katz, 1996). In the vascular muscle cells,
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both the L-type and T-type channels are present and may also be important for vascular 
muscle contraction, but in neurohormonal cells T-type channels predominate. In the 
heart, the two types of channels are not equally distributed: the sinus node cells, 
responsible for the pacemaker, are rich in T-type, whereas the myocardial cells contain 
predominantly L-type channels.
3.2.2 CALCIUM CHANNEL BLOCKERS
Calcium antagonist drugs (calcium channel blockers) were introduced into the market in 
the 1960s. Since then they have been used in the treatment of cardiovascular diseases, 
particularly hypertension and angina pectoris.
3.2.2.1 Chemistry
Calcium channel blockers are conventionally sub-divided into three main chemical 
categories: 1,4-dihydropyridines, phenylalkylamines and benzothiazepines: the 
prototypes of these classes are respectively, nifedipine, verapamil and diltiazem. 
Recently, a new and distinct chemical class was identified through the prototype drug, 
mibefradil, a tetralol derivative. Representative chemical structures of the ‘heart rate 
limiting’ calcium blockers, mibefradil, verapamil and diltiazem are shown in Figure 
3.2.2.
3.2.2.2 Mechanism of Action
The 1,4-dihydropyridines, phenylalkylamines and benzothiazepines are characterised by 
their shared ability to inhibit the inward flux of calcium ions across the cell membrane 
via the L-type calcium channels (long-lasting high voltage activated). At therapeutic 
concentrations, these agents have no effects on T-type calcium channels. In contrast, 
mibefradil preferentially blocks the T-type (transient low voltage activated) calcium 
channels as well as partially affecting the L-type channels (25-70%) (Mishra and 
Hermsmeyer, 1994).
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Figure 3.2.2. Chemical structures of mibefradil, verapamil and diltiazem
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3.2.2.3 Pharmacological Action
Differences in pharmacological action follow differences in mechanism of action. In 
vascular smooth muscle cells, the L- and T-type calcium channel blockers cause 
vasodilatation by a lowering of peripheral vascular resistance with a consequent 
lowering of blood pressure.
Additionally, the action of calcium channel blockers in the sinus node cells slows the 
rate of cardiac conduction to produce a reduction in the heart rate.
3.2.2.4 Pharmacokinetics
Mibefradil is rapidly absorbed after oral administration with peak plasma concentrations 
being reached after 1-2 hours (Welker, 1998). Mibefradil bioavailability is high with a 
low proportion of drug metabolised before reaching the systemic circulation (Clozel et 
al., 1991). A single 80 mg oral dose gives an absolute bioavailability of 70 % but with 
chronic dosing of 50 mg, the bioavailability of mibefradil approaches 90 % due to 
saturation of first-pass metabolism (Brogden and Marklam, 1997). Diltiazem is also 
rapidly and completely absorbed after oral administration with peak plasma 
concentrations reached within 1.5 hours after oral administration of a normal release 
formulation (Buckley et al., 1990). Verapamil is rapidly and almost completely 
absorbed (> 90%) after oral administration, of a normal release formulation. A 
modified slow-release form of verapamil is more slowly absorbed and has an onset of 
action of 6  hours and duration of about 14 hours. However, because of extensive first- 
pass hepatic metabolism, only approximately 2 0  % of the drug reaches the circulation. 
The peak antihypertensive effect following intravenous administration occurs in 5 
minutes, and by 10 to 20 minutes the effect is dissipated (Hamann et al., 1984).
The high volume of distribution of mibefradil (Vss 130-220 L) indicates that it is widely 
distributed in body tissues (Welker et al., 1989). At therapeutic concentrations, it is 
highly (> 95%) bound to oq -  acid glycoprotein in the plasma. Verapamil mean volume 
of distribution ranges from 310 to 406 L (Hamann et al., 1984) and it is highly protein
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bound (80 to 90%). The absolute bioavailability in healthy individuals is 35 to 40% 
(Kirsten et al., 1998). The mean volume of distribution is 209 L (Buckley et al., 1990).
Verapamil exhibits a bi-exponential decline after a single dose of both oral and 
intravenous administration, with an initial distribution phase lasting from 18 to 35 
minutes and a much slower elimination phase with a half-life varying from 3 to 7 hours. 
Seventy per cent of an oral or intravenous dose is excreted by the kidney and 15 % is 
eliminated via the gastrointestinal route. Only 3 to 4 % is excreted unchanged in the 
urine. The terminal elimination half-life for verapamil ranges from 2.7 to 4.8 hours and 
the systemic clearance is reported to be 875 ml min' 1 (Hamann et al., 1984). Several 
metabolites are produced by hepatic metabolism. It is unclear to what extent these 
metabolites contribute to the drug’s therapeutic effects. Diltiazem is metabolised by the 
liver (65%) with the remainder being excreted by the kidneys. The elimination half-life 
after oral administration ranges from 2 to 11 hours (Buckley et al., 1990).
Mibefradil is a lipophilic compound that is extensively metabolised by the liver and less 
than 3 per cent of an oral dose is excreted unchanged in urine. Its metabolism is 
mediated by two competing pathways: a) cytochrome P45o-catalysed oxidative reactions, 
including hydroxylation and dealkylation, and b) hydrolysis of the ester side-chain to 
give the major circulating metabolite, Ro-5966. Activity of the cytochrome P450 
isoenzymes (CYP3A4, CYP1A2 and CYP2D6) is competitively inhibited by mibefradil. 
At steady state, the cytochrome P45o-catalyzed reactions become saturated and 
hydrolysis then becomes the more efficient of the two pathways. The inhibition of the 
first pathway of metabolism combined with low activity of the hepatic esterase is 
responsible for decrease in clearance after multiple dosing resulting in a prolongation of 
half-life. The elimination half-life (ti/2p) after single oral administration is 12 to 14 
hours and 23.7 hours at steady state with a dose of 100 mg daily. This increases further 
with higher doses (> 160 mg). One explanation for that phenomenon is that at low 
doses, plasma concentrations of mibefradil may not be sufficient to inhibit oxidative 
metabolism, but with multiple doses, increased drug concentrations may be sufficient to 
inhibit it. That is confirmed by the decrease in clearance values (CL/F) at steady state.
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Clearance varies between 15.6 and 21.0 L h' 1 after intravenous administration (Welker 
et al., 1989). After oral administration it is reported to be 7.6 L h"1 at steady state after 
the administration of 100 mg per day, as opposed to 13.1 L h' 1 after the administration 
of 100 mg as single dose (Welker et al., 1998). Preclinical trials on Ro 40-5966, the 
major metabolite of mibefradil, have demonstrated that its pharmacodynamic activity is 
only about 10 % that of the parent compound. Thus, it is unlikely to affect mibefradil‘s 
overall pharmacological profile (Brogden and Marklam, 1997).
3.2.3 SELECTION OF THE PHARMACODYNAMIC MODEL 
The description of the linear and Emax model has been given elsewhere (Chapter 1). 
Substituting the Emax parameter in the Emax model equation by the parameter 
representing the maximum velocity of the reaction (Vmax) and EC50 by the parameter 
representing the concentration at which half of the maximum velocity occurs (Km), the 
Michaelis-Menten model is obtained. Similarities of these two models arise from the 
fact that both equations were derived from the law of mass receptor theory as proposed 
by Ariens et al. (1964). The Michaelis Menten equation was first applied to enzymatic 
reactions. Later, it was adapted to pharmacokinetic modelling. It has been reported that 
problems may be encountered in parameter estimation with the Michaelis-Menten 
equation (Godfrey and Fitch, 1984). Estimates of Vmax and Km were associated with a 
high correlation. This is due to the fact that the parameters appear in the equation as a 
ratio and therefore changes in the estimates of Vmax may be compensated for by 
changes in Km. Parameters estimation is hampered by a high correlation between 
estimates of Vmax and Km as occurs when concentrations are below the Km. These 
investigators proposed an approximation to this model by linearization. Similar 
problems were encountered by Ratkowsky (1986) when using the Michaelis-Menten 
model for simple enzymatic reactions. They have suggested a reparameterization of this 
model, in which the two parameters appear in the denominator of the equation. Two 
new parameters were derived given by 1/Vmax and Km/Vmax.
In vivo, studies that achieve high plasma concentrations are limited by the occurrence of
side effects. This can prevent the Emax effect being reached and thus the Emax curve is
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not defined. This is a situation similar to that described for the Michaelis-Menten 
model. The variance-covariance matrix showed that Emax and EC50 were very highly 
correlated. The parameters estimated with a wide variability, rendering the conclusion 
meaningless. Holford et al (1982) proposed the use of a linear model, which is often 
useful in practice but is also limited by how close the data are to a straight line. Linear 
models can be useful when drug concentrations are very low but as plasma 
concentrations increase and the effect reaches Emax, the sigmoid curve became more 
defined and therefore data deviates more from linearity. Under these circumstances, 
fitting a straight line will force the data to fit a line but the slope will depend on the 
curvature and will vary from patient to patient according to the fraction of Emax 
attained by each patient.
Recently, Della Paschoa et al. (1998) proposed the use of an exponential equation 
derived from the sigmoid Emax model to describe the concentration-anticonvulsant 
effect relationship of phenytoin when the Emax values were not reached within 
acceptable electric stimulation levels. Another re-parameterization of the sigmoid Emax 
model was suggested by Bachman et al. (1998). These investigators claimed that the re­
parameterized equation yielded a more precise and accurate parameter estimates than 
the standard sigmoid Emax model.
More recently, a different re-parameterization of the Emax model has been proposed by 
Schoemaker et al. (1998). The reparameterization consists of introducing an alternative 
parameter, SO, equal to Emax/EC50, into the Emax model. After mathematical re­
arrangement, it yields the following equation for the concentration-effect relationship:
E max* SO * Y
E = -------------------  Eq. 3.1
E max+ SO * Y
where SO is a measure of potency of the drug and is equal to the slope of the tangent to 
the Emax curve at zero concentrations and Y is the drug concentration, either predicted 
or measured. The SO model can be used to relate the effect site concentration (Ye) to the 
effect, i.e.
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E = Ema**S0*Ye Eq. 3.2
Emax+SO* Ye
where Ye is the concentration predicted at the effect site.
3.3 AIMS OF THE ANALYSIS
This study had two primary aims:
i) Characterisation of the single-dose pharmacokinetics and pharmacodynamics of 
mibefradil relative to verapamil and diltiazem;
ii) Characterisation of the concentration-effect relationships of single and multiple 
doses of mibefradil and verapamil in hypertensive patients.
3.4 PATIENTS AND METHODS
3.4.1 STUDY DESIGN
The study was carried out in two centres: one in Glasgow (Western Infirmary) and the 
other in Berkshire (Chiltem International Ltd, UK). The protocol was approved by the 
ethics review committees of each centre and all patients gave written informed consent 
before any screening procedures were performed. Patients were withdrawn from 
previous unsatisfactory antihypertensive treatment to enter a 4-week single-blind 
placebo run-in period (Period I). The principal inclusion criterion was a sitting diastolic 
blood pressure of 95-114 mmHg (inclusive) on days 21 and 28 of the placebo run-in, 
prior to drug intake. Patients were required to be in a satisfactory healthy state, as 
assessed by medical history, physical examination and clinical laboratory determination.
Patients were excluded if they had severe or malignant hypertension (WHO stage HI) 
secondary hypertension, or had had a myocardial infarction within the last 6  months, or 
with current or prior evidence of heart failure. Patients with haemodynamically relevant 
rhythm disturbances, 1st degree AV-block (PQ-interval above 200 msec) or higher
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degree AV-block were not enrolled in the study. Patients taking drugs that might affect 
blood pressure or which were known to interact with the effects of calcium channel 
blockers, such as anti-arrhythmics, sympathomimetic drugs, oral contraceptives, 
psychotropic medications, non steroidal anti-inflammatory drugs, were not incorporated 
in the study.
Patients who fulfilled the inclusion criteria were then enrolled in a single-dose, double 
blind, crossover study (Period II) of four different treatments, including placebo. Over a 
four-week period, patients reported at weekly intervals to receive capsules containing 
mibefradil 150 mg, verapamil 240 mg, and diltiazem 240 mg or matching placebo. 
Treatments were administered with 100 ml of tap water and the blood sampling and the 
pharmacodynamic measurements were timed according to the time of the administration 
of the drugs.
After a further washout period of one week, patients entered a second steady-state 
(Period HI). They were randomly allocated to receive either mibefradil 100 mg or 
verapamil 240 mg (slow release) once daily for 4 weeks. Pharmacodynamic and drug 
concentration measurements were made on a fifth occasion, the last day of the steady- 
state period.
3.4.2 PATIENTS
Twenty-three patients aged 18-70 years were entered into this study. Only 20 of the 23 
recruited patients met the inclusion criteria at the end of the placebo period and 18 
completed the single-dose study (Period E). Table 3.4.2 lists the demographic 
characteristics and the clinical status of the patients involved in the single dose study.
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Table 3.4.2 Demographic characteristics and clinical status of the patients 
included in the single-dose study (Period II)
ID Height
(cm)
Weight
(kg)
Sex Smoking
status
Age
(years)
Baseline
DBP
(mmHg)
Baseline HR 
(bpm)
1 173 81 M 1 60 95 65
2 146 52 F 1 58 98 86
3 169 75 M 1 46 93 74
4 163 93 M 0 30 105 92
6 165 74 M 0 50 98 84
7 150 77 F 0 67 92 67
8 157 72 F 0 68 99 71
9 173 107 M 1 61 107 101
11 166 78 F 0 60 96 78
13 173 62 M 1 53 94 70
14 164 76 F 0 69 104 96
16 158 68 F 0 58 94 69
17 178 108 M 0 50 87 71
18 165 77 F 0 59 110 106
19 183 98 M 1 57 99 103
20 169 77 M 0 55 102 94
22 168 79 M 0 60 101 64
23 166 88 M 0 66 97 80
MEAN 166 80 57 98 82
SD 9 14 9 6 14
Key: F  -female; M  - male; DBP - Diastolic blood pressure; HR - Heart rate. 0 - non-smoker; 1 - smoker; 
bpm - beats per minute.
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Of those 18 patients, seventeen underwent the steady-state study (Period El), 10 
receiving mibefradil and 7 receiving verapamil. The ten patients from the mibefradil 
group had a mean age of 59 years and a mean weight of 85 kg. Three were females and 
seven were males, their entry diastolic blood pressure was 98 mmHg and heart rate was 
81 beats per minute (bpm). The verapamil group included three females and four males 
with a mean age of 54 years and a mean weight of 77 kg and the entry diastolic blood 
pressure was 99 mmHg and the heart rate was 82 bpm.
3.4.3 DRUG ASSAY
Venous blood samples were taken at 0, 0.5, 1, 1.5, 2, 3 ,4 , 6 , 8 , 10, 24 and 48 hours after 
the dose, then separated immediately into serum (mibefradil, placebo) or plasma 
(verapamil, diltiazem) and stored at -20° C. Verapamil and norverapamil and diltiazem 
plasma concentrations were measured using liquid/liquid extraction followed by 
reverse-phase high performance liquid chromatography with ultraviolet detection (mean 
coefficients of variation 7.1, 8.9 and 4.7%, respectively) (Dube et al., 1988). Mibefradil 
concentrations were measured using a high performance liquid chromatography- 
fluorescence method (mean coefficients of variation 6.3 and 6.2%, respectively) (Eggers 
et al., 1990). Drug assay of verapamil and diltiazem were performed in Glasgow and 
mibefradil in Roche, Basel.
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3.4.4 PHARMACODYNAMIC MEASUREMENTS
Pharmacodynamic endpoints were changes in diastolic blood pressure (DBP), heart rate 
(HR) and electrocardiographic PQ interval. The times of drug administration were 
defined as time zero and haemodynamic measurements were made at 0.5, 1, 1.5, 2, 3 ,4 , 
6 , 8 , 10, and 24 hours for study Period EL The same schedule was followed for the last 
day of the steady-state study (Period HI) for mibefradil. For verapamil, PD 
measurements were performed only until 1 0  hours of the last dose of the steady-state 
study.
Blood pressure and the heart rate were measured with a Dinamap Critikon (Tampa, 
Florida, USA) semi-automatic sphygmomanometer. Baseline measurements were 
recorded after a 60-minute period of rest in a supine position. Blood pressure and heart 
rate were measured supine (after not less than 1 0  minutes rest) and standing (after 2  and 
4 minutes). Mean values for supine and standing blood pressure were calculated for 
each time point.
PQ intervals were calculated as the mean of five consecutive readings from a 
conventional electrocardiogram (ECG) rhythm strip at 50 mm/s (lead II where 
available). An independent, blind observer measured these using customised software 
with a supergrid 20 x 20 SPGTT Digitizer (Summagraphics, Fairfield, Connecticut, 
USA).
3.4.5 PHARMACOKINETIC DATA ANALYSIS
All calculations in this section were performed on an Opus personal computer, with a 
Pentium 120 MHZ processor under MS Windows version 3.11, using the software 
WinNonlin (1996a).
A hierarchy of pharmacokinetic models was fitted to the individual concentration-time 
profiles for mibefradil, diltiazem and verapamil by nonlinear regression analysis. The 
equations used are described in Appendix I. Drug concentrations below the limit of
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quantification were removed from the analysis, except when they were at the beginning 
of the concentration-time profile (for a single dose). In this case they were set to zero.
The pharmacokinetic model was fitted to the data with and without a weighting scheme. 
The weighting (Wi) was set to the reciprocal of the concentration predicted from the 
pharmacokinetic model as:
where Yj represents the predicted concentration at the jth time. Several values of n 
were tested.
Individual pharmacokinetic parameters were estimated by the least squares method 
using the Gauss-Newton (Levenbergh and Hartley) search algorithm. Initial 
pharmacokinetic parameter estimates for a one-compartment model were calculated by 
the curve stripping method (Gibaldi and Perrier, 1982). Parameters were constrained by 
arbitrary setting of upper and lower boundaries on the initial parameter estimates.
For the single-dose studies with each drug, the following pharmacokinetic models were 
fitted to the concentration-time data set of each individual. The same approach was 
applied to the steady state mibefradil data but parameters for steady state verapamil 
were not estimated because a modified release formulation was used and the data could 
not be modelled. The models were parameterised as shown:
Mono-exponential; first-order absorption 
Mono-exponential; first-order absorption; tlag 
Bi-exponential; first-order absorption 
Bi-exponential; first-order absorption; tlag 
Mono-exponential; zero-order absorption 
Bi-exponential; zero-order absorption 
Bi-exponential; zero-order absorption; tlag
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(V/F, kOl, klO)
(V/F, kOl, klO, tlag)
(V/F, kOl, klO, kl2, k21)
(V/F, kOl, klO, kl2, k21, tlag) 
(V/F, Tmax, klO)
(V/F, Tmax, kl2, k21,k l0) 
(V/F, Tmax, k!2, k21, klO, tlag)
where kOl is the first-order absorption rate constant of drug into compartment 1, klO is 
the first-order elimination rate constant from compartment 1; V is the volume of 
distribution of the central compartment, F is the bioavailability and k l2  and k21 
represent the first-order rate constants associated with the transfer of drug between 
compartments 1 and 2 .
The first four models were selected from compiled models included in the WinNonlin 
pharmacokinetic model library. The last three models were written in ASCII code. 
Examples of relevant model commands are shown in Appendix n. Secondary 
parameters from these models, AUC and clearance, were derived using the equations 
shown in Appendix I. For the mono-exponential decline model, half-life was calculated 
from klO, as shown in Appendix I. In the case of the two-compartment model the 
relationships between the disposition rate constants, Xi and X2 , and the microconstants 
were calculated as follows:
i^> X2 = — [(k12 + k 21 + k10) ±yj (kn + k21 + k 10) — 4 k 21 k ]0 j
and the terminal half-life was:
T i /2 A 2 =  0 . 6 9 3 / ^ 2
3.4.6 PHARMACODYNAMIC RESPONSES
Diastolic blood pressure and heart rate were measured as described previously. For 
modelling the haemodynamic effects, the effect profiles derived on each study day were 
subjected to 3-point smoothing and then at each time the response of patient on placebo 
was subtracted from the responses measured during active treatment.
The normal cardiac cycle is triggered by an electrical impulse originating in the 
sinoatrial (SA) node. The electrical impulse is then transmitted to the AV node where it 
is delayed before being rapidly propagated through the ‘Bundle of His’. It then divides 
in the septum between the ventricles into the right and left (bundle) branches of the 
‘Purkinje System’. The electrical changes associated with contraction of the heart can
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be recorded in an electrocardiogram (ECG). The sinus rhythm cycle begins with a ‘P’ 
wave which corresponds to the contraction of the atria. Following an isoelectrical 
period (PR segment) the ventricles contract causing a large deflection of the ECG and 
this is called the ‘QRS’ complex. The ‘T’ wave of the ECG is caused by the return of 
the ventricular mass to the resting electrical state (repolarisation). Figure 3.4.6 
represents a cycle from the electrocardiogram.
PQ interval - Segments and intervals between waves (P, Q, R, S, T, U) can be 
calculated. The PQ segment is measured from the end of the P wave to the onset of 
QRS, while the PQ interval includes beginning of P to the onset of Q. It corresponds to 
the activation of the atria. The placebo data was corrected in the same manner as 
described for blood pressure and heart rate.
3.4.7 PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS 
To take account of diurnal variations and background changes, pharmacodynamic 
responses were determined after subtraction of the measured responses following active 
drug treatment (both single dose and steady state) from the responses obtained after 
(single dose) placebo.
Predicted concentrations derived from the pharmacokinetic analysis were used when 
fitting the pharmacodynamic model, except for verapamil at steady state where the 
measured concentrations were used. Pharmacodynamic analyses were carried out with 
the weighting scheme set at 1 .
Several models were assessed for relating drug concentrations to measured effects. The 
linear model was used when the pharmacological effect showed a direct proportionality 
with predicted/measured concentrations. The Emax model was used when the time 
course of action was characterised by a hyperbolic shape. Alternatively, the sigmoidal 
Emax model was used to fit to the data and the concentration-effect relationship. 
Detailed description of those models was given in Chapter 1 Section 1.5.2. In addition,
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Figure 3.4.6 Representation of an electrocardiogram cycle
R
Q  S
the alternative parameterization of the Emax model, proposed by Schoemaker 
(Schoemaker et al., 1998), was used in this analysis.
Plots of pharmacological effect against plasma concentration, with points connected in 
time order were used to identify hysteresis. Hysteresis was removed by incorporating a 
hypothetical effect compartment to the pharmacokinetic/ pharmacodynamic model. 
Equations describing the predicted concentration at the effect site, Ye, are listed in 
Appendix I and examples of the command files used are presented in Appendix EL
The population values of pharmacokinetic and pharmacodynamic parameters were 
obtained by calculating the mean values and the standard deviation of the individual 
parameter estimates.
3.4.8 MODEL SELECTION
The criteria used to assess the adequacy of a model in describing the data included the 
ability of WinNonlin to produce estimates for all parameters (including standard errors 
and their magnitudes) and analysis of residual plots. Whenever appropriate, the 
goodness of fit was complemented by statistical tests, such as the general linear test or 
the Aikaike Information Criterion (AIC).
The precision of parameter estimates was used in the assessment of goodness of fit 
(Boxenbaum et al., 1974). The standard errors (SE) and the confidence intervals (Cl) of 
the parameter estimates were used as a tool to assess the parameter estimate precision. 
The precision of parameter estimates was expressed in terms of coefficient of variation 
(cv) defined as follows:
SF
CV (%) = 100 * - s -  
0
where 0  represents the parameter estimates.
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WinNonlin calculates confidence intervals by two different methods, univariate and by 
planar limits. The confidence interval for the planar method takes into account the 
correlation between model parameters and was calculated by:
0 ±  VF*(o,NP.d0 * N P * ( S E ) 2
whereas the univariate method calculates the confidence interval without taking into 
consideration the correlation between parameters and was obtained from the equation:
0 ±(ta,df)(SE)
where 0 represents the parameter estimate, t is the Student t-statistic, a  is the 
probability level, p is the number of parameters, df is the degrees of freedom and F is 
derived from an F distribution table. DF are degrees of freedom calculated by:
DF = N - p
N represents the number of data points.
Correlation between parameters is an indication that there may be insufficient 
information in the concentration-time data to be able to determine both parameters 
accurately and precisely. High correlation may also manifest itself in large standard 
deviations and CL The matrix of correlation coefficients provided in the WinNonlin 
output was inspected.
The condition number from the WinNonlin output is defined as the square root of the 
ratio of the largest to the smallest eigenvalue, and was used as an indication of the 
stability of the parameter estimates. The smaller the condition number the better the fit.
The general linear test (Boxenbaum et al., 1974) was used to evaluate the statistical
significance of the change of the residual sum of squares obtained by fitting a
hierarchical model with an additional parameter. The test entails calculating the ratio of
the model variance F, by:
p _ W SSr-W SSf * DFf
WSSf DFr -  DFf
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where WSSr is the weighted sums of squared deviations obtained from the model with a 
reduced number of parameters, WSSf is the weighted sum of squared deviations 
obtained from the model with an extra parameter. The subscripts r and f represent the 
reduced and the full model, respectively (DFr > DFf). The significance level was set to p 
< 0.05. The calculated F was compared to the critical value derived from an F 
distribution table, where the numerator had ADF (differences in degrees of freedom 
between the two models) and the denominator had DFf (degrees of freedom with the full 
model). If the calculated F value was less than the value from the table, the weighted 
sums of squared deviation from the reduced and full model were not significantly 
different and therefore the reduced model was selected.
The model selection process was also based upon another statistical test, the Akaike 
Information Criterion (AIC) (Yamaoka et al., 1978) calculated as follows:
AIC = N In WSS + 2p
where N is the number of data points, p is the number of estimated parameters, WSS is 
the weighted sum of squared residuals. The Schwarz Criterion (SC) can similarly be 
used in model selection and was calculated as follows (Schwarz, 1978):
SC = N In WSS + p In N
The model which best described the data was the one corresponding to the lowest values 
of the AIC and SC criteria. The AIC and SC were used to compare models with the 
same number of parameters.
The choice of the weighting scheme was based on the inspection of plots of residuals 
(weighted or unweighted) against fitted concentrations. The weighting which produced 
a random, homogeneous scatter of the residuals/weighted residuals about the abscissa 
axis was selected.
Parameters for the competing pharmacodynamic models were estimated for each 
individual. The choice between a linear and an Emax-model was made for each patient 
based on the precision of parameter estimates and the reduction in the sum of squared 
deviations. The choice between an Emax model with or without an intercept was made
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for each patient using the general linear test (Ludden et al., 1994). The statistical 
significance of the incorporation of an effect compartment in the pharmacodynamic 
model was evaluated by the general linear test (Ludden et al., 1994).
3.4.9 STATISTICS
A comparison of individual pharmacokinetic/pharmacodynamic parameters was used to 
assess differences between treatments. Individual parameter estimates obtained for each 
treatment were compared with each other by parametric or non-parametric t-statistics. 
Paired tests were used in the case of the single-dose study as all patients received the 
three drugs. Unpaired tests were used for the steady state study as not all patients 
received each drug at steady state. For mibefradil, pharmacokinetic and 
pharmacodynamic parameters obtained at steady state and after a single dose were 
compared by a paired t-test. Only patients participating in both studies were included. 
Two-sided p values less than 0.05 were considered statistically significant. Statistical 
analyses were carried out using the statistical software, Minitab (1996b).
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3.5 RESULTS I
3.5.1 PHARMACOKINETICS: SINGLE-DOSE STUDY
3.5.1.1 Mibefradil
The data set comprised 195 concentrations from 18 patients with measurements ranging 
from 14.5 to 1727.0 ng ml'1. According to the protocol, all patients in this treatment 
group should have had blood samples taken up to 48 hours post-dose, but patients 4 and 
6  only had blood samples collected up to 24 hours after the dose and one concentration 
at 3 hours for patient 3 was not available. Patient 17 had the lowest range of plasma 
concentrations whereas patient 11 had the widest range of measured plasma 
concentrations.
A mono-exponential open model with first-order input, elimination from the central
compartment and a weighting scheme of Wi = J — best described the concentration-
Y
time data after the administration of a single dose of 150 mg of mibefradil. Secondary 
parameters such as time to peak (Tmax), maximum concentration (Cmax), area under 
the concentration-time curve (AUC), half-life (Tm) and clearance (CL) were derived 
from the equations shown in Appendix I . Table 3.5.1.a shows the individual 
pharmacokinetic parameters estimated from this model and Figure 3.5.1.a presents the 
predicted and measured concentrations against time for each individual.
The lowest estimate of V/F was 96.1 L for patient 11 which reflected a high Cmax of 
1727 ng ml' 1 measured plasma concentration. In contrast, for patient 17 the V/F 
estimate of 530 L corresponded to low measured plasma concentrations (Cmax 267 ng 
ml'1). This range of volume of distribution estimates might reflect variability in both F 
and volume of distribution.
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Figure 3.5.1.a Measured (• )  and predicted (o) concentrations against time for 
mibefradil (single-dose study) for patients 1 to 13.
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Figure 3.5.1.a (cont.) Measured ( • )  and predicted (o) concentrations against time for
mibefradil (single-dose study) for patients 14 to 23.
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Table 3.5.1 a Individual pharmacokinetic parameter estimates of mibefradil, 150 mg
(single-dose study)
ID Modela V/F cv k cv Tlag cv Tl/2 cv Tmax cv Cmax cv R1
(L) % Or1) % (h) % (h) % (h) % (ngml1) %
1 2 179 5.1 0.0384 6.9 0.49 0.4 18.1 6.8 2.77 10.4 769 4.2 0.84
2 2 144 5.9 0.0336 9.1 0.48 0.7 20.7 9.1 2.88 12.2 960 4.9 0.82
3 1 205 3.5 0.0271 6.4 26.0 6.3 2.59 8.2 681 2.9 0.78
4 139 4.8 0.0469 10.1 0.44 2.1 14.8 10.1 2.80 6.3 963 3.5 0.76
6 1 109 15.1 0.0626 24.1 11.1 24.1 2.77 22.1 1155 10.2 0.68
7 145 4.3 0.0388 6.1 0.34 44.0 17.9 6.1 1.37 46.8 993 4.1 0.77
8 1 156 4.6 0.0248 10.6 28.0 10.5 1.33 29.3 930 4.1 0.61
9 1 221 6.4 0.0403 8.6 17.2 8.6 2.20 30.9 621 5.3 0.77
11 96.1 10.1 0.0433 12.6 0.49 1.0 16.0 12.6 2.01 30.5 1462 8.7 0.79
13 1 152 6.7 0.0437 8.7 15.9 8.7 1.43 66.3 929 5.9 0.75
14 1 151 4.3 0.0398 6.4 17.4 6.4 0.81 17.1 961 4.2 0.76
16 1 162 4.0 0.0446 5.1 15.6 5.0 1.48 46.8 869 3.5 0.76
17 1 530 7.4 0.0534 8.1 13.0 8.0 1.12 46.8 267 6.7 0.79
18 1 172 9.6 0.0468 11.1 14.8 11.1 2.08 25.8 793 7.9 0.77
19 175 9.2 0.0348 14.2 0.44 8.5 19.9 14.2 1.94 36.1 814 7.9 0.77
20 1 152 6.6 0.0372 22.0 15.5 22.0 1.96 18.2 906 4.7 0.74
22 1 137 5.4 0.0031 7.3 16.4 7.3 1.37 26.7 1037 4.7 0.77
23 1 190 10.4 0.0423 14.1 16.4 14.1 1.19 64.3 749 9.2 0.72
Mean 179 0.0390 17.4 1.89 881
SD 93.0 0.0125 4.1 0.66 243
Key: F  represents the bioavailability; Tlag the lag time; V  is the volume o f  distribution; Tm is the 
elimination half-life; k the elimination rate constant; cv is the coefficient o f  variation; T  max is the time to 
reach the Cmax and Cmax is the maximum concentration, R2 coefficient o f  determination 
a mono-exponential decline model with first order absorption, with or without tlag.
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Mibefradil was rapidly absorbed and peak concentrations were attained at 1.9 ± 0.7 
hours post dose. It was noted that points collected during the absorption phase were 
scarce. The inclusion of a lag time as an extra parameter in the model improved the fit 
for patients 1, 2 ,4 , 7, 11 and 19. The mean (SD) elimination rate constant was 0.0390 ± 
0.0125 h -1, the mean (SD) value for clearance/F was 7.4 (± 5.0) L h"1 and the average 
elimination half-life was 17.4 hours. Although the profiles suggested a bi-exponential 
decline for patients 18, 22 and 23, this model gave imprecise parameter estimates, with 
a wide cv therefore a mono-exponential decline model was chosen.
3.5.1.2 Verapamil
One hundred and eighty-seven verapamil concentrations were available from the single­
dose study. Concentrations ranged from 8.9 to 1091.6 ng ml"1 and most patients were 
sampled up to 24 hours after the administration of the dose. Patients 3, 4 and 6  only had 
samples up to 10 hours and patients 11 and 14 had drug concentrations measured up to 
48 hours after the dose.
The absorption of verapamil was rapid and best described by a zero-order process. For 
patients 4, 6 , 7, 8 , 11, 17 and 23, the first measured concentration coincided with Cmax, 
and it can be seen in Figure 3.5.l.b that for these individuals peak concentrations were 
attained within 0.5 hours after the dose, therefore no information during the absorption 
phase was available for modelling. The disposition followed a bi-exponential decline 
with elimination from the central compartment.
Predicted and measured concentrations from the best model were plotted against time 
and are shown in Figure 3.5.l.b. Vi/F varied within a wide range (from 168 to 823 L) 
with a mean value of 390 L, as shown in Table 3.5.l.b. Coefficients of variations of
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Figure 3.5.1.b (cont.) Measured ( • )  and predicted (o) concentrations against time
verapamil (single-dose study) for patients 14 to 23
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Table 3.5.1 b Individual pharmacokinetic parameter estimates of verapamil, 240 mg
(single-dose study)
ID V/F cv k cv Tabs cv Tlag cv T V 2 R2
(L) % (h 1) % (h) % (h) % (h)
1 168 4.2 0.270 4.1 0.761 4.7 7.45 0.86
2 227 41.8 0.274 25.5 1.06 33.0 9.83 0.80
3 621 24.3 0.250 280.6 1.99 31.7 10.0 0.85
4 214 * 0.492 * 0.463 * 3.24 0.93
6 341 * 0.328 * 0.325 * 4.29 0.91
7 775 * 0.250 * 0.232 * 0.29 * 11.7 0.88
8 175 * 0.260 * 0.586 * 10.5 0.84
9 446 18.4 0.191 18.2 1.00 26.5 15.0 0.83
11 823 * 0.161 * 0.141 * 0.39 * 39.4 0.89
13 500 16.4 0.220 30.9 1.00 16.7 9.3 0.85
14 250 19.6 0.191 26.7 1.04 10.8 10.9 0.84
16 427 6.8 0.173 8.5 0.634 11.4 19.5 0.82
17 500 21.1 0.276 14.8 0.632 17.6 11.9 0.94
18 301 9.8 0.191 13.8 0.874 14.6 26.1 0.85
19 313 17.9 0.238 14.5 1.00 24.3 13.9 0.86
20 376 18.5 0.337 17.2 1.00 10.1 6.47 0.88
22 221 18.2 0.285 14.3 1.00 25.3 8.99 0.86
23 337 * 0.250 * 0.231 * 0.31 * 12.3 0.90
Mean 390 0.258 0.77 12.8
SD 194 0.076 0.44 8.48
Key: F represents the bioavailability; Tlag the lag time; V is the volume o f  distribution; Tm is the 
elimination half-life; k the elimination rate constant; cv is the coefficient o f  variation; and Tabs is 
the time taken fo r  the drug to be absorbed.
* Not estimated
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the parameter estimates were not estimated for patients 4, 6 , 7, 8 , 11 and 23. However 
the addition of a Tlag to the model further improved the fit for patients 7, 11, and 23. 
The mean estimate for clearance/F for verapamil was 95.2 (± 41.9) L h'1.
3.5.1.3 Diltiazem
Two hundred and one concentrations were available from the single-dose study for 
analysis of diltiazem. Drug concentrations ranged from 2.2 to 1371.0 ng ml’1 and were 
measured up to 48 hours in most patients, but patients 3 ,4  and 19 had the last 
measurement taken at 24 hours post dose. Patient 8  had only nine samples available, the 
last being taken 10 hours post dose. The diltiazem disposition was similar to that of 
verapamil, and was most appropriately described by a model with a zero-order
absorption process and bi-exponential elimination. The weighting scheme was — as
Y 2
before. The pharmacokinetic parameter estimates for diltiazem are shown in Table 
3.5.l.c and Figure 3.5.1.C shows the measured and predicted concentration-time profiles 
for each individual. Rapid absorption and lack of data points for patients 7, 20 and 23 
led to peak drug concentrations being reached within 0.5 hours, therefore there was no 
information available to fully characterise the absorption phase. The average time taken 
to reach the maximum concentration (Tabs) was 1.08 ± 0.74 hours. For patient 16, the 
Tmax occurred 3 hours post dose. Although the zero-order absorption model was the 
best model, it was not always able to predict the peak plasma concentration.
The mean Vi/F estimate was 320 ± 154 L (620 L for patient 20 and 708 L for patient 
23).
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Figure 3.5.1.C Measured ( • )  and predicted (o) concentrations against time for
diltiazem (single-dose study) for patients 1 to 13
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Figure 3.5.1.C (cont.) Measured (•) and predicted (o) concentrations against time 
diltiazem (single-dose study) for patients 14 to 23
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Table 3.5.1 c Individual pharmacokinetic parameter estimates of diltiazem, 240 mg
(single-dose study)
ID V/F cv k cv Tabs cv Tlag Tin R2
(L) % (h-1) % (h) % (h) (h)
1 281 16.0 0.165 21.6 1.39 6.7 9.23 0.91
2 212 31.1 0.232 22.8 1.88 35.7 8.40 0.85
3 344 20.8 0.262 20.3 1.01 27.6 4.58 0.84
4 296 47.6 0.191 34.4 1.83 62.3 7.14 0.83
6 350 7.8 0.162 7.4 1.60 9.1 6.48 0.89
7 383 * 0.212 * 0.291 * 0.21 19.5 0.93
8 256 * 0.168 * 0.802 * 0.37 27.4 0.98
9 300 32.1 0.172 26.3 1.39 36.9 10.9 0.87
11 178 3.1 0.240 2.7 0.61 3.9 8.05 0.99
13 129 5.7 0.238 5.4 0.59 10.8 5.73 0.93
14 209 10.9 0.210 9.9 0.51 12.7 10.1 0.93
16 451 25.9 0.132 25.7 3.15 27.2 9.45 0.88
17 406 4.3 0.189 3.9 0.741 6.0 10.8 0.92
18 195 26.4 0.258 31.9 1.25 31.5 9.59 0.87
19 156 28.6 0.397 17.9 1.06 17.4 7.50 0.87
20 620 * 0.234 * 0.21 * 0.29 7.26 0.94
22 286 10.2 0.199 8.6 0.994 12.9 9.24 0.92
23 708 * 0.201 * 0.12 * 0.43 10.2 0.93
Mean 320 0.215 1.08 10.1
SD 154 0.058 0.74 5.34
Key: F  represents the bioavailability; Tlag the lag time; V is the volume o f  distribution; Tm is the 
elimination half-life; k the elimination rate constant; cv is the coefficient o f  variation, and Tabs is 
the time taken fo r  the drug to be absorbed.
* Not estimated
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3.5.2 PHARMACOKINETICS: STEADY-STATE STUDY
3.5.2.1 Mibefradii
One hundred and thirteen steady-state mibefradil concentrations were available for 
analysis. The range of drug concentrations was 61.9 ng ml' 1 to 1421.0 ng ml'1. Patient 
17 had the lowest range of plasma concentrations after steady- state dose.
The pharmacokinetics of mibefradil at steady state were best described by a mono­
exponential decline with first-order absorption and the weighting scheme was the same 
as described for the single-dose study. Table 3.5.2 contains the individual 
pharmacokinetic parameter estimates obtained from this model. The mean V/F estimate 
was 259 ± 94 L and ranged from 148 L to 438 L. The mean elimination rate constant 
was 0.0282 ± 0.0127 h'1, which is smaller than after the single dose. At steady state the 
mibefradil elimination half-life was 28.1 hours, which is longer than after the single 
dose (17.4 hours). Plots of predicted and measured concentrations against time are 
shown in Figure 3.5.2.a.
3.5.2.2 Verapamil
After multiple doses of verapamil SR 240 mg, plasma concentrations ranged from 16.1 
to 1015.5 ng ml'1. Seventy-eighty concentrations were available. Individual plots of 
measured concentration against time are shown in Figure 3.5.2.b and showed a slow 
absorption. As these profiles were difficult to model, the measured concentrations were 
used in the pharmacodynamic model.
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Figure 3.5.2.a Measured (•)  and predicted (o) concentrations against time for 
mibefradil (steady-state study)
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Figure 3.5.2.b Measured concentrations against time for verapamil (steady-state 
study)
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3.6 RESULTS II
The mean values for changes of peaks and troughs in diastolic blood pressure, heart rate 
and PQ interval for mibefradil, verapamil and diltiazem are shown in Table 3.6.
3.6.1 PHARMACODYNAMICS: SINGLE-DOSE STUDY
The mean values for changes in diastolic blood pressure, heart rate and PQ interval with 
time after single doses of mibefradil, verapamil and diltiazem are represented in Figures 
3.6.1a and 3.6.1.b and 3.6.l.c, respectively.
3.6.1.1 Mibefradil
Pharmacodynamic data available for analysis after the administration of a single dose of 
mibefradil 150 mg comprised data from 18 patients and contained 198 measurements 
(11 per patient) for each pharmacodynamic endpoint. Typical examples of the time- 
course of action for the placebo-subtracted changes in diastolic blood pressure (DBP), 
heart rate (HR) and PQ interval are illustrated in Figure 3.6.l.d.
Blood Pressure - The DBP decreased by 10-19 mmHg with the maximum effect 
occurring between 1.5 to 3 hours post dose. In patients 8  and 23 the peak effect 
occurred earlier, at 1 hour post dose. In patient 3 the peak effect was delayed to 3 hours 
after the dose and was associated with a drop in blood pressure of only 10 mmHg. The 
most accentuated drop in DBP, 19 mmHg, occurred in patient 18. Twenty-four hours 
after the dose, the DBP measurements had not returned to the placebo values.
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Figure 3.6.1.a Mean values (SD) for changes in DBP, HR and PQ interval after a
single dose of mibefradil (150 mg)
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Figure 3.6.1.b Mean values (and SD) for changes in DBP, HR and PQ interval after a
single dose of verapamil (240 mg)
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Figure 3.6.1.C Mean values (SD) for changes in DBP, HR and PQ interval after a single
dose of diltiazem (240 mg)
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Figure 3.6.1.d Typical examples of the time-course of action for DBP (solid line and 
close circles), HR (broken line and open circles) and PQ interval after a single dose of 
mibefradil (150 mg)
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Table 3.6 The mean placebo corrected effects of mibefradil, verapamil and diltiazem 
after single dose and at steady state
MIBEFRADIL VERAPAMIL DILTIAZEM 
Peak Trough Peak Trough Peak Trough
Single dose (n=18) (n=■18) (n=:18)
DBP (mmHg) -15 ± 3  -8  ± 2 -26 ± 5 -3 ± 3 -27 ± 3 -4 ± 2
HR (bpm) -11 ± 4 -7 ± 3 -15 ± 5 - 2  ± 2 -9 ± 4 -1  ± 2
PQ interval (msec) 1 2 ± 2  5 ± 2 42 ± 8 4 ± 5 52 ±10 5 ±5
Steady state (n=1 0 ) (n=7)
DBP (mmHg) -15 ± 3 -11 ± 3 -21 ± 4 -10 ± 3
HR (bpm) -11 ± 5 -8  ± 4 -14 ± 4 -7 ± 3
PQ interval (msec) 11 ± 2 7 ± 2 25 ± 10 9 ± 4
Data are mean values ± SD
Key:DBP represents diastolic blood pressure and HR represents heart rate
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Heart Rate - It can be seen from Figure 3.6. l.d, that the changes in HR were small and 
therefore the profile was nearly flat. Patients 1 and 8  had more than one peak effect.
The maximum effect occurred between 1 to 3 hours after the dose. Patients 18 and 19 
had the greatest fall in heart rate, of 17 bpm. Heart rate started to return to normal 
values 8-10 hours after the dose, but by 24 hours post dose it had not yet returned to 
placebo values.
PQ interval - The PQ interval increased during the first hours after dosing, with the 
maximum effect occurring between 1.5 and 4 hours. The increase in PQ interval ranged 
from 8 msec for patients 3 and 9 to 16 msec for patient 7. After the peak effect, the 
extent of the PQ prolongation started to decrease slowly, although again it was sustained 
for more than 24 hours.
3.6.1.2 Verapamil
The data set contained information collected from 18 patients who had received 
verapamil 240 mg. Each patient had 11 measurements for each pharmacodynamic 
endpoint. Typical profiles for the time-course of action for the placebo-subtracted 
changes in DBP, HR, and PQ interval are represented in Figure 3.6 .I.e.
Blood Pressure -  The peak effect of verapamil on DBP occurred 1 hour after the 
administration of the dose for most patients, although it occurred at 2 hours in patient 3, 
as shown in Figure 3.6 .I.e. The fall in DBP ranged from 22 (patient 7) to 37 mmHg 
(patient 6 ). Twenty-four hours post-dose the DBP values were close to placebo values 
for all patients.
Heart Rate - The change in HR was pronounced (Figure 3.6.l.e) with the maximum 
effect ranging from 7 bpm (for patient 1) to 26 bpm (for patients 9 and 18). The peak 
effect was generally achieved between 0.5 to 1 hours. Only patient 3 had the maximum 
effect delayed to 2  hours post dose. Twenty-four hours after the dose the heart rate 
values were similar to placebo values.
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Figure 3.6.1.e Typical examples of the time-course of action for DBP (solid line and close
circles), HR (broken line and open circles) and PQ interval after a single dose of verapamil
(240 mg)
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PQ interval - The maximum effect for PQ interval was attained between 0.5 and 1 hour 
in most patients. For patients 2 and 8 the maximum effect occurred 1.5 hours after the 
dose and for patient 3 at 2 hours after the dose. The PQ changes varied from 24 msec to 
52 msec.
3.6.1.3 Diltiazem
Eighteen patients received 240 mg of diltiazem and each had 11 measurements for 
analysis. Figure 3.6.l.f  shows typical effect-time profiles for DBP, HR and PQ interval.
Blood Pressure -  The maximum decrease in DBP was reached at 1.5 -  2 hours after the 
dose, apart from patient 16 in whom the maximum effect occurred 3 hours after the 
dose. The reduction in DBP varied from 20 (for patient 17) to 31 mmHg (for patient 
14). The DBP values had returned to the placebo values by 24 hours post dose.
Heart Rate - The reduction in heart rate ranged from 5 bpm to 17 bpm. Maximum 
changes in HR occurred 1-2 hours post dose, except for patient 16 in whom the peak 
was delayed and occurred 3 hours post dose. After 24 hours HR had returned to placebo 
values.
PQ interval - For most patients the maximum effect or PQ interval occurred within 1 to 
2 hours, apart from patients 2 and 16 who had the peak effect at 3 hours after the dose. 
The increases were marked and ranged from 33 to 6 6  msec, as shown in Figure 3.6.l.f.
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Figure 3.6.1.f Time-course of action for DBP (solid line and close circles), HR (broken
line and open circles) and PQ interval after a single dose of diltiazem (240mg)
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3.6.2 PHARMACODYNAMICS: STEADY-STATE STUDY 
The mean values for changes in DBP, HR and PQ interval after multiple doses of 
mibefradil (100 mg) and verapamil SR (240 mg) are represented in Figure 3.6.2.a and 
Figure 3.6.2.b, respectively.
3.6.2.1 Mibefradil
One hundred and ten measurements for each pharmacodynamic endpoint were available 
from 10 patients who had multiple doses of 100 mg mibefradil. Figure 3.6.2.C shows 
the time-course of action of DBP, HR and PQ interval.
Blood Pressure - For DBP the peak effect was reached after 1.5 to 2 hours, with the 
exception of patient 17 in whom the peak effect was reached 6  hours after the dose. The 
peak effect was not marked, with a fall in DBP of only 3-6 mmHg. DBP at time 0 
ranged between -3 to -2. After 48 hours it ranged from -11 to -4 mmHg.
Heart Rate - The peak effect for changes in heart rate occurred within 1 to 2 hours after 
the dose. For all patients the time course of action was sustained with changes of 6  
bpm, and the profile was relatively flat, as shown in Figure 3.6.2.d. The placebo- 
subtracted values of HR at time 0 varied between -2  to 2 bpm whereas at 48 hours it 
ranged from -13 to -2  bpm.
PQ interval - PQ interval was prolonged for 3 to 5 msec and the peak effect occurred 1.5 
to 3 hours after the dose. At time 0 the placebo subtracted PQ interval values ranged 
from -3 to 20 msec and after 48h were between 1 and 7 msec.
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Figure 3.6.2.a Mean values ( and SD) for changes in DBP, HR and PQ interval after
multiple doses of mibefradil (100 mg)
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Figure 3.6.2.b Mean values (and SD) for changes in DBP, HR and PQ interval after
multiple doses of verapamil (240 mg)
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Figure 3.6.2.C Time-course of action for changes in DBP (solid line, close circles), HR
(broken line, open circles) and PQ interval after multiple doses of mibefradil (100 mg)
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Figure 3.6.2.d Time-course of action for changes in DBP (solid line, close circles),
HR (broken line, open circles) and PQ interval after multiple doses of verapamil SR
(240 mg)
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3.6.2.2 Verapamil
Each of the 7 patients who were enrolled in the study had 11 measurements recorded for 
each pharmacodynamic endpoint after the administration of multiple doses of verapamil 
SR 240 mg. Figure 3.6.2.d shows the time-course of action for changes in DBP, HR 
and PQ interval.
Blood Pressure - At steady state the peak changes in DBP varied from 5 (patient 4) to 12 
mmHg (patients 1 and 20). The peak effect generally occurred between 3 and 10 hours 
after the last dose but occurred 1.5 hours after the last dose in patient 4. At time zero the 
placebo-corrected values of blood pressure varied from -23  to -4  mmHg but 10 hours 
later they ranged from -19 to -10  mmHg.
Heart Rate - The maximum reduction in HR for verapamil varied from 3 hours (patient 
4) to 10 hours (patient 18) post dose. The peak effect for patient 4 occurred at 1 hour 
after the dose, for the remaining patients it occurred from 3 to 10 hours after the dose. 
The values of HR at time 0 was -15 to -3  bpm 10 hours later they ranged from -17 to -  
7 bpm.
PQ interval - PQ interval was prolonged by 6  msec for patient 16; in contrast, for patient 
1 it was prolonged by 20 msec. The peak occurred between 3 to 6  hours, except for 
patient 4. The placebo corrected PQ interval at time 0 varied from 2 to 28 msec and at 
10 hours it ranged from 7-29 msec.
126
3.7 RESULTS III
3.7.1 PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS: SINGLE­
DOSE STUDY
3.7.1.1 Mibefradii
Blood Pressure - The existence of hysteresis was checked by inspection of the plots of 
the reductions in DBP against predicted concentrations in individual patients and is 
shown in Figure 3.7.1.a. Visual inspection of curves showed that hysteresis could be 
excluded and the data from most subjects appeared to correspond to Emax-type 
behaviour. There were no consistent indications of a sigmoidal Emax-type 
concentration-effect relationship and this was ultimately confirmed by the fact that the n 
values were not statistically different from 1. The suitability of the linear and Emax 
models was compared and the results are shown in Table 3.7.1.a. Aikaike information 
criterion (AIC) values obtained from the Emax model were smaller for most patients 
than the ones obtained from linear model, although the difference was negligible. The 
Emax model was considered superior to the linear model. The Emax model re­
parameterized in terms of SO parameter was used to avoid correlation between Emax 
and EC50. The coefficient of variation for EC50 from the model from patient 9 was 
89.7%, whereas the SO parameter was associated with a cv of 34.8%.
As illustrated, only patient 17 had a very high decrease of AIC and therefore an effect 
compartment was included in the pharmacodynamic model of this patient. Figure 
3.7.1.b shows the predicted and measured effects against time obtained with the SO 
model (or SO model with effect compartment).
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Figure 3.7.1.a Decrease in diastolic blood pressure against predicted concentrations of
mibefradil (single-dose study) for patients 1 to 13
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Figure 3.7.1.a (cont.) Decrease in diastolic blood pressure against predicted 
concentrations of mibefradil (single-dose study) for patients 14 to 23
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Figure 3.7.1.b Time-course of response (A DBP) to a single dose of mibefradil using 
the SO model, for patients 1 to 13 ( •  measured data; O  predicted response)
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Figure 3.7.1.b (Cont.) Time course of response (A DBP) to a single dose of mibefradil 
using the SO model, for patients 14 to 23 ( •  measured data; O  predicted response)
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Table 3.7.1.b Parameter estimates from the SO model with a link model for changes
in blood pressure after single dose of mibefradil (150 mg)
LINK MODEL3
ID Emax cv% SO cv% KeO cv% AIC AAIC R2
1 -89.7 151.4 -0.0119 22.7 2 .2 2 25.1 27.5 4.6 0.97
2 -45.6 186.2 -0 .0 2 1 1 59.1 1.72 59.2 46.3 13.0 0.93
3 -27.0 60.2 -0.0858 30.3 0.472 2 0 .8 32.7 -7.2 0.96
4 -37.4 44.6 -0.0280 28.6 1.95 32.5 36.6 13.0 0.98
6 -89.4 17.5 -0.0350 2 0 .8 7.77 63.9 29.1 -1.1 0.99
7 -25.0 9.6 -0.0390 12 .8 3.56 18.7 16.1 1.2 0.99
8 -80.1 233.5 -0.0151 37.8 50.2 814.4 30.1 1.8 0.97
9 -52.0 117.3 -0.0270 3.32 46.9 720.8 36.1 1.2 0.96
11 -50.0 98.4 -0.0157 39.8 1 .68 36.9 44.0 20.9 0.94
13 * * * * * * * -
14 -50.0 44.4 -0.0330 24.9 4.35 34.8 37.0 -2.6 0.98
16 -27.9 37.6 -0.0240 25.0 6 .1 0 48.3 25.6 -2.2 0.98
17 -25.1 38.7 -0.0650 23.0 2.85 27.2 23.2 -10.5 0.97
18 -59.8 67.7 -0.0300 23.9 9.83 82.2 34.7 0.1 0.98
19 -40.0 99.3 -0.0258 47.4 2.42 48.0 42.0 12.7 0.96
2 0 -29.5 22.3 -0.0360 2 2 .2 8.39 62.3 26.6 -2 .0 0.98
2 2 -33.1 26.8 -0.0290 21.4 18.4 181.5 27.5 1.4 0.98
23 -15.1 19.7 -0.129 32.5 18.2 292.7 35.6 -2.3 0.95
a Equation 3.2, Chapter 3.
* Not estimated
Key: Emax is the maximum effect; SO is Emax/EC50; Keo is the constant rate fo r  drug loss from  the 
effect compartment; AIC represents the Akaike Information Criterion; R 2 coefficient o f  
determination and AAIC is the difference in AIC between SO modeol with and without effect 
compartment.
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Heart Rate - The existence of hysteresis was inspected from the plot of individual 
changes of HR against predicted concentration. Close examination of these shows that 
the amplitudes of the heart rate reductions were very small and the profile was nearly 
flat so that an Emax shape was not well defined (Figure 3.7.l.c). Both models were 
tried and the parameter estimates and the AIC values obtained. The choice between the 
linear and Emax models was not clear. For patient 1 the search algorithm did not 
converge with the Emax model. Inclusion of an intercept parameter and the power 
parameter in the sigmoidal Emax model were not justified.
Results from the Emax, reparameterized as SO models and linear model are shown 
in Table 3.7.I.e. The SO model performed better than the linear model as judged by 
the coefficient of determination and AIC. The SO model was further evaluated.
The inclusion of an effect compartment in the SO model was also tested. From the plots 
it can be seen that patients 3, 13 and 17 required an effect compartment. This was 
confirmed by the results shown in Table 3.7.l.d. Figure 3.7.l.d shows the predicted 
values of the responses from the SO model and the measured heart rate responses against 
time for mibefradil; it is apparent that the model predicted effects were in close 
agreement with those measured.
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Figure 3.7.1.C Decrease in HR against predicted concentrations of mibefradil (single­
dose study) for patients 1 to 13
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Figure 3.7.1.C (cont.) Decrease in heart rate against predicted concentrations of
mibefradil (single dose study) for patients 14 to 23
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Figure 3.7.1.d Time-course of response (A HR) to a single dose of mibefradil using the
SO model, for patients 1 to 13 ( •  measured data; O  predicted response)
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Figure 3.7.1.d (Cont.) Time-course of response (A HR) to a single dose of mibefradil 
using the SO model, for patients 14 to 23 ( •  measured data; O  predicted response).
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Table 3.7.1.C Parameter estimates from the linear and SO models for changes in heart rate
after a single dose of mibefradil (150 mg)
LINEAR MODEL3 SO MODEL
ID m cv% AIC R2 Emax cv% SO cv% AIC R2
1 -0.0041 16.6 17.8 0.86 -2.38 20.8 -0.056 86.2 38.5 0.71
2 -0.010 3.3 23.4 0.97 -19.1 29.2 -0.019 24.8 18.1 0.99
3 -0.0052 14.2 34.7 0.91 -5.00 180.7 -0.011 252.4 39.8 0.82
4 -0.013 6.5 43.3 0.89 -13.8 6.9 -0.066 23.0 21.7 0.99
6 -0.0091 7.1 41.6 0.87 -13.5 32.0 -0.027 58.9 39.1 0.94
7 -0.013 8.3 50.7 0.81 -13.6 19.9 -0.086 95.6 42.8 0.96
8 -0.005 5.3 19.9 0.87 -5.10 31.3 -0.034 168.8 16.0 0.91
9 -0.022 2.5 25.9 0.98 -33.4 28.8 -0.035 16.4 19.7 0.99
11 -0.006 5.8 34.1 0.92 -10.3 17.5 -0.029 58.2 28.1 0.96
13 -0.0074 6.3 30.9 0.86 -7.82 23.4 -0.035 79.0 25.8 0.94
14 -0.016 2.9 31.1 0.98 -25.5 16.5 -0.033 17.6 19.1 0.99
16 -0.010 5.5 32.9 0.93 -10.3 19.5 -0.040 54.8 25.2 0.95
17 -0.028 7.4 35.5 0.81 -7.54 15.2 -0.194 77.9 25.6 0.90
18 -0.024 4.9 47.8 0.92 -25.0 11.9 -0.078 24.2 28.8 0.98
19 -0.024 4.8 46.6 0.96 -23.0 10.8 -0.087 26.4 34.4 0.98
20 -0.015 4.5 38.7 0.92 -17.8 15.6 -0.048 31.5 26.3 0.98
22 -0.0055 5.5 23.5 0.88 -6.71 22.4 -0.021 62.0 17.8 0.93
23 -0.0095 4.6 24.5 0.96 -13.0 57.5 -0.018 52.4 27.6 0.97
a Equation 1.78; Chapter 1; Equation 3.1, Chapter 3.
* Not estimated.
Key: Emax is the maximum effect; m is the slope o f linear model; SO is EmaxJEC50; AIC is the Akaike
Information Criterion and R2 represents the coefficient o f determination.
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Table 3.7.1.d Parameter estimates from the SO model with a link model for changes in
heart rate after a single dose of mibefradil (150 mg)
LINK MODEL3
ID Emax cv% SO cv% KeO cv% AIC AAIC R2
1 * * * * * * * -
2 -2 2 .0 62.6 -0.0239 45.5 0.58 41.7 34.7 16.7 0.96
3 -15.0 360.8 -0.00810 118.5 1.4 109.0 34.7 -5.2 0.94
4 -14.9 14.4 -0.0580 43.1 1.1 43.9 31.1 9.3 0.97
6 -13.1 32.9 -0.0302 71.3 5.9 171.6 40.6 1.5 0.94
7 -13.8 21.7 -0.0825 98.3 2 .2 123.4 44.5 1.7 0.96
8 -5.5 43.1 -0.0250 164.4 6 .0 226.2 17.8 1.8 0.92
9 -33.1 32.8 -0.0350 19.4 56 489.6 2 1 .8 2.1 0.99
11 -1 0 .0 29.8 -0.0312 109.0 0 .8 96.7 38.5 10.4 0.95
13 -1 0 .0 25.9 -0.0217 44.4 2.4 50.0 2 1 .2 -4.7 0.97
14 -25.4 18.0 -0.0329 19.3 53 1703.8 2 1 .2 2.1 0.99
16 -1 1 .0 24.1 -0.0344 55.4 6.7 132.0 26.6 1.4 0.96
17 -8.98 15.5 -0 .1 2 2 42.7 1.4 42.5 20.5 -5.1 0.96
18 -2 2 .0 9.2 -0 .1 1 0 28.9 1 0 0 1898.5 29.5 0.7 0.98
19 -40.0 43.6 -0.0390 31.7 2.9 34.9 36.9 2.4 0.97
2 0 -19.0 19.8 -0.0420 34.3 54.4 954.4 28.2 1.9 0.98
2 2 -7.36 24.5 -0.01800 52.8 3.7 74.4 17.4 -0.4 0.95
23 -47.5 270.6 -0 .0 1 0 0 42.1 17 278.9 28.2 0 .6 0.96
a Equation 3.2, Chapter 3.
* Not estimated.
Key: Emax is the maximum effect; SO is Emax/EC50; Keo is the constant rate fo r  drug loss from  the 
effect compartment; AIC is the Akaike Information Criterion; R2 is the coefficient o f  determination and 
AAIC is the difference in AIC between SO model with and without effect compartment
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Figure 3.7.1.e Changes in PQ interval against predicted concentrations of mibefradil
(single-dose study) for patients 1 to 13.
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Figure 3.7.1.e (cont.) Changes in PQ interval against predicted concentrations of
mibefradil (single-dose study) for patients 14 to 23.
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Figure 3.7.1.f Time-course of response (A PQ interval) to a single dose of mibefradil 
using the linear model, for patients 1 to 13 ( •  measured data; O  predicted response)
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Figure 3.7.1.f (Cont.) Time-course of response (A PQ interval) to single dose of 
mibefradil using the linear model, for patients 14 to 23 ( •  measured data; O  predicted 
response)
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Figure 3.7.1.g Decrease in DBP against predicted concentrations of verapamil (single­
dose study) for patients 1 to 13
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Figure 3.7.1.g (cont.) Decrease in DBP against predicted concentrations of verapamil
(single-dose study) for patients 14 to 23
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Figure 3.7.1.h Time-course of response (A DBP) to a single dose of verapamil using
the SO model, for patients 1 to 13 ( •  measured data; O  predicted response)
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Figure 3.7.1.h (Cont.) Time course of response (A DBP) to a single dose of verapamil 
using the SO model, for patients 14 to 23 ( •  measured data; O  predicted response).
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PO interval - Figure 3.7.l.e shows the changes in PQ interval along with the predicted 
concentrations. The relationship was close to a straight line and the linear model 
generally proved satisfactory (Table 3.7.l.e). The linear model produced a greater 
reduction in the residual sum of squares for all patients except patient 7. For this 
patient, the reduction in the residual sum of squares differed by only of 0.95 points 
(Table 3.7.l.e). Figure 3.7.l.f  shows the measured and predicted effects from the linear 
model for PQ interval. The linear model satisfactory described the data and therefore 
was chosen. The estimation of EC50 for the Emax model was bounded.
3.7.1.2 Verapamil
Blood pressure - Analysis of the plots in Figure 3.7.l.g  indicated the likelihood of 
hysteresis in patients 1, 2, 8 , 11, 22 and 23. Examination of plots suggested that an 
Emax model might describe the relationship between DBP and the predicted 
concentration. This was confirmed by the AIC values which favoured the Emax model. 
Table 3.7.l.f  shows the parameter estimates and AIC for the two competing models.
The sigmoidal Emax model showed no improvements in the fit and an intercept was not 
necessary.
The SO parameter estimated from SO model had a smaller coefficient of variation than 
that of EC50 from the Emax model. The presence of hysteresis was tested (Table
3.7.l.g). Patients 1, 2, 8 , 11, 22 and 23 had the highest decrease in AIC after the 
inclusion of effect compartment in the model. The effect predicted from the SO model 
and the measured effects with time is shown in Figure 3.7.l.h.
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Table 3.7.1.e Parameter estimates from the Emax and linear models for changes
in PQ interval after a single dose of mibefradil (150 mg)
EMAX MODEL3 LINEAR MODELb
ID Emax cv% EC50 cv% AIC R2 m cv% AIC R2
1 29.8 173.0 1977 231.5 38.1 0.93 0 .0 1 1 2 6.9 36.2 0.92
2 27.6 94.4 1999 133.9 29.9 0.99 0.0097 3.7 24.6 0.99
3 15.3 597.4 1997 738.4 44.3 0.82 0.00591 17.1 41.3 0.85
4 44.9 109.5 1999 154.5 46.4 0.94 0.0158 5.8 44.6 0.93
6 38.2 65.1 1999 96.5 39.0 0.95 0.0128 3.7 34.3 0.96
7 30.9 51.0 1534 79.7 34.3 0.96 0.0127 4.3 35.3 0.95
8 32.6 133.0 1999 188.7 35.0 0.92 0.0115 3.9 31.0 0.94
9 36.0 140.0 1999 178.2 30.7 0.91 0.0142 4.0 25.9 0.94
11 45.9 83.5 2998 118.8 38.9 0.96 0.0107 4.0 37.3 0.96
13 45.4 6 8 .1 2999 86.7 19.0 0.98 0.0119 1.9 14.5 0.98
14 50.8 98.2 2986 126.3 30.7 0.96 0.0132 3.2 29.2 0.97
16 25.3 40.6 1060 69.3 27.7 0.96 0.0138 3.5 30.2 0.97
17 41.0 160.6 848.6 204.7 37.2 0.90 0.0378 5.5 35.4 0.90
18 46.3 162.1 2998 199.7 33.9 0.91 0 .0 1 2 0 4.4 30.6 0.93
19 44.2 147.1 2999 182.6 30.6 0.95 0.0118 4.1 27.8 0.95
2 0 28.2 74.5 1422 115.3 36.2 0.91 0.0127 4.7 35.5 0.92
2 2 41.6 78.0 2999 10 1 .8 23.8 0.97 0.0106 2.3 19.1 0.98
23 42.8 241.0 2997 294.5 37.2 0.93 0.0117 5.5 33.2 0.94
a Equation 1.18, Chapter 1; b Equation 1.17, Chapter 1.
Key: Emax is the maximum effect; EC50 is the concentration that produces ha lf o f  Emax effect; m is the 
slope o f  linear model; AIC  Akaike Information Criterion and R2 coefficient o f  determination
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Table 3.7.1.g Parameter estimates from the SO model with a link model for changes
in blood pressure after a single dose of verapamil (240 mg)
LINK MODEL3
ID Emax cv% SO cv% KeO cv% AIC AAIC R2
1 -31.8 4.6 -0.122 8.8 4.61 28.7 28.8 -6.7 0.99
2 -42.7 19.0 -0.140 22.6 1.17 27.3 53.1 -14.0 0.96
3 -45.8 37.6 -0.120 19.2 4.22 43.0 39.5 22.3 0.98
4 -40.2 7.9 -0.212 9.4 99.9 4695.1 26.3 12.3 0.99
6 -49.8 21.4 -0.157 21.4 2.52 34.6 49.9 10.0 0.99
7 -27.4 9.8 -0.531 26.2 99.8 15052.0 32.1 3.4 0.99
8 -33.8 5.3 -0.194 14.3 2.71 35.4 38.8 -4.1 0.99
9 -45.1 18.5 -0.165 19.0 5.47 51.1 48.7 -2.6 0.97
11 -31.3 10.1 -0.615 20.2 1.04 28.0 42.1 -6.0 0.98
13 -58.1 31.6 -0.073 12.2 99.5 519.0 31.7 2.1 0.99
14 -42.2 4.4 -0.199 6.6 10.5 40.4 27.2 -2.4 0.99
16 -30.2 7.2 -0.270 15.6 4.89 54.8 39.1 -1.3 0.99
17 -25.9 20.5 -0.089 16.0 7.16 48.3 29.8 -1.8 0.99
18 -47.3 13.6 -0.134 15.6 14.8 120.3 46.2 1.0 0.99
19 -69.8 69.4 -0.057 24.7 7.18 66.1 49.7 -0.6 0.96
20 -39.7 10.2 -0.141 10.3 100 591.2 32.5 2.3 0.99
22 -39.1 4.9 -0.161 7.8 2.84 15.8 30.9 -20.1 0.99
23 -42.0 36.5 -0.068 23.5 3.10 37.7 42.3 -5.3 0.98
a Equation 3.2, Chapter 3.
Key: Emax is the maximum effect; SO is Emax/EC50 and AIC  is the Akaike Information Criterion; Keo 
is the constant rate fo r  drug loss from  the effect compartment; R2 coefficient o f  determination and 
AAIC is the difference in AIC between SO model with and without effect compartment.
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Heart Rate - The relationship between HR and predicted concentration is shown 
in Figure 3.7. l.i. Patients 2, 13, 19, and 22 showed signs of hysteresis (Table 
3.7.l.i). The relationship between heart rate and predicted concentrations agreed 
well with an Emax response. Table 3.7.l.h shows the values of AIC for the 
linear and SO models. For the SO model, the AIC values were smaller than with 
the linear model, and accordingly, the SO model was further evaluated. Figure
3.7.1.j shows the responses predicted from the SO model and the measured 
responses following single-dose verapamil.
PQ interval - The changes in PQ interval with the predicted concentrations are 
shown in Figure 3.7.1.1. The Emax model did not converge for patients 3 and 4. 
Results obtained from fitting the linear and Emax model are listed in Table
3.7.1.j. Figure 3.7.1.m shows the time-course of the PQ interval responses 
following verapamil. The linear model was chosen..
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Figure 3.7.1.i Decrease in HR against predicted concentrations of verapamil (single­
dose study) for patients 1 to 13
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Figure 3.7.l . i  (cont.) Decrease in HR against predicted concentrations of verapamil
(single-dose study) for patients 14 to 23
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Figure 3.7.1.j Time-course of response (A HR) to a single dose of verapamil for
patients 1 to 13 ( •  measured data; O  predicted response) using the SO model
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Figure 3.7.1.j (Cont.) Time-course of response (A HR) to a single dose of verapamil
for patients 14 to 23 ( •  measured data; O  predicted response) using the SO model
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Figure 3.7.1.1 Change in PQ interval against predicted concentrations of verapamil
(single-dose study) for patients 1 to 13
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Figure 3.7.1.1 (cont.) Change in PQ interval against predicted concentrations of
verapamil (single-dose study) for patients 14 to 23
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Figure 3.7.l.m  Time-course of response (A PQ interval) to a single dose of verapamil
using the linear model, for patients 1 to 13 ( •  measured data; O  predicted response)
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Figure 3.7.1.m (Cont.) Time-course of response (A PQ interval) to a single dose of 
verapamil using the linear model, for patients 14 to 23 ( •  measured data; O  predicted 
response)
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Table 3.7.l . i  Parameter estimates from the SO model with a link model for
changes in heart rate after a single dose of verapamil (240 mg)
LINK MODEL3
ID Emax cv% SO cv% KEO cv% AIC AAIC R2
1 -1 2 .2 2 0 .8 -0.0245 26.6 99.9 1780.3 29.4 2 .2 0.95
2 -19.2 19.7 -0.117 34.5 0.81 38.2 46.8 -8.9 0.92
3 -12.9 46.6 -0.132 60.0 0.84 60.6 47.5 30.5 0.94
4 -20.3 7.5 -0.1845 20.4 4.74 108.2 35.4 23.1 0.99
6 -24.6 14.8 -0.0956 18.2 3.16 38.8 32.5 8.4 0.99
7 -9.59 15.1 -0.191 40.8 51.4 12084.9 19.0 2 .0 0.98
8 -1 1 .0 4.4 -0.130 17.8 10 .6 327.6 20.4 1.8 0.98
9 -25.3 18.0 -0.180 30.3 4.19 76.8 50.1 -0 .1 0.95
11 -13.6 8.9 -0.397 30.4 5.42 336.7 35.1 1.8 0.97
13 -1 2 .2 6 .2 -0.070 8.7 10 .6 46.1 4.16 -2 .2 0.99
14 -2 1 .2 5.8 -0.170 13.1 10.3 92.1 26.6 1 .0 0.99
16 -11.5 27.5 -0.052 31.1 1.28 37.3 29.6 -9.1 0.96
17 -1 2 .0 1 1 .2 -0.247 29.5 4.27 135.1 35.6 1.1 0.94
18 -29.6 8.4 -0.147 14.8 78.5 896.3 38.0 2 .1 0.99
19 -28.1 12.3 -0.124 17.3 4.52 45.1 40.0 -2.7 0.99
2 0 -2 0 .6 6 .0 -0.193 11 .8 9.90 80.1 26.3 0.7 0.99
2 2 -21.3 5.9 -0.124 1 2 .0 3.13 28.2 27.9 -10.9 0.99
23 -12.3 14.2 -0.115 34.2 1.84 76.5 33.9 0 .1 0.95
a Equation 3.2, Chapter 3.
Key: Emax is the maximum effect; SO is Emax/EC50; Keo is the constant rate fo r  drug loss from  
the effect compartment; and AIC is the Akaike Information criterion; R 2 coefficient o f  
determination, and AAIC is the difference in AIC between SO model with and without effect 
compartment
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Table 3.7.1.j Parameter estimates from the Emax and linear models for changes in
PQ interval after a single dose of verapamil (240 mg)
EMAX MODEL LINEAR MODEL
ID Emax cv% EC50 cv% AIC R2 m cv% AIC R2
1 10 0 23.3 966 36.9 52.9 0.98 0.0629 4.5 58.4 0.98
2 78.0 53.2 585 98.5 78.5 0.83 0.0661 11.3 78.5 0.85
3 * * * * * * 0.0844 3.9 25.1 0.72
4 * * * * * * 0.0635 4.0 41.0 0.84
6 1 0 0 17.1 1266 2 2 .8 19.0 0.99 0.0580 2.4 26.3 0 .8 8
7 77.4 17.3 488 30.3 49.7 0.99 0.838 5.9 61.6 0.99
8 63.3 10.7 274 30.5 63.7 0.96 0.0579 11.7 83.4 0 .8 8
9 10 0 54.6 8 6 8 74.9 55.5 0.96 0.0828 4.7 52.9 0.97
11 10 0 49.8 1164 77.2 66.9 0.94 0.0544 5.9 63.6 0.96
13 1 0 0 185.4 1480 224. 59.3 0.98 0.0568 8 .0 54.2 0.98
14 1 0 0 20.5 781 31.0 49.2 0.98 0.0819 3.7 53.8 0.99
16 53.4 8.4 307 16.9 33.9 0.99 0.0792 5.5 57.8 0.97
17 32.5 14.3 56.4 46.7 62.1 0 .8 8 0.105 14.3 75.5 0.89
18 1 0 0 55.8 1125 78.5 57.8 0.98 0.0633 3.4 46.5 0.99
19 54.3 25.2 211 62.6 72.3 0 .8 6 0.0839 10.5 76.1 0.93
2 0 81.7 27.0 605 41.1 48.3 0.98 0.0849 5.2 54.3 0.99
2 2 * * * * * * 0.0539 5.2 57.7 0.97
23 41.7 19.4 221 47.4 62.1 0.92 0.0557 14.1 74.9 0.83
a Equation 1.18, Chapter ; Equation 1.17, Chapter 1.
* Not estimated
Key: Emax is the maximum effect; EC50 is the concentration that produces ha lf o f  Emax effect; m is the 
slope o f  linear model; AIC is the Akaike Information Criterion, and R2 coefficient o f  determination
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3.7.1.3 Diltiazem
Blood Pressure - The plots for DBP against the predicted concentration for patient 16 
failed to show signs of hysteresis, as illustrated in Figure 3.7.l.n. These plots show that 
an SO model could satisfactorily describe the decrease in DBP and the parameter 
estimates are shown in Table 3.7.1.1. The SO model was fitted to the data and the results 
were compared with the linear model (Table 3.7.1.1). The link model was used for 
patients 3, 4, 6 , 11, 16 and 18, Table 3.7.l.m. Plots for the time course of action for the 
decrease in blood pressure are shown in Figure 3.7.l.o. The DBP measured at 10 hours 
after the dose in patient 18 was unexpectedly low and was not predicted by the model 
(Figure 3.7.l.o).
Heart Rate - The profile of the decrease in heart rate with predicted concentration is 
shown in Figure 3.7.l.p and was best described using the SO model (Table 3.7.l.n). The 
existence of hysteresis could not clearly be identified in the plots although the link 
model was necessary for patients 2 ,4  and 18 (Table 3.7.l.o). Figure 3.7.l.q shows the 
predicted and measured time course of effect for each patient. The fall in HR for patient 
17 was very small, causing problems in the convergence of the algorithm for the SO 
model.
PQ interval -  The changes in PQ interval (Figure 3.7.l.r) were best described by a linear 
model and the results from this model are shown in Table 3.7.l.p.
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Figure 3.7.1.n Decrease in DBP against predicted concentrations of diltiazem (single­
dose study) for patients 1 to 13
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Figure 3.7.1.n (Cont.) Decrease in DBP against predicted concentrations of diltiazem
(single-dose study) for patients 14 to 23
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Figure 3.7.1.0 Time-course of response (A DBP) to a single dose of diltiazem using the
SO model for patients 1 to 13 ( •  measured data; O  predicted response).
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Figure 3.7.l.o  (Cont.) Time-course of response (A DBP) to a single dose of diltiazem 
using the SO model, for patients 16 to 23 ( •  measured data; O  predicted response)..
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Figure 3.7.1.p Decrease in HR against predicted concentrations of diltiazem (single­
dose study) for patients 1 to 13
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Figure 3.7.1.p (Cont.) Decrease in heart rate against predicted concentrations of
diltiazem (single-dose study) for patients 14 to 23
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Figure 3.7.1.q Time-course of response (A HR) to a single dose of diltiazem using the 
SO model, for patients 1 to 14 ( •  measured data; O  predicted response)
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Figure 3.7.l.q  (Cont.) Time-course of response (A HR) to a single dose of diltiazem 
using the SO model, for patients 16 to 23 ( •  measured data; O  predicted response)
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Figure 3.7.1.r Changes in PQ interval against predicted concentrations of diltiazem
(single-dose study) for patients 1 to 13
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Figure 3.7.1.r (Cont.) Changes in PQ interval against predicted concentrations of
diltiazem (single-dose study) for patients 14 to 23
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Table 3.7.l.m  Parameter estimates from the SO model with a link model for
changes in blood pressure after a single dose of diltiazem (240 mg)
LINK MODEL3
ID Emax cv% SO cv% KeO cv% AIC AAIC R2
1 -34.3 7.1 -0.252 11.9 0.78 12.2 31.5 18.4 0.99
2 -79.9 58.1 -0.0829 23.2 0.67 18.7 52.5 1.0 0.97
3 -65.6 46.7 -0.0606 17.3 5.18 37.3 41.4 -5.8 0.99
4 -64.6 51.9 -0.0780 27.0 2.75 46.2 55.3 -5.4 0.96
6 -33.3 8.1 -0.179 15.6 12.7 103.5 38.6 -2.3 0.99
7 -39.3 19.8 -0.285 21.1 1.39 33.1 47.8 20.0 0.97
8 -60.0 86.6 -0.284 42.4 0.45 32.8 61.0 2.4 0.94
9 -30.0 70.0 -0.381 89.4 0.51 82.4 69.0 6.0 0.82
11 -34.9 4.3 -0.120 8.3 6.89 40.2 28.3 -3.0 0.99
13 -33.1 3.9 -0.117 9.5 16.5 144.5 28.2 20.5 0.99
14 -38.4 8.7 -0.107 12.7 12.4 110.8 39.0 1.2 0.99
16 -17.6 62.6 -0.0297 31.9 98.7 2065.4 27.6 -16.2 0.93
17 -30.1 6.6 -0.157 9.9 99.2 699.3 27.8 1.7 0.99
18 -26.1 23.3 -0.131 41.3 1.25 56.6 58.6 -4.6 0.87
19 -44.5 7.5 -0.157 10.1 15.2 100.7 39.1 0.7 0.99
20 -38.9 9.2 -0.334 14.6 6.17 98.5 40.7 0.9 0.99
22 -34.4 19.8 -0.0990 25.3 99.4 1515.3 50.1 2.2 0.96
23 -35.5 3.8 -0.617 9.1 3.27 40.7 29.3 10.0 0.99
aEquation 3.2, Chapter 3.
Key: Emax is the maximum effect; SO is Emax/EC50 and Keo is the constant rate fo r  drug loss from  
the effect compartment; AIC  is the Akaike Information Criterion; R 2 represents the coefficient o f  
determination and AAIC is the difference in AIC between SO model with and without effect 
compartment
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Table 3.7.1.0 Parameter estimates from the SO model with a link model for changes
in heart rate after a single dose of diltiazem (240 mg)
LINK MODEL3
ID Emax cv% SO cv% KeO cv% AIC AAIC R2
1 -5.81 13.5 -0.0451 23.2 -0.73 2 2 .8 7.0 6.4 0.97
2 -40.0 173.4 -0.0183 30.5 0.60 22.3 29.6 -2 .1 0.97
3 -78.4 2872.6 -0.0072 105.9 2.71 136.2 41.4 0 .2 0.96
4 -35.4 194.6 -0.0310 59.2 0 .6 8 49.5 50.6 -5.6 0.83
6 -12.7 26.6 -0.0226 20.7 99.9 1113.0 18.0 3.4 0.98
7 -22.3 22.9 -0.161 23.6 1.27 35.0 37.3 8.9 0.96
8 -48.0 67.5 -0.205 29.7 0.43 22.5 46.9 -1.4 0.93
9 -30.0 149.2 -0 .1 0 2 53.8 -0.46 41.5 47.5 1.3 0.92
11 -12.49 17.1 -0.0245 22.4 20.7 284.6 25.0 2 .0 0.98
13 -1 0 .0 10 .8 -0.0280 22.3 58.4 1252.3 20.7 2 .1 0.98
14 -19.34 6.5 -0.0487 8.7 9.92 54.3 15.0 -0.9 0.99
16 -15.7 68.4 -0.0319 38.8 0.77 31.2 29.8 4.1 0.92
17 * * * * * * * * -
18 -17.5 25.3 -0.0312 23.3 2.73 41.3 32.9 -6.3 0.96
19 -12 .8 4.7 -0.0443 5.9 99.4 450.3 -0.77 1.5 0.99
2 0 -11.5 38.4 -0 .2 0 1 42.6 32.3 16989.5 27.3 2.1 0.97
2 2 -16.0 91.2 -0 .0 1 0 2 43.3 49.9 969.3 34.6 2.3 0.93
23 -14.7 28.5 -0.0701 24.1 4.26 74.8 24.6 1.1 0.99
a Equation 3.2, Chapter 3.
* Not estimated
Key: Emax is the maximum effect; SO is Emax/EC50 and Keo is the rate constant fo r  drug loss from  
the effect compartment; AIC is the Akaike Information Criterion; R2 represents the coefficient o f  
determination and AAIC is the difference in AIC  between SO model with and without effect 
compartment
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Table 3.7.l.p Parameter estimates from the Emax and linear models for changes in
PQ interval after a single dose of diltiazem (240 mg)
EMAX MODEL3 LINEAR MODELb
ID Emax cv% EC50 cv% AIC R2 m cv% AIC R2
1 1 0 0 2 1 .2 951 32.1 46.5 0.98 0.0680 2.7 47.0 0.99
2 100 36.2 684 61.3 70.1 0.93 0.0820 6.7 71.4 0.94
3 99.9 145.3 11 2 0 197.5 75.7 0.85 0.0670 1 1 .0 71.5 0 .8 8
4 74.6 37.1 477 6 8 .0 68.5 0.91 0.0790 8 .2 72.0 0.89
6 78.1 24.8 417 46.7 61.5 0.97 0.0929 6.5 69.0 0.98
7 1 0 0 8 6 .1 1250 126.7 78.0 0.95 0.0530 10.9 75.0 0.92
8 * * * * * * 0.0530 8 .8 6 8 .6 0.84
9 10 0 84.3 1092 116.8 67.8 0.93 0.0661 6 .8 62.9 0.94
11 10 0 15.1 761 28.9 58.3 0.98 0.0637 5.1 67.9 0.98
13 10 0 15.5 803 31.7 63.8 0.98 0.0567 3.6 63.6 0.99
14 84.8 14.6 446 32.1 64.9 0.97 0.0720 8 .6 79.5 0.96
16 10 0 152.7 12 0 0 189.3 61.9 0.97 0.0680 7.1 56.0 0.97
17 75.7 18.5 4500 30.8 45.2 0.99 0.0872 4.7 56.2 0.99
18 * * * * * * 0.0605 8 .6 72.3 0.91
19 100 22.9 913 35.6 54.7 0.98 0.0667 5.5 61.4 0.98
2 0 93.9 18.2 620 32.1 58.1 0.98 0.0604 7.1 71.0 0.93
2 2 84.8 38.2 592 68.4 70.3 0.92 0.0747 8 .0 72.8 0.92
23 * * * * * * 0.0504 4.1 60.6 0.98
a Equation 1.18, Chapter ; b Equation 1.17, Chapter 1.
* Not estimated
Key: Emax is the maximum effect; EC50 is the concentration that produces ha lf o f  the Emax effect; m is the 
slope o f  linear model; AIC  is the Akaike Information Criterion and R2 coefficient o f  determination
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The linear model produced predictions that were close to the measured effects, as 
shown in Figure 3.7.l.s.
3.7.1.4 Summary o f Final Results: Single-Dose Study
After a single dose of mibefradil and for DBP the mean value of EC50 estimate 
obtained from the Emax model was (1012.1 ± 484.7 ng ml"1). For verapamil was
320.4 ± 238.4 ng ml"1 and for diltiazem was 421.7 ± 292.3 ng ml"1. The mean Emax 
values and the mean SO values estimates for each drug are presented in Table 3.7. lq.
For heart rate, the EC50 estimate for mibefradil was 423.2 ± 202 ng ml"1, for 
verapamil was 228.0 ± 87.4 ng ml"1 and for diltiazem was 567.1 ± 420.6 ng ml'1. 
Table 3.7.l.q shows the result from the SO model, Emax and SO paramters estimates.
For mibefradil the EC50 estimates obtained from the Emax model, for changes in PQ 
interval was 2212.0 ± 724.0 ng ml"1. Smaller values of EC50 were obtained for 
verapamil (693.3 ± 440.3 ng ml"1) and diltiazem (788.6 ± 286.0 ng ml'1). The results 
obtained for changes in PQ interval from the linear model are shown in Table 3.7.l.q
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Figure 3.7.l.s  Time-course of response (A PQ interval) to a single dose study of diltiazem 
using the linear model, for patients 1 to 13 ( •  measured data; O  predicted response)
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Figure 3.7.1.S (Cont.) Time-course of response (A PQ interval) to a single dose study of 
diltiazem using linear model, for patients 14 to 23 ( •  measured data; O  predicted 
response)
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3.7.2 PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS: 
STEADY-STATE STUDY
3.7.2.1 Mibefradil
Blood Pressure - The pharmacokinetic/ pharmacodynamic relationship for 
mibefradil after multiple doses, was satisfactorily described by an Emax model 
without an intercept (Table 3.7.2.a). Better parameter estimates were obtained 
with the SO model than with the Emax model and the link model provided no 
advantage. Figure 3.7.2.a shows the individual plots of measured and predicted 
values obtained from the SO model for DBP against time and Figure 3.7.2.b 
shows the predicted response using SO model.
Heart Rate - Inspection of the plots (Figure 3.7.2.c) and analysis of the results 
(Table 3.7.2.b) showed that the time course of action for the heart rate effect was 
best described by the Emax model. The magnitude of the decrease in heart rate 
was small, so the profile of the course of action was relatively flat (Figure
3.7.2.d). The SO model proved to have advantages over the Emax model and the 
comparison of the results is shown in Table 3.7.2.b. The SO model predicted an 
effect close to the measured one (Figure 3.7.2.d).
PQ interval - The superiority of the linear model over the Emax model was not 
marked, as shown in Table 3.7.2.C, and this was in agreement with the plots in 
Figure 3.7.2.e. Figure 3.7.2.f shows the predicted and measured effects with 
time. The plots for patients 6 , 8 , and 17 suggested that the linear model failed to 
describe the effect around 10 hours. However, the AIC values obtained from the 
linear and Emax models were similar suggesting that the Emax model offered no 
advantage for these patients. The estimation of EC50 from Emax model was 
bounded due to difficulties in converging.
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Figure 3.7.2.a Decrease in DBP against predicted concentrations of mibefradil (steady-
state study)
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Figure 3.7.2.b Time course of response (A DBP) to multiple dose of mibefradil using
the SO model ( •  measured data; O  predicted response)
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Figure 3.7.2.C Decrease in HR against predicted concentrations of mibefradil (steady-
state study)
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Figure 3.7.2.d Time course of response (A HR) to multiple dose of mibefradil using the 
SO model ( •  measured data; O  predicted response)
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Figure 3.7.2.f Time course of response (A PQ) to multiple dose of mibefradil using the 
linear model ( •  measured data; O  predicted response)
Patient 14
10
9
7
5
4
3
2 T0 ~r20"T“10
Tune (hours)
Patient 6
14
13
12
11
_  10
°  9Q. 9
8
7
6
5
4
0 10 20
TIME-old(hours) 
Patient 17
16
IS
14
13
11
10
9
8
0 10 20
TIME-old(hours) 
Patient 7
8
7
6
£
O s
Q_
4
3
2
0 10 20
TIME-old(hours) 
Patient 19
5 “ 
4 -  
3 -  
2 -
_____
TIME-old(hours) 
Patient 8
O 10-
200 10
TIME-old(hours) 
Patient 22
16
15
14
13
11
10
9
8
0 2010
TIME-old(hours) 
Patient 9
o  1 0 “
10 200
TIME-old(hours) 
Patient 23
10
9
6
6
5
4
0 10 20
14
13
12
11
10
7
6
5
4
10 200
TIME-old(hours) TIME-old(hours)
Ta
bl
e 
3.7
.2.
a 
Pa
ra
m
et
er
 e
st
im
at
es
 f
rom
 
the
 
lin
ea
r 
and
 
SO 
m
od
els
 f
or
 c
ha
ng
es
 i
n 
bl
oo
d 
pr
es
su
re
 
aft
er
 m
ul
tip
le 
do
se
s 
of 
m
ib
ef
ra
di
l 
(1
00
o
H
Q
O
s
o
>
>
x
E
w
w
Q
O
S
g
<
uhH
<3
►
b£»
a
r "
o
ON
0 0
r -
c -
NO
OO
3—H
O n
c n
O n
'si-
o o
c n
ON
c n
O n
■si-
0 0
d d o o O d o o O d
i n r - s t r-H O C"; CN i n r H
cn
CN
i n
r H
ON NO
r-H
d
<N
CN
CN
r H
CN
NO
r H
i n
c n
o o ON NO r H i n 0 0 v n p r H 0 0i n
r H
c o r H
s t
c n
r H
CN
00
I-H
i n
r H
i n
CN
■St
r H
i n
CN
o
s t
s t
CN
r -
CN
s t
o
c n
CN
o
» n
(N
c n
o
r -
00
s
o o
c n
c n
o
o o
CN
i n
o
o o
r H
'S t
O
o
ON
CN
O
CN
m
CN
o
o
i
o
i
o
i
o
i
o
i
o
i
o
i
o
i
o i o i
i n r H NO NO NO r H c n CN i n r H
i n 0 0 r Hs t
s t
r H
l >
i-H
i >
r H
s t
CN
CN
I-H r H
CN
i n
s t CN O o s t p ON O p r H
r H
CN
i n
CN
NO
CN
NO
CN
r H
c n
i n
r H
s t
c n
CN
c n
NO
c n
o
NO
r H
00
r H
o NOC"-
r H
00 ON00 r- oO n OOo o i nr -
d o d d o o o d o d
° ° O n ■st ■St s t S t O n CN c n
S t
i n
r H
■St
o
<N
CN
c n
CN
c n
s t
c n
ON
CN
s t
c n
00
CN
o
c n
■st
r H
f "o i nON
o o
s t
ON
0 0
ON r-
r H
CN
c n
o
r H
c n
o o
r H ■St r H CN CN CN CN CN CN
00
s to
,-H  0 0
3  S
p  8O ^
s t
c n
o
o
o
o
s t
s t
o
o
o of"
ONoo
o
c n  no OO O n
r -  on
o o
s t
ONoo
o
CN
CN
C"(N
O
o
c n<N
<o
9*43
u
c_o"OcS
=3CT
W
£
u
(
W Ap
y:
 E
ma
x 
is 
the
 
ma
xim
um
 
ef
fe
ct
; 
m 
is 
the
 
slo
pe
 
of 
lin
ea
r 
m
od
el
; 
SO 
is 
the
 
Em
ax
/E
C
50
; 
AIC
 
re
pr
es
en
ts 
the
 A
ka
ik
e 
In
fo
rm
at
io
n 
Cr
ite
rio
n 
an
d 
/T 
co
ef
fic
ie
nt
 o
f 
de
te
rm
in
at
io
n
bO
S
oo
nd
c3V-<l+H(D
£>
<4-1o
C/3uC/3
OT3
«
3
6
<D-C
c/3<DbO
c
ccJ
-Co
(h
£
<DT3O
O
00
rO
CccS
i-io3<D
C
<DJ3
c3
Oh
-Q
ci
o[
c*5
£3cd
H
w
Q
O
o05
Pi
U
<1
>w
oCO
>u
s
a
w
A
w
A
O
OS
<
&
u
<5
►u
or- or-
o o NO
0 0
i—H
On c nON c noo c nOn CNON H"oo
o o o o O o O d o o
CN in On C"; c n t > m CN CN On
On
CN
in
CN
'^ t
CN
ini—H CNCN o o NOCN NOrH H"rH
CN c n c n 0 0 CN r-; r-H o o «n
H"H- inc n
t-H
t-HrH
T t
t-~
ONr-H NOCN inCN c nc n ONH - c nc n
ON
ON
ONo
NO
c nH-o
oN-rH
o
c n
0 0
©
■*tm
0 0o
O
c n
NOo
in
ON
c n
O
Om
NOo
O
O
o
oin
c no
o1 oi oi oi oi oi 9 di oi oi
c n h- 0 0 t-» c n r - H" in
CNT—H di—H 0 0On Onc n 0 0 o r-^rH c nr-H oin in^H
o NO O CN 0 0 o r-~ CN o 0 0
c n
o o
c n
r H
OrH rH oCN oCN
H ;
0 0
NO
CN
dT—H rHrH
in OO r"oo On On
o o O
ON H- H;
ON d inNO OO NO
00ON
o
OnOnin
On o o 0 0 ON 0 0 OOOn On ON ON ON On
O O d d o O
i—H O t" ; NO 0 0 O
S c n CN c n o
o o 0 0 NO ON NO o
o r H c n
0 0 0 0 c n
ON H" O
i n H -
i n
c n
NO
oCNOnO
ONr-OnOn
O
CN
c n
c n
c n
Oo
o
ON c n O n C"<NNOoo
in _ NO oo CN ooin O n NO c n r- m oo in O
r H O O CN r H r H i-H o rHo O O o o o o o o
oi di di o oi oi oi di oi ol
©
©©<N
s
<3
s©
s*.
&
.3
m  ^
H  Ci<U K>•4—« ^
&1 ^
£  s-
0  -  w  t/)
t-H <W
cn -S 
c .2
i  s
3  r** cr ©
' ^  
~  SSa s
9*'§
U S .r- -c
W
c n  no OO On ON CNCN c nCN
S 3 
■g S
W 
.  ^
Table 3.7.2.C Parameter estimates from the Emax and linear models for changes in PQ
interval after multiple doses of mibefradil (100 mg)
EMAX MODEL3 LINEAR MODELb
ID Emax cv% EC50 cv% AIC R2 m cv% AIC R2
3 9.87 7.6 1 0 2 30.1 20.3 0.85 0.0185 9.3 44.4 0.89
6 33.0 30.8 1945 48.8 23.2 0.91 0.0106 2.7 28.6 0.91
7 46.0 136.0 2983 171.0 22.3 0.75 0.0123 2.4 20.4 0.76
8 40.8 63.8 2833 90.1 24.8 0.82 0 .0 1 0 2 2.3 24.8 0.84
9 28.7 51.0 1546 70.1 14.1 0.91 0.0135 2.3 15.5 0.91
14 45.9 60.7 2998 78.2 2 0 .0 0.94 0.0119 2 .1 18.8 0.94
17 34.1 138.3 1939 162.0 15.7 0.87 0.0150 3.5 14.2 0 .8 8
19 44.7 55.9 2999 74.4 17.8 0.93 0 .0 1 1 2 1.6 14.7 0.93
2 2 44.2 42.2 2999 55.8 1 0 .6 0.96 0 .0 1 1 1 1.3 9.61 0.96
23 45.7 131.7 2999 165.1 31.1 0 .8 6 0 .0 1 2 1 3.4 27.4 0.87
a Equation 1.18, Chapter ; Equation 1.17, Chapter 1.
Key: Emax is the maximum effect; EC50 is the concentration that produces ha lf o f  the Emax effect; m is the 
slope o f  linear model; AIC represents the Akaike Information Criterion and R2 coefficient o f  determination
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3.7.2.2 Verapamil
Blood Pressure - Decreases in blood pressure with measured concentrations were best 
described by the SO model. Individual results are shown in Table 3.1.2.6.. Figure
3.7.2.g shows the decrease in blood pressure along with the predicted concentration for 
verapamil after multiple-dose administration and the effect against time profile is shown 
in Figure 3.7.2.h.
Heart Rate -  Figure 3.7.2.i represents the changes in heart rate against predicted 
concentration. The SO model gave the best fit to the changes in heart rate with 
measured concentration. The parameter estimates from the Emax and linear models are 
shown in table Table 3.7.2.e. The predicted course of action for SO model is represented 
in Figure 3.7.2.j.
PQ interval -  Changes in the PQ interval were adequately described by the linear model. 
In Table 3.7.2.f are listed the parameter estimates from both models. Figure 3.7.2.1 
shows the change in PQ interval against predicted concentration and Figure 3.7.2.m 
shows the measured and predicted time-course of action.
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Figure 3.7.2.g Decrease in DBP against predicted concentrations of verapamil (steady-
state study)
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Figure 3.7.2.h Time-course of response (A DBP) to multiple dose of verapamil using
the SO model ( •  measured data; O  predicted response)
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Figure 3.7.2.i Decrease in HR against predicted concentrations of verapamil (steady-
state study)
Patient 1 Patient 16
-9
-10
n
•12
•13
•14
•15
60 100 120 140 160 160
-4
-5
-6
-7
-6
0 200100 300 400
Concentration (ng/ral) Concentration (ng/ml)
Patient 4  Patient 18
-6
•13
-18
200 400 600 800 1000
Concentration (ng/ml)
-7
•12
■17
50 100 150
Concentration (ng/ml)
Patient 11 Patient 20
-6
-7
-6
-9
-10
-11
200 300 400
-3
-4
-5
-6
-7
-8
-9
•10
2000 100
Concentration (ng/ml) Concentration (ng/ml)
Patient 13
-3
-4
•5
-6
-7
-8
-9
50 150 250 350
Concentration (ng/ml)
H
R
(b
pm
) 
H
R
(b
pm
) 
H
R
(b
pm
) 
H
R
(b
pm
) 
H
R
(b
pm
)
Figure 3.7.2.j Time course of response (A HR) to multiple doses of verapamil using the
SO model ( •  measured data; O  predicted response)
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Figure 3.7.2.1 Changes in PQ interval against predicted concentrations of verapamil
(steady-state study)
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Figure 3.7.2.m Time-course of response (A PQ) to multiple doses of verapamil, using 
the linear model ( •  measured data; O predicted response).
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Table 3.7.2.f Parameter estimates from the Emax and linear models for changes in PQ
interval after multiple doses of verapamil SR (240 mg)
EMAX MODEL3 LINEAR MODEL5
ID Emax cv% EC50 cv% AIC R2 m cv% AIC R2
1 1 0 0 31.3 955 39.3 29.5 0.98 0.0824 2.9 32.1 0.83
4 76.0 33.7 862 65.4 59.3 0 .8 6 0.0446 4.3 63.0 0.85
11 10 0 2 1 .0 1052 26.9 25.6 0.98 0.0735 2 .1 34.6 0.98
13 10 0 12.3 999 15.5 14.0 0.99 0.0780 2 .2 30.9 0.99
16 67.8 24.6 635 30.0 4.8 0.98 0.0873 1.4 14.1 0.99
18 55.8 67.4 504 81.5 27.0 0.95 0.0907 4.7 27.4 0.77
2 0 56.4 44.6 490 56.3 31.3 0.96 0.0897 4.4 33.9 0.96
a Equation 1.18, Chapter ; b Equation 1.17, Chapter 1.
Key: Emax is the maximum effect; EC50 is the concentration that produces ha lf o f  the Emax effect; m is the 
slope o f  linear model and AIC represents the Akaike Information Criterion; R2 coefficient o f  determination
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3.7.2.3 Summary of Final Results: Steady-State Study
At steady state the mean EC50 value for DBP estimated from the Emax model was
731.3 ± 340.2 ng ml' 1 for mibefradil. That contrast with the value obtained for 
verapamil, 391.2 ± 215.2 ng ml'1.
For changes in heart rate, after multiple doses the mean value of EC50 estimate was
421.4 ± 137.3 ng ml' 1 for mibefradil and 337.2 ± 204.6 ng ml' 1 for verapamil.
The mean values for DBP and HR obtained from the SO model are presented in Table
3.7.2.g.
The Emax model for changes in PQ interval produced an estimate of EC50 of 2334.5 ±
963.2 ng ml"1 for mibefradil and 785.2 ± 238.3 ng ml"1 for verapamil. The results 
obtained from the linear model are shown in Table 3.7.2.g.
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Table 3.7.2.g Mean values of parameter estimates from the best model for the
multiple-dose study
MIBEFRADIL VERAPAMIL
DBP (mmHg) Emax -26.0 ± 8 .0 -34.0 ± 7.9
SO -0.058 ± 0.066 -0.176± 0.06
HR (bpm) Emax -14.0 ±6.1 -20.2 ± 10.7
SO -0.047 ± 0.03 -0.140 ±0.084
PQ interval (msec) m 0.013 ±0.003 0.078 ±0.016
Values represent mean ± SD.
Key: DBP represents the diastolic blood pressure; HR is the heart rate; Emax is the maximum effect 
and SO is Emax/EC50.
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3.7.3 STATISTICAL ANALYSIS
The pharmacodynamic parameters obtained from DBP, HR, and PQ interval, after the 
administration of a single dose of mibefradil were compared. The results from 10 
patients included in the analysis are presented in Table 3.7.3.a. For blood pressure and 
heart rate, the Emax was higher after a single dose than at steady state, whereas the SO 
parameter was higher at steady state for both PD endpoints. For PQ interval there was 
an increase in potency, measured by the SO parameter, at steady state.
The differences between the parameters were not statistically significant but on the basis 
of the 95% confidence level it cannot be concluded that the two sets of figures are in 
close agreement. Thus it is not possible to make any definitive conclusions regarding 
change in sensitivity (or lack of it) during the translation from single dose to steady state 
treatment. This can be explained, in part by the small number of patients.
The pharmacodynamic parameters obtained after the administration of a single dose of 
verapamil and at steady state, for 7 patients, are shown in Table 3.7.3.b. For blood 
pressure the mean Emax and SO values were lower at steady state than after a single 
dose. In contrast, for heart rate the mean values of those parameters were higher at 
steady state than after single dose. For PQ interval a higher value of the parameter m 
was obtained at steady state, indicating an increase in potency. As for mibefradil, the 
difference between the parameters after single dose and at steady state was not 
statistically significant.
For both drugs the parameter estimates after single dose and at steady state were poorly 
correlated (Figure 3.7.3). A larger study population would have been necessary to 
assess the differences.
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Figure 3.7.3 Pharmacodynamic parameter estimates after the administration of a single 
dose of mibefradil against the parameter estimates at steady state
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3.8 DISCUSSION
This study was designed to evaluate and compare the antihypertensive efficacy of 
mibefradil, verapamil and diltiazem when administered as a single dose or as multiple 
doses to mildly hypertensive patients. The effect of these drugs on heart rate and on 
atrio-ventricular conduction was also studied.
Pharmacokinetics -  Mibefradil, verapamil and diltiazem were all rapidly absorbed after 
oral administration of a single dose. For verapamil and diltiazem, the fast absorption 
led to difficulties in model selection. For some patients the first concentration, sampled 
at 0.5 hours after the dose, corresponded to the peak concentration and therefore for 
these patients, information on absorption was not available. In the case of verapamil, 9 
out of 18 patients had a similar problem whereas for diltiazem it occurred in only 5 
patients. For diltiazem, patient 16 had the peak concentration at 3 hours after the dose 
administration. The unusual profile observed in this patient (see Figure 3.5.1.c) created 
problems with pharmacokinetic/ pharmacodynamic modelling. The delay can be caused 
by problems with absorption. For patient 3 the incorporation of a time lag was justified, 
as the concentration measured at 0.5 hours was not available. The inclusion of a lag 
time, as an extra parameter in the model, was necessary for some patients. The lag time 
was incorporated in the cases that sampling information was missing at 0.5 hours or the 
drug concentration at that point was very low (e.g. patients 1, 2, 4, 7, 11, 19 of 
mibefradil).
The model selected to describe the absorption process, the zero-order model, was the 
model, which more closely described the observed profiles. For verapamil and 
diltiazem the absorption process was not well characterised due to the lack of early data 
points. Mibefradil had a slower absorption than the other two drugs, with an estimated 
time to peak (Tmax) of 1.9 ± 0.7 hours after a single dose and 2.5 ± 0.6 hours at steady 
state. Welker et al. (1998) reported similar values. A first-order absorption model was 
used to characterise the data.
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Results from mibefradil revealed that it possesses particular pharmacokinetic features, 
which were shared neither by verapamil nor by diltiazem. Mibefradil half-life after a 
single dose of 150 mg (17.4 ± 4.1 hours) and at steady state on 100 mg daily (28.1 ±
10.2 hours) were in agreement with what has been published, 15.1 ± 4.4 and 23.7 ± 7.8 
hours, respectively (Welker et al., 1989; Welker et al., 1998). This increase in 
elimination half-life after multiple doses can be a result of the self-inhibition of one 
metabolic pathway, CYP3A4-mediated oxidative metabolism. For verapamil and 
diltiazem the estimated terminal half-life was higher than previously reported (Hamann 
et al., 1984; Buckley et al., 1990) at 12.8 hours and 10.1 hours, respectively. However, 
these values were estimated with imprecision, as they were defined only by one point, 
sampled at 24 hours. For some patients the coefficient of variation of parameter 
estimates were not obtained (see Table 3.5.1.b and Table 3.5.1.c). The verapamil half- 
life ranged from 3.2 to 39.4 hours and diltiazem ranged from 4.6 to 27.4 hours. These 
points were low concentrations and therefore high assay error was associated with them.
For mibefradil the volume of distribution (V/F) was increased compared with the single 
dose and could be another factor contributing to the long half-life along with the 
decrease in clearance (CL/F). An investigator reported that clearance (CL/F) is reduced 
with increasing dose indicating that bioavailability (F) increases as doses increase 
(Welker, 1998). This finding is mostly likely to be due to a reduction in first-pass 
metabolism. This can in part explain differences in volume of distribution (V/F) after 
single dose and at steady state. Values of CL/F obtained after a single dose of 
mibefradil were lower than expected, 7.2±5.6 L h'1. Welker reported a clearance of 14.0 
± 9.3 L h'1 after a single dose of 150 mg of mibefradil (Welker, 1998). Differences in 
bioavailability could also explain the discrepancies in the results.
The mono-exponential decline model best described the disposition of mibefradil for all 
patients. Although the profiles suggested a bi-exponential decline for patients 18, 22 
and 23, this model gave imprecise parameter estimates, with a wide coefficient of 
variation and therefore a mono-exponential decline model was chosen. More data 
points beyond 48 hours would have been necessary to fully characterise the terminal
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elimination as only one measurement was available to characterise the second 
compartment. A bi-exponential decline model was selected for verapamil and 
diltiazem, but for some patients the coefficient of variation of pharmacokinetic 
parameters could not be estimated. For verapamil, patient 1 had pharmacokinetic 
parameters estimated with great precision, contrasting with patients 4, 6 , and 7 in whom 
parameters had a wider coefficient of variation. In both cases the model provided a 
good fit of the data as judged by coefficient of determination and residual plots.
Pharmacodynamics - The findings of the study showed that mibefradil in doses of 150 
mg smoothly lowered the diastolic blood pressure (DBP) during a 24-hour period. The 
effect on DBP was more sustained than after single doses, with a more marked effect 24 
hours after administration, which was similar to verapamil SR 240 mg. Verapamil 240 
mg and diltiazem 240 mg, after single doses, had a more pronounced effect on DBP 
than mibefradil but the effect was less sustained after 24-hours. Mibefradil lOOmg and 
Verapamil SR 240 mg at steady state had a more attenuated effect on DBP than after 
single doses (Table 3.7.3.b).
Following single dose, the three drugs produced a decrease in heart rate with the greatest 
effect being observed after verapamil and the least effect with diltiazem. At steady state 
verapamil SR showed a more marked (Table 3.7.3.a and Table 3.7.3.b) and sustained 
decrease up to 24 hours than mibefradil.
Mibefradil and verapamil showed a greater PQ prolongation at steady state than after a 
single dose (Table 3.7.3.a). Verapamil and diltiazem had a more marked effect on the 
PQ interval than mibefradil. Studies with diltiazem suggested that the effect on atrio­
ventricular conduction might be dependent on the pharmaceutical formulation used. 
Rapidly absorbed formulations led to high drug concentrations, causing a greater 
prolongation of the PQ interval.
Pharmacokinetic/Pharmacodynamic relationships -  The Emax model, parameterised as 
the SO model was selected as appropriate to describe the time-course of action of blood
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pressure of mibefradil. The results of mibefradil presented in table 3.7.1.a show that at 
concentrations ranging from 61.9-1421.0 ng ml'1, marked reductions in DBP could be 
expected. This was reflected by a relatively low estimated value of EC50 of 1012.1 ng 
ml'1 for the blood pressure lowering effect. The Emax values could be estimated 
precisely as is evident by the relatively narrow coefficient of variation. Furthermore, 
there was less interindividual variability for Emax than for EC50. The EC50 values 
revealed wide interindividual variability. Individual variation in pharmacokinetics has 
long been recognised. Pharmacokinetic variability may be pronounced in drugs such as 
the other calcium antagonists, which undergo extensive CYP-mediated metabolism.
The reduction in DBP, after a single dose administration, caused by verapamil and 
diltiazem was associated with a much lower EC50 concentration (320.4 ± 238.4 ng ml' 1 
and 421.7 ± 292.3 ng ml'1, respectively) than mibefradil (1012.1 ± 484.7 ng ml"1). The 
interindividual variability in EC50 for mibefradil was wider than with verapamil and 
diltiazem.
For mibefradil the concentration-effect relationship for HR was difficult to model as the 
changes in HR were small, conferring a nearly flat profile. This contrasted with 
verapamil.
As with verapamil and diltiazem, mibefradil increases the PQ interval, and caution 
should be taken when treating patients who are susceptible to drugs that affect atrio 
ventricular conduction. However, with mibefradil the atrio-ventricular nodal 
conduction times were minimally affected at the therapeutic doses, as shown by much 
higher concentrations needed to induce changes in the PQ interval, and the EC50 value 
was 3-fold higher than the one for the DBP. The EC50 for changes in PQ interval was 
smaller with verapamil (693.4 ng ml"1) than with diltiazem (789.6 ng ml'1) or with 
mibefradil (2212.0 ng ml'1). The same conclusions were reached by other investigators 
(Rosenquist et al., 1997). For changes in PQ interval a linear model was more 
appropriate for all drugs. The Emax model estimated an EC50 for DBP (2212.0 ng ml' 
L) outside the range of plasma concentrations obtained after a single dose of mibefradil, 
rendering the linear model more appropriate. For the other two calcium antagonists, the
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EC50 estimates from the Emax model were lower. For verapamil at steady state the 
prolongation in PQ interval could have been fitted with an Emax model, since similar 
values of the Akaike Information Criteria were obtained with both models. In this 
analysis the changes in PQ interval were fairly described by a linear model. Although 
the conclusions drawn from the Emax and linear were similar, the variability with the 
linear model was smaller.
An interesting issue was identifying the drug concentration-effect relationships. The 
concentration-effect relationship for DBP and HR were best described by an Emax type 
model for the three drugs, either after single dose or multiple doses. Although the linear 
model yielded precise parameter estimates, the Akaike information criterion favoured 
the Emax model. For some patients (e.g. patient 3, mibefradil single doses DBP, Table
3.7.1.a) the algorithm did not converge. The EC50 estimates were imprecisely 
estimated. This occurred because the drug concentrations were not high enough to fully 
characterise the Emax effect, generating correlation between the model’s parameters 
during the estimation process. After a single dose of mibefradil the estimated EC50 for 
DBP was 1012.1 ± 484.7 ng ml' 1 and the mibefradil plasma concentrations ranged 
between 14.5 and 1727.0 ng ml'1. This correlation caused problems during the 
estimation of EC50, but not Emax. The correlation matrix between Emax and EC50 
was very high. To overcome this problem, the Emax model was re-parameterized in 
order to remove EC50 as a parameter from the model. The new parameter, SO, was 
better estimated than EC50, as it avoided the correlation. This contrasted with the Emax 
estimates that were obtained similarly in both models. The SO parameter can also be 
used as a measure of potency (Schoemaker et al., 1998) to compare the action of drugs. 
Plasma concentrations of verapamil and diltiazem were higher relative to EC50 
estimates for DBP and therefore the problem of parameter correlation was less 
noticeable.
The use of Emax model, when effect-concentration relationships are linear can cause 
problems in parameter estimation due to over parameterization. The routine use of the 
Emax model should be recommended. In pratice, the linear concentration-effect
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relationships are only obtained in a very narrow range of concentrations. As the 
concentration increases the effect approaches the Emax effect and deviates from linear. 
At very low concentrations the measurement error is high, deflecting the data from 
linearity and therefore the use of linear model is not appropriate. The lowest 
concentration the slope estimates from linear model are less variable than the 
corresponding SO estimates from the SO model. Problems in parameter estimates can 
arise when the concentrations are not high enough to define the Emax model that 
prompted Schoemaker et al. (1998) to recommend the routine use of SO model. In this 
study the parameterization proposed for the Emax model proved to have advantages 
over the traditional Emax model.
For DBP and after a single dose, hysteresis was observed in some patients, indicating a 
delay between the concentration of the drug and its concentration at the effect site.
For the PQ interval, hysteresis was not observed. For verapamil more patients showed 
hysteresis than for diltiazem. No hysteresis was observed at steady state, therefore DBP, 
HR and changes in PQ interval were directly correlated to drug concentrations.
From the comparative analysis between single dose and steady state of the 
pharmacodynamic parameters in the individual patients it was concluded that the 
parameters were not correlated. That contrasts with the results published by some 
investigators (Donnelly et al., 1994), as they reported that responsiveness to the first 
dose correlates with parameters obtained after 4 to 6  weeks of treatment with calcium 
antagonists. The discrepancies found in the results can be explained by either the 
insufficient statistical power of the study or by a change in responsiveness as seen with 
one of the verapamil parameters. This could only be addressed by a larger study 
population.
In conclusion, the findings of this study indicate that a once-daily administration of 
mibefradil 1 0 0  mg was associated with reductions in diastolic blood pressure.
This long half-life renders mibefradil suitable for once daily administration without the 
need for a modified formulation. Mibefradil has long-lasting and potent
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CHAPTER 4 COMBINING PHARMACOKINETIC AND 
PHARMACODYNAMIC DATA DURING POPULATION ANALYSIS
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4.1 SUMMARY
In this chapter the mixed effect modelling approach was utilised in the assessment of the 
influence of covariates on pharmacokinetic and pharmacodynamic parameter estimates. 
In addition, four different approaches of combining pharmacokinetic/ pharmacodynamic 
data were explored and compared.
4.2 INTRODUCTION
Sheiner and co-workers (1977) proposed carrying out a covariate analysis by iteratively 
incorporating the covariates in the model, using NONMEM. However, several 
alternative strategies have been suggested in the literature to deal with the incorporation 
of covariates into a population model (Mallet et al., 1988; Maitre et al., 1991; Mandema 
et al., 1992; Mentre and Mallet, 1994). The first was a three-step approach (Maitre et 
al., 1991) integrating the individual Bayes parameter estimates (POSTHOC) with 
graphical exploratory analysis. This approach consisted of plotting the POSTHOC 
parameter estimates obtained from the best structural model against each covariate in 
order to identify and describe possible relationships. Only the covariates showing an 
influence were used in further NONMEM runs. This approach has some drawbacks: the 
influence of POSTHOC parameter estimates and covariates is less obvious than the 
relationship between the true individual parameters, because POSTHOC parameter 
estimates are biased towards the typical population values. This is more noticeable in 
the case of sparse data with high variability. Another disadvantage is that the graphical 
method does not take into account the correlation among covariates.
A subsequent extension of this approach was proposed by Mandema (1992), who 
applied stepwise multiple linear regression analysis and a spline smoothing function in 
stepwise generalised additive modelling (GAM) to identify and describe the 
relationships between individual parameter estimates and covariates. Generalised 
additive modelling has the advantage of allowing non-linear relationships to be 
expressed (Hastie and Tibshirani, 1996). It is represented by the mathematical equation:
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P i= a+  2 g k(X ij)
i=l
where gk (Xy) repressents a function, such as natural splines, Pi is the POSTHOC 
parameters and a  is an intercept.
One of the drawbacks of the GAM procedure is that it can be influenced by outlying 
individuals that can interfere with the expression of covariate-parameter relationships.
It has been applied in population analysis of pharmacokinetic and pharmacodynamic 
data (Davidian and Gallant, 1992). An integrated approach to the selection of covariates 
comprising multiple linear regression, stepwise generalised additive modelling, tree- 
based modelling and linearisation of the non-linear mixed effect model was suggested 
by Ette et al. (1995). Jonsson et al. (1999) developed a program, Xpose® that performs 
plots and auxiliary analyses to assist in the covariate selection.
All of the approaches mentioned above were implemented using parametric 
methodology. Alternative strategies have been proposed using the semi-nonparametric 
(SNP) method (Davidian and Gallant, 1992) or the nonparametric method (Mentre and 
Mallet, 1994).
4.3 AIMS OF THE ANALYSIS
The data analysis was carried out to:
i) Determine the influence of covariates on the PK and PD parameter estimates 
obtained after the administration of single and multiple doses of mibefradil.
ii) Compare different approaches for combining 
pharmacokinetic/pharmacodynamic data during the modelling process using data 
obtained after a single dose of mibefradil.
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4.4 M ETHODS
The data used in the present analysis were obtained from the study described in Chapter
3. For the single-dose study, 18 patients were included who were given 150 mg of 
mibefradil. Details of the demographic characteristics and clinical status were given in 
section 3.4.2 and presented in Table 3.4.2. In addition, steady-state data were obtained 
from 1 0  patients who were given 1 0 0  mg of mibefradil.
4.5 DATA ANALYSIS
The analysis was carried out on an Opus Personal Computer with a Pentium 120 MHZ 
processor. Data were analysed by a nonlinear mixed effects model using the NONMEM 
software package, version V, level 2 (Beal and Sheiner, 1998). Fortran Power-Station® 
(version 1.0a, Microsoft Corporation) was used as the compiler. Statistical analysis was 
carried out using the software Splus® (1998) installed on a Compaq Armada 7792 
DMT, computer.
Data were first entered into an Excel® spreadsheet. The data set for single dose analysis 
contained information on time, dose, measured concentrations and measured 
pharmacodynamic variables. Models were implemented using either the PRED 
subroutine or the PREDPP library. The data item TYPE was included as a flag to 
distinguish between drug concentration and pharmacodynamic measurements. Items 
required by the PREDPP subroutine, such as Event Identification Data Item (EVID) and 
Compartment Data Item (CMT) were also included. From the full data set, two new 
data sets, one with the rows corresponding to drug measurements removed and the other 
with the PD measurements removed were produced. For the steady-state analysis, the 
data set included date, time, dose, measured observations, either concentration or 
pharmacodynamic variables, and TYPE. The additional items required by PREDPP 
were EVID, SS, II and CMT. SS indicates that the dose is a steady state dose and II is 
the dosing interval. Both data sets were checked for errors and outliers by the
172
“Checkout” option available in NONMEM. Exploratory analysis was carried out to 
identify possible outliers.
4.5.1 PHARMACOKINETIC DATA ANALYSIS
Structural Model - Mono- and bi-exponential decline models were fitted to the 
concentration-time data. Models were parameterised to give estimates of absorption 
rate constant (ka), for the first-order or duration of the absorption for the zero-order 
model, volumes of distribution of the central and peripheral compartments (V/F, Vi/F, 
V2/F), clearance/bioavailability (CL/F), intercompartmental clearance (Q) and lag time 
(Tlag). The PREDPP subroutines ADVAN2/TRANS2 and ADVAN4/ TRANS4 were 
selected to run mono- and bi-exponential decline models, respectively. A data set 
without PD measurements was used to identify the pharmacokinetic structural model.
The mathematical equations used to model zero-order and first-order oral absorption 
processes after single-dose administration for mono- and bi-exponential declines are 
described in Gibaldi & Perrier (Gibaldi and Perrier, 1982). The elimination half-life 
was derived from the microscopic rate constants as described in section 2.4.3.
The interindividual variability was assumed to follow a logarithmic, Gaussian 
distribution. The models for residual variability, described in section 1.4.5, were fitted 
to the data and the selection was made as indicated from graphical analysis. Choice of 
estimation method was made between the FO (First Order Method) and FOCE (First 
Order Conditional Estimation Method). FOCE was used providing such an estimation 
method was warranted. Diagonal elements of the £2-matrix were first estimated. In 
addition, once the structural pharmacokinetic model was finalised, covariance terms of 
the lower triangle of the £2 -matrix were estimated (full variance-covariance matrix) and 
retained providing successful completion of the NONMEM run. POSTHOC parameters 
were estimated from the “best” (basic model-without covariates) pharmacokinetic 
model.
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Covariate Model - Covariates were incorporated into the pharmacokinetic model by a 
two step approach using individual ‘POSTHOC’ estimates. Linear and nonlinear 
relationships between individual pharmacokinetic parameter estimates and covariates 
were investigated graphically. A generalised additive model (GAM, available in the 
statistical package Splus (1998)) was used to investigate relationships between the 
POSTHOC estimates of individual parameters (from the basic model) with covariates. 
For each covariate a hierarchy of models such as: not included, linear and non-linear 
models (spline) were tried. The model selection for the GAM fitting was made based on 
the Akaike Information Criterion (AIC) and the models that produced the lowest AIC 
were selected. Plots of the AIC against each model were also produced to help in the 
model selection. The demographic characteristics and clinical status of the patients 
(Table 3.4.2) were used as covariates in the modelling process. If no covariates showed 
an influence on the primary pharmacokinetic parameter, the covariate submodel was 
omitted. Covariates selected through the GAM were then evaluated using NONMEM 
by testing each covariate individually on each parameter as described in Chapter 1 
section 1.4.8 and model selection was based on the criteria described in Chapter 1 
section 1.4.7. A reduction on objective function value of more than 7.9 points was 
considered statistically significant at 99.5 % confidence level.
4.5.2 PHARMACOKINETIC/PHARMACODYNAMIC DATA ANALYSIS 
Structural Model -  Once the best-fit pharmacokinetic population model was obtained 
the mean and variance estimates of the final population pharmacokinetic parameters 
were fixed during the subsequent pharmacodynamic modelling process. A full data set 
including PK and PD measurements was used in the analysis. Only one response 
variable was used for population pharmacodynamic modelling, the diastolic blood 
pressure. As a result of the previous analysis, the Emax pharmacodynamic model re- 
parameterised as proposed by Schoemaker (1998) and described in Chapter 3 was 
implemented. The interindividual variability on the pharmacodynamic parameters were 
assumed to follow a logarithmic, Gaussian distribution. The residual error on the
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pharmacodynamic measurements was assumed to be homoscedastic and therefore the 
additive model was used.
Covariate Model - The influence of covariates was tested on the pharmacodynamic 
(Emax, and SO) parameter estimates. Covariate model building was carried out as 
described in section 4.5.1.
4.5.3 COMBINING PHARMACOKINETIC/PHARMACODYNAMIC DATA 
Four different approaches were used to analyse the pharmacokinetic/pharmacodynamic 
relationships of mibefradil to changes in diastolic blood pressure after single-dose 
administration:
1. All pharmacokinetic parameters for each individual were fixed to the population 
averages previously obtained. Pharmacodynamic parameters were estimated (PD 
data set)
2. Pharmacokinetic parameters and their variances were fixed to the population 
estimates previously obtained and the pharmacodynamic parameters were estimated, 
but the pharmacokinetic data were left in the data set under DV (the dependent 
variable)
3. The pharmacokinetic and pharmacodynamic models were fitted simultaneously 
using the same NMTRAN subroutines as in 1).
4. The pharmacodynamic parameters were estimated using individual predicted 
concentrations (IPRED) obtained from the pharmacokinetic model fit. Individual 
predicted concentrations were included as an extra item in the data set and a PRED 
control file was written.
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4.6 RESULTS
4.6.1 PHARMACOKINETIC MODEL
4.6.1.1 Single-Dose Study
Structural Model - One hundred and ninety-five concentrations, ranging from 14.5 to 
1727.0 ng ml"1, were available after a single oral dose of mibefradil. Eighty-three per 
cent of the patients had 11  measured concentrations each and the remainder had 10  
concentrations each.
A comparison of mono- and bi-exponential decline models and zero- and first order 
absorption models showed that the pharmacokinetics of mibefradil were better described 
using an open model with first-order absorption and a bi-exponential decline. Details of 
this comparison are shown in Table 4.6.1.a. Comparing the mono- and bi-exponential 
decline models estimated under the FO method, the parameters were estimated with 
similar degree of confidence and there was a decrease in the proportional component of 
the residual error from 84.1 to 27.7%. Clearance was estimated with similar precision 
by both models. The oral absorption rate and lag time estimates were better estimated 
with a bi-exponential decline model than with a mono-exponential decline model. 
However, the variability in the peripheral compartment volume was poorly estimated 
with the two-compartment model. The value of the objective function was reduced by
49.5 points when the bi-exponential decline model was fitted to the data. Plots of 
weighted residuals against time after the dose obtained from both models are shown in 
Figure 4.6.1.a. The bi-exponential decline model yielded a more random scatter of 
weighted residuals around zero than the mono-exponential decline model, especially at 
later time points, and therefore was selected for further analysis.
The FO and FOCE methods estimated clearance to be 6 .8  and 6.4 L h"1 respectively, 
with an error of 8.7 and 10.3%. Difficulties in estimating interpatient variance in CL/F, 
Q, Vi/F, Ka and Tlag were experienced with the FOCE approach, while interpatient 
variability in V2 was poorly characterised by the FO method. In addition, residual error
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Figure 4.6.1.a Weighted residuals versus time obtained from mono-exponential and bi­
exponential decline models using the FO method with single dose mibefradil data
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Table 4.6.1.a Pharmacokinetic parameter estimates with mono- and bi-exponential
decline models after a single dose of mibefradil (150 mg)
Mono-exponential Bi-exponential
Parameters FO FOCE FO FOCE
ka (h'1) 2.30 9.93 3.05 2.38
(% SE) 27 20 13 22
Variability ka (%) 114 101 92.0 42.5
(% SE) 25 48 33 61
CL/F (Lh1) 6.60 7.10 6.81 6.64
(% SE) 7.3 12 8.7 10
Variability CL (%) 30.4 35.4 35.9 40.1
(% SE) 49 88 53 81
V,/F (L) 168 164 148 114
(% SE) 6.3 6.8 6.1 11
Variability Vi (%) 25.6 30.6 26.7 41.1
(% SE) 51 64 46 66
V2/F(L) - 32.5 63.5
(% SE) - 15 17
Variability V2 (%) 10.2 28.0
(% SE) 1854 89
Q (L h') - 3.20 47.3
(%SE) - 16 40
Variability in Q (%) 171 85.7
(% SE) 50 49
Tlag (h) 0.38 0.45 0.4 0.3
(% SE) 13 5.8 11 20
Variability Tlag (%) 54.9 6.65 35.6 49.8
(% SE) 70 70 53 80
Residual error
at 20 ng ml'1(%) 84.1 153.6 27.70 72.9
at 1200 ng mf,(%) 9.92 12.0 7.70 8.10
OFV 2039.449 2071.793 1989.896 1999.630
Key: SE denotes the standard error o f the parameter estimate; ka - oral absorption rate constant; CL - 
clearance, Vt - Volume of the central compartment; V2 - Volume of distribution o f the peripheral compartment; 
Q - intercompartmental clearance; OFV - objective function value
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increased from 27.7% to 72.9% when the FOCE method was used (Table 4.6.1.a). Plots 
of weighted residuals against time did not suggest an improvement in the fit by using the 
FOCE method (Figures 4.6.1.a and 4.6.l.b). Considering the ten-fold increase in 
computing time and the lack of obvious improvement when FOCE was used, the FO 
method was applied to subsequent analyses.
Performing the Anderson-Darling normality test on POSTHOC parameter estimates 
checked the assumption in the model about the logarithmic normal distribution of the 
interindividual variability. The combined (proportional and additive) residual error 
structure proved to be superior to the additive, as judged by the drop in objective 
function value of 24.5 points.
It was concluded that the most appropriate model to describe the data was the two- 
compartment open model with a combined residual error model and that the FO method 
was satisfactory for parameter estimation.
Covariate Model -  Only the baseline value for blood pressure and weight had an 
influence on clearance according to the generalised additive modelling (GAM) analysis 
(as shown in Table 4.6.l.b). The same covariates were selected when the POSTHOC 
estimates of the volume of the central compartment were analysed (Table 4.6.l.b). All 
covariates were subsequently evaluated in the nonlinear mixed effect model, testing 
each covariate individually on each parameter. The linear model for covariates 
wasinvestigated with GAM but when it was tested with NONMEM it did not improve 
the fit. No covariates showed a statistically significant influence either on clearance 
(CL/F) or on volume (V/F) when the stepwise procedure was implemented within 
NONMEM (Table 4.6.l.c).
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Figure 4.6.1.b Weighted residuals versus time obtained from mono-exponential and
bi-exponential decline models using the FOCE method with single dose mibefradil
data
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Table 4.6.1.b Results obtained from applying the generalised additive 
modelling approach to the POSTHOC pharmacokinetic parameter estimates 
after a single dose administration of mibefradil
Parameter Model AIC DF
CL/F 446 17
-Weight 361 16
-BASB+Weight 337 15
~ns(B ASB ,df=2)+Weight 274 14
~ns(BASB,df=2) 261 15
V l/F 98542 17
-Weight 77297 16
-BA SB+W eight 69591 15
~ns(BASB,df=2) + Weight 61037 14
~ns(BASB,df=2) 61008 15
Key: CL represents the clearance; F  is the bioavailability; VI is the volume o f  distribution o f  
the central compartment; BASB is the baseline value fo r  diastolic blood pressure, DF is the 
degrees o f  freedom; AIC is the Akaike Information Criterion and ‘n s ' represents the natural 
spline model.
Table 4 .6 .1 .C  Results of individual covariates tested by NONMEM in the 
pharmacokinetic parameter estimates from single dose administration of 
mibefradil
Parameter Model OBFV AOBFV3
CL/F 1989.90
03 * (Age/57) 07 1989.87 -0.03
03 * (Height/166)07 1994.53 4.63
03 * (Weight/80)07 1993.92 4.02
03 * (BASB/89)07 1988.65 -1.25
V l/F 08 * (Age/57) 09 1989.55 -0.35
08 * (Height/166)09 1987.16 -2.74
08 * (Weight/80)09 1986.75 -3.15
08 * (BASB/89)09 1989.61 0.28
Key: OFV - Objective Function Value; VI is the volume o f  distribution o f  the central 
compartment; CU F is the clearance and F  is the bioavailability. 6 is a parameter estimate; 
BASB is the baseline value fo r  diastolic blood pressure.
a A reduction in objective function value o f  7.9 points was considered statistically significant, 
at the 99.5% confidence level.
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4.6.1.2 Steady-State Study
Structural Model - One hundred and thirteen steady state concentrations were available 
for analysis, ranging from 9.1 to 1421.0 ng ml'1. The number of data points per patient 
ranged from 9 to 12. The bi-exponential decline model fitted the data better than a 
mono-exponential decline model (objective function value drop of 23.5 points). Figure
4.6.l.d shows that with a bi-exponential decline model, the weighted residuals against 
time were more scattered around the abscissa-axis towards the late times than with one- 
compartment model. However, the parameter estimates of the bi-exponential decline 
model were associated with problems.
The oral absorption rate constant had a value of 0.167 h' 1 and an error of 41% therefore 
could not be estimated satisfactorily. The interindividual variability on oral absorption 
rate was estimated at 30% with an error of 88.7%. Similar values of clearance were 
obtained with both models. The mono-exponential decline model estimated the volume 
of distribution of the central compartment to be 277 L with a degree of confidence of 
8.7%. However, the interindividual variability on this parameter was indeterminate.
The value of Vi obtained with a bi-exponential decline model was poorly estimated and 
the interindividual variability in this parameter was high at 1 1 2 %.
The interindividual variabilities on the volume of distribution of the peripheral 
compartment and on intercompartmental clearance were not well characterised by a bi­
exponential decline model. However, due to the overall improvement in fit observed on 
the plots, the bi-exponential decline model was selected for future analysis.
The FOCE method offered no advantage over the FO method. Standard errors of the 
pharmacokinetic parameters were not estimated and the interindividual variability in V2 
and on Q was indeterminate (Table 4.6.l.d). Figures 4.6.l.c  and 4.6.l.d show the plots 
of weighted residuals against time obtained from both approaches. No improvement in 
plots was observed using the bi-exponential decline model.
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Figure 4.6.1.d Weighted residuals versus time obtained using mono-exponential and
bi-exponential decline models using the FOCE method with steady state mibefradil
data
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Figure 4.6.1.C Weighted residuals versus time obtained using mono-exponential and
bi-exponential decline models and the FO method with steady state mibefradil data
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Table 4.6.1.d Pharmacokinetic parameter estimates obtained using mono- and bi­
exponential decline models with multiple dose mibefradil data
Mono-exponential Bi-exponential
Parameters FO FOCE FO FOCE
ka (h'1) 0.65 1.58 0.17 0.95
(% SE) 20 16 41 *
Variability ka (%) 185 51.3 29.6 42.4
(% SE) 58 66 89 *
CL/F (L h 1) 6.5 6.50 6.5 6.66
(% SE) 13 14 14 *
Variability CL (%) 37.3 43.5 37.5 42.7
(% SE) 56 37 58 *
V,/F(L) 277 221 24.4 166
(% SE) 8.7 11 47 *
Variability V! (%) indeterminate 22.4 56.3 35.2
(% SE) * 110 112 *
V2/F(L) - 256 140
(% SE) - 11 *
Variability V2 (%) indeterminate indeterminate
(% SE) * *
Q(Lh') - 22.4 14.8
(%SE) - 39 *
Variability in Q (%) - 175 indeterminate
(% SE) - 420 *
Residual error
at 20 ng ml'1 191.5 263.3 61.1 9.57
at 1200 ng ml'1 8.29 9.91 8.90 9.57
OFV 1142.815 1158.181 1119.262 1125.580
Key: SE denotes the standard error of the parameter estimate; ka - oral absorption rate constant; 
CL - clearance, V] - Volume of the central compartment; V2 - Volume of distribution of the 
peripheral compartment; Q - intercompartmental clearance; OFV - objective function value; * not 
estimated.
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Although the objective function value dropped only 2 points with the combined 
structure (proportional and additive) compared to the additive model, the combined 
structure was selected for further analysis due to its flexibility.
Covariate Model -  Volume of distribution of the central compartment and clearance 
were influenced by age, according to the GAM analysis results. After the inclusion of 
age as a covariate for VI, the AIC was 1709, (df=8 ), representing a decrease from the 
model without covariates. For clearance, the AIC decreased after the inclusion of age 
compared to the model without covariates. No covariates had an influence on volume 
of distribution of the peripheral compartment. The results of the GAM analysis are 
presented in Table 4.6.I.e.
No covariates had a statistically significant influence on any pharmacokinetic 
parameters when modelled using NONMEM. Similar conclusions were obtained by 
Welker (Welker, 1998).
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Table 4.6.1.e Results obtained from applying the generalised additive modelling 
approach to the POSTHOC pharmacokinetic parameter estimates obtained after 
multiple dose administration of mibefradil
Parameter Model AIC DF
CUF 149 9
-BASB 138 8
-AGE 134 8
-Height 158 8
-Weight 151 8
V l/F 2213 9
-BASB 1869 8
-AGE 1709 8
-Height 2552 8
-Weight 2543 8
Key: CL represents the clearance; F the bioavailability; VI is the volume of distribution of the 
central compartment; BASB is the baseline value for diastolic blood pressure, dfis the degrees 
of freedom; AIC is the Akaike Information Criterion and ns represents the spline model.
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4.6.2 PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS 
4.6.2.1 .Single-Dose Study
Structural Model -  The SO model was fitted to the diastolic blood pressure data by 
fixing the pharmacokinetic parameters presented in section 4.6.1.1 while fitting the PD 
data. A full data set, comprising PK and PD measurements, was used in the analysis. 
(This corresponds to the method described in section 4.5.3).
Emax was estimated to be -22.4 mmgHg with an interindividual variability of 42.2%. 
The estimate of SO was -0.0225 mmHg/(ng/L) with a wide interindividual variability of 
34.9 %. Figure 4.6.2 illustrates the weighted residuals plot obtained for predicted 
diastolic blood pressure and shows a scattered distribution.
Covariate Model -  The GAM analysis identified the baseline value of blood pressure 
as a covariate that influenced Emax and two covariates, the baseline value of blood 
pressure and smoking status, that influenced the POSTHOC estimates of the SO 
parameter. However, when baseline value was incorporated in the Emax parameter 
using NONMEM, only 5.1 points decrease ocurred whereas for the SO parameter the 
drop in objective function was 6.4 points. When smoking status was included in the 
model as a second covariate, the objective function decreased further 5 points. No 
covariates were therefore selected from the NONMEM runs.
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Figure 4.6.2 Weighted residuals against predicted DBP obtained from the SO model, 
fixing pharmacokinetic parameters (Method 2) and after the administration of a single dose 
of mibefradil
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4.6.2.2 Steady-State Study
Structural Model -  The parameter estimates obtained in the PD analys 
in Table 4.6.2. It was not possible to obtain standard errors of these esti 
steady-state analysis.
Covariate Model -  Difficulties in the estimation step led to no covarial 
identification. Interpatient variability in Emax was not estimated and th 
step was aborted. It is likely that the small number of patients and the h 
variability contributed to the problems with the parameter estimation.
4.6.2.2 Steady-State Study
Structural Model -  The parameter estimates obtained in the PD analysis are presented 
in Table 4.6.2. It was not possible to obtain standard errors of these estimates in the 
steady-state analysis.
Covariate Model -  Difficulties in the estimation step led to no covariate model 
identification. Interpatient variability in Emax was not estimated and the covariance 
step was aborted. It is likely that the small number of patients and the high interpatient 
variability contributed to the problems with the parameter estimation.
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Table 4.6.2 Pharmacokinetic/pharmacodynamic parameter estimates obtained after 
the administration of multiple doses of mibefradil, for diastolic blood pressure
(N=10)
PK FIXED 
Full data set
PK parameters
ka (h'1) 0.17
(% SE) 40.
Variability ka (%) 29.6
(%SE) 89
CL/F (L h 1) 6.5
(% SE) 14
Variability CL (%) 37.5
(% SE) 58
V|/F (L) 24.4
(% SE) 47
Variability Vj (%) 56.3
(% SE) 112
v 2/F(L) 256
(% SE) 11
Variability V2 (%) indeterminate
(% SE) *
Q(Lh') 22.4
(% SE) 39
Variability in Q (%) 175.0
(% SE) 420
Residual error 
at 20 ng ml'1 61.1
at 1200 ng ml"1 8.9
PD parameters
Emax (mmHg) -22.9
(% SE) 6.4
Variability Emax (%) indeterminate
(% SE) *
SO (mmHg/(ng/L) -0.0378
(% SE) *
Variability SO (%) 17.2
(% SE) 53
Residual error 42.5
Key: SE denotes the standard error of the parameter estimates; ka oral absorption rate constant, CL
clearance, V] Volume of the central compartment; V2 Volume of distribution of the peripheral 
compartment; Q intercompartmental clearance; F is the bioavailability; OFV objective function value, * 
not estimated
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4.6.3. COMBINING PHARMACOKINETIC/PHARMACODYNAMIC DATA 
The results from fitting the SO model to the single-dose data using the four different 
approaches are presented in Table 4.6.3. Simultaneously fitting the PK and PD data led 
to difficulties in estimating the interpatient variability on V2. The remaining PK 
parameter estimates were similar across the three methods. The Emax estimates were 
slightly lower with Method 1 and 2 than with Method 3 and Method 4. The interpatient 
variability for Emax with Method 1 was indeterminate and with Method 2 was much 
higher than with the other two methods. For the SO parameters, the estimates from the 
four methods were similar.
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Table 4.6.3 Pharmacokinetic/pharmacodynamic parameter estimates obtained from
four different methods, after the administration of a single dose of mibefradil, for
diastolic blood pressure (N=17)
METHOD 1 
PK fixed 
(PD data set)
METHOD 2 
PK fixed 
(FULL data set)
METHOD 3 
Simultaneous 
PK/PD
METHOD 4 
IPRED
PK parameters FIXED FIXED
ka (h1) 3.10 3.10 3.30
(% SE) 13 13 13
Variability ka (%) 92.0 92.0 86.0
(% SE) 33 33 37
CL/F (L h 1) 6.81 6.81 6.50
(% SE) 8.7 8.7 6.2
Variability CL (%) 35.9 35.9 33.0
(% SE) 53 53 42
V,/F(L) 148 148 137.0
(% SE) 6.1 6.1 6.3
Variability Vj (%) 26.7 26.7 26.4
(% SE) 46 46 42
V2/F(L) 32.5 32.5 34.4
(% SE) 15 15 15
Variability V2 (%) 10.2 10.2 0.43
(% SE) 1854 1854 *
Q(Lh') 3.20 3.20 3.40
(%SE) 16 16 16
Variability in Q (%) 171 171 145
(% SE) 50 50 52
Tlag (h) 0.40 0.40 0.35
(% SE) 11 11 12
Variability Tlag (%) 35.6 35.6 45.1
(% SE) 53 53 62
Residual error
at 20 ng ml'1 27.7 27.7
at 1200 ng ml'1 7.7 7.7
PD parameters ESTIMATED
Emax (mmHg) -23.7 -22.4 -27.2 -26.0
(% SE) 6.2 9.0 5.9 5.4
Variability Emax (%) * 42.2 10.9 8.40
(% SE) indeterminate 74 142 186
SO (mmHg/(ng/L) -0.0294 -0.0225 -0.0300 -0.0300
(% SE) 12 14 7.3 7.3
Variability SO (%) 37.9 34.9 32.4 34.5
(% SE) 38 57 26 29
Residual error 0.90 0.90 1.00 1.30
Key: SE denotes the standard error of the parameter estimate; ka - oral absorption rate constant CL - 
clearance, Vj - Volume of the central compartment; V2 - Volume of distribution of the peripheral 
compartment; Q - intercompartmental clearance; OFV - objective junction value; *not estimated
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4.7 DISCUSSION
The most appropriate model describing the pharmacokinetics of mibefradil after a single 
dose was the bi-exponential decline model with first-order absorption, and a lag time. 
The variability in V2 was estimated to be very high. That can be explained in part by the 
fact that the drug concentrations were only sampled long enough to identify, but not 
define the second compartment. The results obtained here contrast with the results 
obtained in chapter 3, where a mono-exponential decline model was selected for the 
individual fits. The population approach allows the combination of information from 
each individual to be used simultaneously in the estimation of the mean population 
parameters. Problems encountered during the modelling process due to deficient 
sampling times where associated with limitations in the traditional approach. A mono­
exponential decline model was selected in a previous population study of mibefradil 
using NONMEM (Welker and Banken, 1998), but they only had samples up to 24 hours 
after the last dose and were therefore unable to identify the second compartment. The 
pharmacokinetic parameters reported by these investigators were similar to the ones 
obtained in this study.
The GAM procedure selected the baseline value for diastolic blood pressure as a 
covariate correlated with Emax. The influence of the same covariate was selected by 
Welker et al. (1998) using NONMEM. However, NONMEM failed to detect such a 
relationship in the present study. This might be explained by the small number of 
patients. The use of GAM to identify relationships between POSTHOC parameter 
estimates and covariates was found to be useful, although in the present study, the 
amount of data available was limited therefore the methodology could not be fully 
explored. However, in the presence of a high number of covariates the time required to 
test all covariates individually in NONMEM can be very time consuming. GAM is an 
exploratory technique that can be used in conjunction with graphical analysis to reduce 
the time spent testing covariates within NONMEM. The preliminary results obtained in 
the present study indicate that the technique could offer potential advantages in 
covariate modelling.
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The result obtained for the PK parameters when the PK/PD data were fitted 
simulaneously were similar to those obtained on sequential analysis. This indicated that 
the inclusion of PD data did not seriously compromise the PK parameter estimation on 
this occasion. However, the simultaneous approach failed to obtain an estimate of the 
standard error of interpatient variability on V2. This can be explained by the fact that 
the misspecification of PD model caused distortion in the PK parameters. Fixing the 
PK parameters is particular useful when the uncertainty on PD data is higher than with 
the PK data (Holford and Sheiner, 1981).
In contrast, for the PD parameters, the simultaneous fitting performed better than the 
sequential fitting as judged by the precision in the parameter estimates. The BPRED 
method yielded similar results to the simultaneous fitting. Fixing the PK parameters 
while fitting the PD data has the advantage of being faster than the simultaneous fitting. 
Fixing the PK parameters removes variability from the data that can affect the 
estimation of the PD parameters. In this study, the interindividual variability on Emax 
was indeterminate when the PK parameters were fixed. In contrast, the interindividual 
variability was estimated when the PK data were left in the data set while estimating PD 
parameters. Similar conclusions were reached in a preliminary simulation study by 
other investigators (Wade and Karlsson, 1999). They carried out a simulation study in 
PK and PD data from 30 data sets with 50 subjects each. The variability in PK and PD 
parameters were set to 10 and 30 % and NONMEM was used to analyse the data. These 
investigators discourage the practice of removing the PK data while estimating the PD 
parameters. Although the PK parameters are not being estimated in Method 2, the 
inclusion of the concentration measurements influences the estimation of PD 
parameters.
The results obtained in this study raised some points for discussion regarding the 
selection of the best approach of combining PK and PD data. Much work has however 
to be done before firm conclusions can be drawn.
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CHAPTER 5 GENERAL DISCUSSION AND CONCLUSIONS
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5.1 POPULATION PHARMACOKINETICS OF GENTAMICIN IN CANCER 
PATIENTS
Gentamicin is an antibiotic widely prescribed for the management of fever in 
neutropenic patients. Although efficacious, its utilisation in clinical practice is limited 
by its toxicity, in particular, nephrotoxicity and otoxicity, which are related to the trough 
concentration. Efficacy is determined by the early achievement of high peak 
concentrations, which are determined by the dose and the volume of distribution. In 
order to obtain an optimal dosage regimen, the clearance and volume of distribution 
estimates have to be tailored to the specific patient population.
The identification of gentamicin pharmacokinetics in this particular group of patients is 
crucial to the selection of a rational initial dosage regimen. This can be achieved by 
population modelling techniques. To date, no reports were available in the published 
literature characterising the population pharmacokinetics of gentamicin in adults with 
oncological disease using nonlinear mixed effects models. Such model was developed 
in this thesis, and used to evaluate the applicability of two common dosage regimens in 
this particular group of patients. Both dosage regimens should achieve satisfactory 
concentrations in this group of patients.
Although population-based methods provide an aid for initial dosage selection, data 
from this study indicate that a high-degree of variability in the pharmacokinetics of 
gentamicin in cancer patients is still present. It is therefore important to analyse 
individual gentamicin plasma concentrations and further dosage adjustment may be 
necessary to maximise efficacy and minimise toxicity.
The usefulness of the population model was extended to include an evaluation of 
creatinine clearance estimates as a measure of gentamicin clearance in cancer patients. 
The assessment of renal function is important for aminoglycosides because they are 
renally excreted. For that reason, creatinine clearance is one of the most widely used 
factors for adjustment in clinical settings. However, the accuracy of the nomograms to
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estimate creatinine clearance depends on normal production and elimination of 
creatinine. Creatinine production in cancer patients is often reduced due to a reduction 
in muscle mass, thus the serum creatinine concentration is expected to be lower than 
normal, leading to an overestimation of creatinine clearance values, resulting in a 
potential drug overdose. This problem was confirmed in the population analysis. The 
study concluded that either setting the lower creatinine limit to 88.4 pmol L'1, or using 
the measured creatinine concentration, provided inaccurate predictions of gentamicin 
clearance and concentrations. Better fits were obtained when the lower limit of 
creatinine was set to 60 or 70 pmol L"1. These results were consistent with those 
obtained by other investigators.
One of the attractive aspects of the population pharmacokinetic approach is that all 
relevant pharmacokinetic parameters were estimated using routine data from therapeutic 
drug monitoring and therefore no extra costs were involved in the generation of the data. 
This technique is of value in the analysis of sparse sampling data with variable numbers 
of samples per patient, as was the case with gentamicin.
194
5.2 A PHARMACOKINETIC-PHARMACODYNAMIC COMPARISON OF 
MIBEFRADIL, DILTIAZEM AND VERAPAMIL
The data included in this analysis were obtained from phase II clinical trials. As it was a 
rich data set obtained under experimental conditions, the two-stage approach was used 
to characterise the pharmacokinetics and pharmacodynamics of mibefradil, verapamil 
and diltiazem. The results in this analysis agreed with previous studies reported in the 
literature (Welker, 1998). Peak plasma concentrations at steady state were reached 
within 2.5 hours after dose administration and at steady state mibefradil had a longer 
half-life than after single dose. The pharmacokinetics of mibefradil were characterised 
by low clearance. After single doses, the high values of clearance obtained for 
verapamil and diltiazem contrasted with the values obtained for mibefradil. The low 
clearance and long elimination half-life of mibefradil enabled once-daily dosing without 
the requirement to develop a slow-release formulation. In contrast, both verapamil and 
diltiazem require slow-release formulations to permit once daily dosing and this leads to 
the need for “brand” name prescribing to avoid variability in response due to 
formulation differences. Consequently, in contrast to verapamil and diltiazem, these 
favourable pharmacokinetic characteristics of mibefradil enable once-daily dosing 
without the requirement to develop a slow-release formulation.
The antihypertensive efficacy of mibefradil has been evaluated in several large placebo- 
controlled trials (Bemink et al., 1996; Bursztyn et al., 1997; Oparil et al., 1997; Carney 
et al., 1997). The results of these studies have shown mibefradil to be efficacious in the 
treatment of essential hypertension and doses of 50 and 100 mg once daily were 
recommended. At these doses mibefradil effectively reduced blood pressure over a 24- 
hour period with low trough/peak ratios and with a gradual onset, reaching maximum 
within 1-2 weeks. The findings in this thesis were that at steady state, 100 mg of 
mibefradil given once daily lowered the diastolic blood pressure smoothly for the 24- 
hour period. At steady state, the effect on blood pressure was more pronounced than in 
the single dose study.
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Studies designed to compare the antihypertensive efficacy of mibefradil with that of 
other calcium antagonists are scarce. Although a series of comparisons have been made 
between mibefradil and diltiazem and mibefradil and nifedipine, there were no previous 
studies that compared mibefradil and verapamil. The findings of this analysis indicate 
that mibefradil has a longer-lasting antihypertensive action than verapamil and 
diltiazem.
At steady-state, no hysteresis loops occurred; this contrasted with single dose results. 
Like verapamil and diltiazem, a decrease in heart rate was observed with mibefradil, 
however as with verapamil and diltiazem, mibefradil prolonged PQ interval but much 
higher concentrations were needed to induce changes in PQ interval.
The complexities encountered in the PK/PD modelling of calcium antagonists warrant 
discussion. In vivo experiments are limited by the occurrence of side-effects when drug 
concentrations are increased. Consequently, in some cases, the drug concentration is not 
high enough to fully characterise the concentration-effect relationship. In the mibefradil 
study, the data did not permit an entirely satisfying determination of effect-concentration 
relationship. For blood pressure and heart rate, the Emax model was justified in some 
patients, while for other patients the linear model was more appropriate. The problem 
was more marked for mibefradil than for verapamil. As the aim of this analysis was to 
compare the pharmacokinetic/pharmacodynamic relationships of mibefradil with those 
of verapamil and diltiazem, the inability to select a uniform model for all patients 
rendered the analysis difficult. The SO parameter was more accurately estimated than 
the EC50 parameter and this re-parameterization of the Emax model solved the problem 
by enabling the characterisation of effect-concentration relationships, when the Emax 
effect was not attained. This approach then permitted conclusions to be drawn about the 
relative therapeutic and adverse effects of each drug within the normal concentration 
range.
Individual fitting was appropriate for rich data as illustrated in mibefradil study. The 
PK analysis identified changes in PK parameters whereas the PK/PD analysis allowed
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comparison of responses after single dose and steady state dosing. Additional and 
useful potential applications of the technique were the comparison of response/toxicity 
profiles among three drugs with similar clinical characteristics. The analysis was able to 
identify that mibefradil had a bigger separation between the decrease in blood pressure 
and the increase in PQ interval than diltiazem, however difficulties were encountered 
because of model differences.
Comparison of single dose and steady state pharmacodynamic parameters in individual 
patients suggested that the parameters were poorly correlated. This in part could be 
accounted for by the imprecise estimates in individual patients and by the relatively 
small population. The relative contribution of each of these factors could only be 
addressed in a larger study population.
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5.3 COMBINING PHARMACOKINETIC AND PHARMACODYNAMIC DATA
The initial studies examined individual PK/PD relationships but an extension of the 
work investigating the influence of different techniques for analysing PK/PD data using 
a population approach was lacking in the literature. In this thesis, four different 
methods for combining PK and PD data were applied to the modelling of diastolic blood 
pressure data after the administration of a single dose of mibefradil. It was concluded 
that in those situations where the linking model between drug concentration and effect is 
known, the PK and PD modelling should be carried out simultaneously. However, most 
frequently, the PK model is better known than the pharmacodynamic model and more 
reliable estimates of the PK parameters can be obtained from drug concentration alone. 
So, the PD parameters should be estimated using a full data set while fixing PK 
parameters. Moreover, the use of full data set has the advantage of reducing the data 
manipulation. Due to the small number of patients the present analysis had some 
limitations which have been discussed previously, therefore caution is recommended 
before definitive conclusions can be drawn.
In this thesis the application of different modelling techniques were explored. The 
relevance of nonlinear mixed effect modelling to sparse data situations was 
demonstrated (Chapter 2). The nonlinear mixed effect modelling was applied to rich 
data (Chapter 4). Using nonlinear mixed effects modelling for full concentration-time 
profiles allowed the characterisation of the individual pharmacokinetic parameters as 
well as the mean population trend. Another advantage of nonlinear mixed effects 
modelling was the flexibility to handle error models to perform such analysis. This 
contrasts with the results obtained with the standard two-stage approach (Chapter 3) 
which did not differentiate between intra and interindividual variability. Combining 
pharmacokinetic and pharmacodynamic information using nonlinear mixed effects 
approach was also investigated (Chapter 4). The advantages and disadvantages of the 
techniques used in this work were applied and discussed. It can only be speculated that 
the use of these techniques would improve patient care.
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APPENDICES
APPENDIX I
Equation 1 -  Intravenous infusion administration with a bi-exponential decline 
C (t)= C, (e~X|t - e ~ X|t’) + C2 (e - * ’1
where
c ,  = — (k2i - ^ 1) and O 0 11 I
*
3
1° 0^2 ~ ^2 l)
V! A-i(A,i - X 2) _ Vi _X2 (A,i - X 2)_
t ’ represents the time after the infusion is stopped, and t is the total time; Vy is the volume o f  the central 
compartment; Ro is the rate o f  administration, given by dose/time o f  infusion. Ay and A2  are distribution 
rate constants. K21 is a microconstant that represents the tranfer rate from  compartment 2 to 1.
Equation 2 -  Intravenous bolus administration with bi-exponential decline 
C (t) = C, e~X,t + C2 e - ^;t
where
C, = — ~ .k2 l) and c 2 = 5 - ^ i z M
VjCXj - X j ) VKXj -X .2)
V] is the volume o f  the central compartment; D is the dose; Ay and A2  are distribution rate constants. K21 
is a microconstant that represents the tranfer rate from  compartment 2 to 1.
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Equation 3 -  Mono-exponential decline with first-order absorption, with or 
without lag time.
c  = D *k01*F  - klO ( t - tlag) _ e-k O l(t- tlag)
V (kOl-klO)
c  (t) = (C-klO t _ e- k0 1 1 )
V(kOl-klO)
Secondary parameters:
1 i kOl ,
Tmax = ---------------  In   + tlag
(kO l-klO ) klO
For the model without a lag time the last term of the equation is not included
Cmax = ^ ( e - k l0 (Tmax- tlaS) )
V
tlag is not included in the equation for models without lag time
D *F
AUC =
VklO
0.693
T1/2 —
klO
CL = V * klO
Key: koi is the first-order absorption rate constant o f drug into compartment 1; kjo is the first- 
order elimination rate constant o f  drug from  compartment 1; D is the dose administered; t is the 
time from  administration o f  drug; Tmax is the time to reach the maximum concentration; Cmax is 
the maximum concentration; AUC is the area under the concentration-time curve; tlag is the lag 
time, V is the volume o f  distribution, CL is the clearance and F is the bioavailability
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Equation 4 - Zero-order absorption with bi-exponential decline during and after 
absorption, with or without lag time 
With lag time:
C(t)=
D
TV,
(kar'S) , -AiT e-Ai((t-tlag-T). ^^((t-tlag-T).
(k -h )h
Without lag time
C(t)=
D
TV,
(k2i - \ )  (e- XiT _ e- \  (t - T). _ (k21-Xa) XaT _ e- Xz (t - TX
(Xi-X2)Xz
The relationships between kio, the first-order elimination rate constant of drug 
from compartment 1, and and X2 are described in the text, section 3.5.1.
Secondary parameters 
FD
AUC=
V,klO
T 1/2x2-
0.693
CL=
^ 2
FD 
T* AUC
Key: kOl is the first-order absorption rate constant o f  drug into compartment 1; D is the dose 
administered; t is the time from  administration o f  drug; T  is the time fo r  the absorption to occur; 
Cmax is the maximum concentration; AUC is the area under the concentration-time curve; tlag is 
the lag time, V; is the volume o f  distribution o f  compartment 1 and CL is the clearance. Aj and A2 
represent disposition rate constants.
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Equation 5 - Effect-site concentration with first-order oral absorption, mono­
exponential decline
Ce=
D *k01*keo
V
-kOlt -klOt keot
+■ +•
(k!0 -k 0 1 )(keo-k0 1 ) (k0 1 -k ! 0 )(keo-kl0 ) (k0 1 -keo)(k!0 -keo)
Equation 6  - Effect-site concentration with zero order oral absorption, bi­
exponential decline
Ce=
D *keo
V !*T
(k2 j-X I)
(Xl(X.2 -X l) (k eo-X l)
+
(k2] X2) ^  Xx (t T ) _ e~A,2t-j
(X2 (A, -  A2) (keo -  X2)
(k21 - keo) -  keo (t - T) _ e-  keo t j
(keo (A,, -  keo) (X2 -  keo)
Key: kOl is the first-order absorption rate constant o f  drug into compartment 1; D is the dose 
administered; t is the time from  administration o f  drug; T  is the time fo r  the absorption to occur; 
Cmax is the maximum concentration; AUC is the area under the concentration-time curve; tlag is 
the lag time, Vj is the volume o f  distribution o f  compartment 1 and CL is the clearance. A; and A2  
represent disposition rate constants from  compartment 1 and 2, respectively. Keo is the first-order 
elimination rate constant from  the effect-compatment.
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APPENDIX II 
Chapter 3 WinNonlin Model Commands
Commands for two compartment model; with zero-order absorption.
M O D E L
ic Ic'k 'kJe'k'k'k'kJt lcic -k' ic'k-k lt-kJc-klc'k-k-k-k'k'k'k-k-k-k-k'k-k-kic'k-k'k'k-klc ic'k'k'k'k'klc'klc'k'k-k
r e m a r k  D e v e l o p e r :  M . R o s a r i o  
r e m a r k  D a t e :  0 2 - 1 7 - 1 9 9 8
r e m a r k  V e r s i o n :  1 . 0
r e m a r k  T w o - c o m p a r t m e n t ;  z e r o - o r d e r  a b s o r p t i o n
■k 'k 'kJeJe lc 'k -k ie ir 'k 'k 'k 'k 'k 'k 'kJe ie 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'kJe lc ’k ie 'k 'k i t ' k ' k ' k ic i t - k 'k 'k 'k ' k ' k ' k ic 'k 'k 'k
r e m a r k
r e m a r k  -  d e f i n e  m o d e l - s p e c i f i c  c o m m a n d s
C O M M A N D S
N P A R A M E T E R S  5
P N A M E S  ' V ' ,  ' k l 2 ' ,  ' k 2 1 ‘ , ' k l O ' ,  ' T m a x '
e n d
r e m a r k  -  d e f i n e  t e m p o r a r y  v a r i a b l e s
T E M P O R A R Y
v = p ( 1 )
k l 2 = p ( 2 )
k 2 1 = p ( 3 )
k l 0 = p ( 4 )
t m a x = p ( 5 )
t = x
d o s l = c o n ( 1 )
E = d o s l / T m a x
E N D
r e m a r k  -  d e f i n e  m o d e l  e q u a t i o n
F U N C T I O N  1
F = 0 . 0
r l = D S Q R T ( ( K 1 2 + K 2 1 + K 1 0 ) *  * 2  - ( 4 * K 2 1 * K 1 0 ) )  
a l p h a = ( ( K 1 2 + K 2 1 + K 1 0 ) + r l ) / 2  
b e t a = ( ( K 1 2 + K 2 1 + K 1 0 ) - r l ) / 2  
i f  t < =  t m a x  t h e n
F = ( E * ( k 2 1 - a l p h a ) * ( d e x p ( - a l p h a * t ) - 1 ) ) / ( V * a l p h a * ( a l p h a - b e t a ) ) &
+  ( E * ( b e t a - k 2 1 ) * ( d e x p ( - b e t a * t ) - 1 ) ) / ( V * b e t a * ( a l p h a - b e t a ) ) 
e n d i f
i f  t > t m a x  t h e n
F = ( E * ( k 2 1 - a l p h a ) * ( d e x p ( - a l p h a * T m a x ) - 1 ) ) &
/ ( V * a l p h a * ( a l p h a - b e t a ) ) * d e x p ( - a l p h a * ( t - T m a x ) ) &
+ ( E * ( b e t a - k 2 1 ) * ( d e x p ( - b e t a * T m a x ) - 1 ) ) &
/ ( V * b e t a * ( a l p h a - b e t a ) ) * d e x p ( - b e t a * ( t - t m a x ) )
e n d i f
E N D
r e m a r k  -  e n d  o f  m o d e l  
E O M
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Commands for a two-compartment model, zero-order absorption, with Tlag
M O D E L
********************************************************* 
r e m a r k  D e v e l o p e r :  M . R o s a r i o  
r e m a r k  D a t e :  0 2 - 1 7 - 1 9 9 8
r e m a r k  V e r s i o n :  1 . 0
r e m a r k  t w o - c o m p a r t m e n t ;  z e r o - o r d e r  a b s o r p t i o n ;  t l a g
x 'o m d . x ' l c
r e m a r k
r e m a r k  -  d e f i n e  m o d e l - s p e c i f i c  c o m m a n d s
C O M M A N D S
N P A R A M E T E R S  6
P N A M E S  ' V \  1 k l 2  1 , ' k 2 1 \  ' k l O ' ,  ' T m a x ' ,  ' T l a g '
e n d
r e m a r k  -  d e f i n e  t e m p o r a r y  v a r i a b l e s
T E M P O R A R Y
v = p ( 1 )
k l 2 = p ( 2 )
k 2 1 = p ( 3 )
k l 0 = p ( 4 )
t m a x = p ( 5 )
T l a g = p ( 6 )
t = x - t l a g
d o s l = c o n ( l )
E = d o s l / T m a x
E N D
r e m a r k  -  d e f i n e  m o d e l  e q u a t i o n  
F U N C T I O N  1  
F = 0  . 0
r l = D S Q R T ( ( K 1 2 + K 2 1 + K 1 0 ) * * 2 - ( 4 * K 2 1 * K 1 0 ) ) 
a l p h a = ( ( K 1 2 + K 2 1 + K 1 0 ) + r l ) / 2  
b e t a = ( ( K 1 2 + K 2 1 + K 1 0 ) - r l ) / 2  
i f  t < =  t m a x  t h e n
F = ( E * ( k 2 1 - a l p h a ) * ( d e x p ( - a l p h a * ( t + t l a g ) ) - 1 ) ) / ( V * a l p h a * ( a l p h a - b e t a ) ) &  
+  ( E * ( b e t a - k 2 1 ) * ( d e x p ( - b e t a * ( t + t l a g ) ) - 1 ) ) / ( V * b e t a * ( a l p h a - b e t a ) ) 
e n d i f
i f  t > t m a x  t h e n
F = ( E * ( k 2 1 - a l p h a ) * ( d e x p ( - a l p h a * ( T m a x + t l a g ) ) - 1 ) ) &
/ ( V * a l p h a * ( a l p h a - b e t a ) ) * d e x p ( - a l p h a * ( t + t l a g - t m a x ) ) &
+ ( E * ( b e t a - k 2 1 ) * ( d e x p ( - b e t a * ( T m a x + t l a g ) ) - 1 ) ) &
/ ( V * b e t a * ( a l p h a - b e t a ) ) * d e x p ( - b e t a * ( t + t l a g - t m a x ) )
e n d i f
E N D
r e m a r k  -  e n d  o f  m o d e l  
E O M
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Commands for SO model
MODEL
r e m a r k  * * * * * * * * * *  
r e m a r k  D e v e l o p e r :  
r e m a r k  D a t e :
M  R o s a r i o
0 6 - 2 5 - 1 9 9 8
1 . 0r e m a r k  V e r s i o n :  
r e m a r k  S O  m o d e l  
r e m a r k  * * * * * * * *
r e m a r k
r e m a r k  -  d e f i n e  m o d e l - s p e c i f i c  c o m m a n d s
C O M M A N D S
N P A R A M E T E R S  2
P N A M E S  ' E M A X ' , 1 S O  1
E N D
F U N C T I O N  1  
E M A X = p ( 1 )
S0 =p(2 )
F = ( E M A X * x * S 0 ) / ( x * S 0 + E M A X )
E N D
r e m a r k  -  e n d  o f  m o d e l  
E O M
Commands for link model between a two-compartment model with zero-order 
absorption and SO model
M O D E L
r e m a r k  D e v e l o p e r :  M  R o s a r i o
r e m a r k  D a t e :  0 7 - 0 6 - 1 9 9 8
r e m a r k  V e r s i o n :  1 . 0
r e m a r k  S O  M O d e l ;  T w o - c o m p a r t m e n t ;  z e r o - o r d e r  a b s o r p t i o nrlc *★*★**★★★********★**★*********★***********★■*★********* 
r e m a r k
r e m a r k  -  d e f i n e  m o d e l - s p e c i f i c  c o m m a n d s
C O M M A N D S
N P A R A M E T E R S  3
P N A M E S  ' e m a x ' ,  ' S O  1 ,  ' k e o '
n e o n  1
E N D
r e m a r k  -  d e f i n e  t e m p o r a r y  v a r i a b l e s
T E M P O R A R Y
V = 4 5 0 . 8 4
k l 2 = 0 . 0 4
k 2 1 = 0 . 1 2
k l 0 = 0 . 1 3
t a b s = l
e m a x = p ( 1 )
S O = p ( 2 )  
k e o = p ( 3 )  
d = c o n ( 1 )  
t = x
d e l = t - t a b s  
t s t a r = m a x ( 0 , d e l )
r l = d s q r t ( ( k l 2 + k 2 1 + k l 0 ) * * 2 - ( 4 * k 2 1 * k l 0 ) ) 
a l p h a = ( ( k l 2 + k 2 1 + k l 0 ) + r l ) / 2  
b e t a = ( ( k l 2 + k 2 1 + k l 0 ) - r l ) / 2  
E N D
r e m a r k  -  d e f i n e  m o d e l  e q u a t i o n  
F U N C T I O N  1  
c o e f = k e o * d / ( v * t a b s )
c e l = ( ( k 2 1 - a l p h a ) / ( a l p h a * ( b e t a - a l p h a ) * ( k e o - a l p h a ) ) )
c e l = c e l * ( e x p ( - a l p h a * t s t a r ) - e x p ( - a l p h a * t ) )
c e 2 = ( ( k 2 1 - b e t a ) / ( b e t a * ( a l p h a - b e t a ) * ( k e o - b e t a ) ) )
c e 2 = c e 2 * ( e x p ( - b e t a * t s t a r ) - e x p ( - b e t a * t ) )
c e 3 = ( ( k 2 1 - k e o ) / ( k e o * ( a l p h a - k e o ) * ( b e t a - k e o ) ) )
c e 3 = c e 3 * ( e x p ( - k e o * t s t a r ) - e x p ( - k e o * t ) )
a m t = c o e f * ( c e l + c e 2 + c e 3 )
s u m = a m t
c e = s u m
F =  e m a x * c e * S 0 / ( c e * S 0 + e m a x )
E N D
r e m a r k  -  e n d  o f  m o d e l  
E O M
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Commands For Linear model
M O D E L
r e m a r k
r e m a r k D e v e l o p e r :  M .  R o s a r i o
r e m a r k D a t e :  0 2 - 1 0 - 1 9 9 8
r e m a r k V e r s i o n :  1 . 0
r e m a r k L i n e a r  m o d e l
r e m a r k ■k'k 'k ic ic 'k lc 'k 'k ic 'k 'k 'k 'k ic 'k ic 'k 'k ie 'k
r e m a r k
r e m a r k  - L I N E A R  M O D E L
C O M M A N D S
N P A R A M E T E R S  1
P N A M E S 1 B 1  '
E N D
r e m a r k  - d e f i n e  m o d e l  e q u a t i o n
F U N C T I O N 1
F =  B l * x
E N D
r e m a r k  - e n d  o f  m o d e l
E O M
APPENDIX III
Chapter 4: The NMTRAM code file for the several methods of combining the PK and 
PD data.
METHOD 1 and 2
$PROB M IBEFRADIL PK/PD M ODELLING - USING FIXED PK RUN 15
$ INPUT ID TIME AMT A=DROP DV HR=DROP PQ=DROP EVDD TYPE CMT BASB BASH AGE HGT WGT SEX SMOK 
SDATA MIBEFRA2.PRN IGNORE=#
SSUBROUTINE ADVAN4 TRANS4 
$PK
TV KA=THET A( 1)
TVV2=THETA(2)
TVCL=THETA(3)
TVQ=THETA(4)
TVV3=THETA(5)
TALAG1 =THET A(6)
K A = T V K A * E X P ( E T A (  1 ) )
V2=TVV2*EXP(ETA(2))
CL=TVCL*EXP(ETA(3))
Q=TVQ*EXP(ETA(4))
V3=TVV3*EXP(ETA(5)>
ALAG 1 =TALAG 1 *EXP(ETA(6))
S2=V2
EM AX=THETA(7) *EXP(ETA(7))
SO=THETA(8)*EXP(ETA(8»
SERROR
EFF=EMAX*F*SO/(EMAX+SO*F)
Y=EFF+ERR(1)
STHETA
3.05 FIXED ;KA-FIXED TO PREV EST
148 FIXED ; V2-FDCED TO PREV EST
6.81 FIXED ;CL-FDCED TO PREV EST
3.2 FIXED .Q-FDCED TO PREV EST
32.5 FIXED ;V3-FIXED TO PREV EST
0.402 FIXED ;ALAG-FIXED TO PREV EST
(-40,-25.7,-10) ;EMAX-ESTIMATED
(-1,-0.029,1) ;S0-ESTIMATED
SOMEGA
0.847 FIXED ;KA-FIXED TO PREV EST
0.0714 FIXED ;V2-FIXED TO PREV EST
0.129 FIXED ;CL-FIXED TO PREV EST 
2.93 FIXED ;Q-FDCED TO PREV EST
0.0104 FIXED ;V3-FIXED TO PREV EST 
0.127 FIXED ;LAG-FIXED TO PREV EST
0.0226 ;EMAX-ESTTMATED
0.0294 ;S0-ESTIMATED
$SIGMA 1
SESTIMATION PRINT=10 SIG=3 MAXEVALS=9000 NOABORT POSTHOC 
$COVAR
STABLE ID AMT TIME TYPE WRES FILE=MIBE15A.TAB NOPRINT ONEHEADER
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METHOD 3
$PROB M IBEFRADIL SIM ULTANEOUS PK/PD RUN 12 
$ INPUT ID TIME AMT A=DROP DV HR=DROP PQ=DROP EVED TYPE CMT 
BASB=DROP BASH=DROP 
$DATA MIBEFRA1 PRN IGNORE=#
SSUBROUTINE ADVAN4 TRANS4 
$PK
TVKA=THETA(1)
TVV2=THETA(2)
TV CL=THET A(3)
TVQ=THETA(4)
TVV3=THETA(5)
TALAG1=THETA(6)
KA=TVKA*EXP(ETA( 1))
V2=TVV2*EXP(ETA(2))
CL=TV CL*EXP(ET A(3))
Q=TVQ* EXP(ET A(4))
V3=TVV3*EXP(ETA(5))
ALAG 1 =TALAG 1 *EXP(ETA(6))
S2=V2
SERROR
EM AX=THET A(7) * EXP(ET A(7))
SO=THETA(8)*EXP(ETA(8))
EFF=EMAX*F*SO/(EMAX+SO*F)
W=( 1 +THETA(9)*THETA(9)*F*F)**0.5 
Y 1 =F+W*ERR( 1)
Y2=EFF+ERR(1)
A=0
IF (TYPE.EQ.O) A=1 
Y=A*Y1+(1-A)*Y2 
STHETA (0,3 2,15) (0,140,500) (0,6.5,40) (0,3.2,60) (0,32.5,200) (0,0.4,5)
(-60,-26,60) (-1,-0.01,5) (-5,0.07,5)
SOMEGA 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
$SIGMA 0.5
$ ESTIMATION PRINT=10 SIG=3 MAXEVALS=9000 NOABORT POSTHOC 
SCOVAR
STABLE ID AMT TIME WRES TYPE FILE=MIBE12.TAB NOPRINT ONEHEADER
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METHOD 4
SPROB M IBEFRADIL IPRED PK/PD RUN18
$ INPUT ID TIME AMT DV HR=DROP PQ=DROP MDV EVED TYPE CMT BASB=DROP BASH=DROP IPR 
$DATA MIBEFRA3.PRN IGNORE=#
$PRED
EM AX=THETA( 1 )*EXP(ETA( 1))
SO=THETA(2)*EXP(ETA(2))
EFF=EMAX*IPR*SO/(EMAX+SO*IPR)
SERROR
Y=EFF+ERR(1)
STHETA (-60,-21,60) (-1,-0.05,5)
SOMEGA 0.3 0.3 
SSIGMA 0.5
$ ESTIMATION PRINT=10 SIG=3 MAXEVALS=9000 NOABORT POSTHOC 
SCOVAR
STABLE ID AMT TIME FILE=MIBE18A.TAB NOPRINT ONEHEADER
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